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ABSTRACT 
Chronic kidney disease (CKD) is highly prevalent and recognised as a global public health 
problem. It has been consistently associated with hypertension and cardiovascular 
disease; many more patients with a glomerular filtration rate (GFR) below 60 
ml/min/1.73m2 die from cardiovascular causes than progress to end-stage renal disease. 
Nevertheless, observational studies of cardiovascular disease in CKD remain hard to 
interpret because renal impairment is forever accompanied by residual confounding 
factors. These may include the underlying disease process (e.g. diabetes mellitus), or 
the complications of CKD, such as hypertension, anaemia, bone mineral disease and 
inflammation. The prospective study of living kidney donors presented in this work 
provided an ideal experimental model to assess the longitudinal effects of reduced renal 
function in healthy subjects without manifest cardiovascular disease. Compared with 
healthy controls, the modest reduction in GFR in donors accompanying uninephrectomy 
caused increased left ventricular (LV) mass, LV dysfunction, and increased aortic 
stiffness. There was no change in blood pressure but there were increases in 
parathyroid hormone, uric acid and highly sensitive C-reactive protein. The size of the 
reduction in GFR independently predicted the extent of adverse LV remodelling. 
Reduced GFR should therefore be regarded as a causative risk factor for LV disease and 
increased arterial stiffness.  
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1. INTRODUCTION: UNDERSTANDING THE EFFECTS OF CHRONIC KIDNEY DISEASE 
ON CARDIOVASCULAR RISK 
 
1.1. The Kidneys 
 
The kidneys are retroperitoneal organs located within the paravertebral gutters between the 
vertebral levels T12 and L3. Each kidney receives blood from the renal artery, and drains 
blood into the renal vein, which courses beside the ureter. The blood flow to the two 
kidneys under resting physiological conditions equates to roughly 25% of the cardiac output 
(approx. 1.25 L/min) despite the organs only constituting less than 0.5% of the total body 
weight. The basic functional unit of the kidney is the nephron and each human kidney 
contains between 1 and 1.5 million nephrons (Lote, 2012). The nephron consists of a 
glomerulus, a proximal tubule, a loop of Henle, a distal tubule and a collecting system. 
Ultrafiltration occurs at the glomerulus with passive movement of a protein-free fluid from 
the glomerular capillaries into Bowman’s space. The amount of plasma that is filtered in the 
glomerulus over time is the glomerular filtration rate (GFR). Ultrafiltration is followed by 
selective reabsoprtion of water and electrolytes at the proximal tubule and concentration of 
the filtrate at the loop of Henle and collecting duct, ultimately resulting in the formation of 
urine (Berne, 1993). 
 
By excretion of water and solutes, the kidneys are able to regulate body fluid osmolality and 
maintain the normal cell volume in all tissues. As well having an important excretory role, 
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the kidneys have several other major functions including: regulation of electrolyte and acid-
base balance, and the production and secretion of hormones. Indeed, the kidneys are 
important endocrine organs that produce and secrete renin, prostaglandins, kinins, 1,25-
dihydroxyvitamin D (calcitriol), and erythropoietin. Renin is produced by the granular cells of 
the juxtaglomerular apparatus and activates the renin-angiotensin-aldosterone system 
(RAAS), which has subsequent effects on salt and water retention and permits modulation of 
blood pressure. In conjunction with angiotensin II, prostaglandins and kinins also influence 
systemic blood pressure (Berne, 1993). In the proximal tubule of the nephron, the 
mitochondrial enzyme 25-hydroxyvitamin D3 1-alpha-hydroxylase converts 25-
hydroxyvitamin D (calcidiol) to 1,25-dihydroxyvitamin D (calcitriol). Calcitriol circulates as the 
biologically active form of vitamin D, causing increased uptake of calcium from the gut into 
the blood, and increases the release of calcium into the blood from bone. Erythropoietin 
(EPO) is a glycoprotein hormone produced by interstitial fibroblasts in the kidney and serves 
as a cytokine for erythrocyte precursors in the bone marrow to stimulate red blood cell 
production (Berne, 1993).  
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1.2. The Cardiorenal Axis 
 
Besides dynamic alterations in cardiac function, the regulation of intravascular volume is 
central to maintaining cardiovascular haemostasis and permitting adequate end-organ 
perfusion. To this end, the kidney integrates various haemodynamic, neural and endocrine 
factors as depicted in Figure 1-1. As part of the cardiorenal axis, changes in volume and 
pressure within the atria and ventricles initiate reflexes that affect renal function (Heywood, 
2012). The heart can also affect the kidney by activating high-pressure arterial baroreceptors 
found in the carotid sinus, aortic arch and afferent arteriole of the glomerulus. A decline in 
arterial pressure results in vagal inhibition and an increase in sympathetic efferent activity 
stimulating RAAS via the beta-adrenergic pathway. When renal perfusion is lowered, renin is 
secreted which cleaves angiotensinogen to angiotensin I, which itself is cleaved by the 
angiotensin converting enzyme (ACE) to angiotensin II. Angiotensin II causes systemic 
vasoconstriction increasing blood pressure and preferentially vasoconstricts the efferent 
arteriole of the glomerulus, increasing renal perfusion pressure and the glomerular filtration 
rate. It also stimulates secretion of the mineralocorticoid aldosterone and release of anti-
diuretic hormone (ADH) thereby promoting sodium and water retention. By contrast, 
increased cardiac filling pressures from an expanded extracellular fluid volume stimulates 
the release of ADH (so-called “Henry-Gauer reflex”) and atrial natriuretic peptide (ANP) from 
the atria and the release of B-type natriuretic peptide (BNP) from the ventricles. Their 
combined effect is to promote vasodilatation, sodium and water excretion, as well as to 
suppress aldosterone (Heywood, 2012, O'Connor, 2005). 
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The dysregulation of the cardiorenal axis and its negative feedback loop appears important 
for the development of left ventricular (LV) dysfunction, which is characterised by a 
deleterious sympathetic overactivation leading to excessive sodium and fluid retention. 
Although the exact mechanisms for this process remain poorly understood, it is fundamental 
in contributing to the evolution from asymptomatic to symptomatic LV dysfunction. The 
phenomenon may be explained by the “body volume regulation hypothesis” where despite 
an increase in total blood volume, arterial underfilling develops secondary to a decrease in 
cardiac output (Heywood, 2012). Under such circumstances, RAAS activation attenuates the 
normal renal response to the natriuretic peptides. Resistance to the natriuretic response of 
ANP and BNP appears to result from the neurohumoral-mediated diminished sodium 
delivery to their site of action, the collecting duct (Heywood, 2012). 
 
In summary, there are many bidirectional physiological pathways whereby the heart and 
kidney may affect one another. In health, these are vital for maintaining optimal cardiorenal 
homeostasis under normal physiological conditions but in disease states, these 
compensatory mechanisms may prove maladaptive in the long-term. The term “cardio-renal 
syndrome” has been coined to describe a disorder of the heart and kidneys whereby acute 
or chronic dysfunction in one organ may induce acute or chronic dysfunction of the other. 
The five subtypes of this syndrome were originally described by Ronco et al. (2008) and their 
pathophysiological mechanisms are described in Figure 1-2. This classification has been 
subsequently endorsed by a consensus group under the auspices of the Acute Dialysis 
Quality Initiative (ADQI) (Ronco et al., 2010).  
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Figure 1-1. Schematic of the Cardiorenal Axis. 
Abbreviation: RAAS, renin-angiotensin-aldosterone system. Adapted from Heywood, 2012. 
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Figure 1-2. Pathophysiology of the Five Subtypes of Cardiorenal Syndrome. 
Abbreviations: AKI, acute kidney injury; Ca, calcium CHF, congestive heart failure; CKD, chronic 
kidney disease; GFR, glomerular filtration rate;, P, phosphate (Ronco et al., 2010).  
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1.3. Definition of Chronic Kidney Disease 
 
Chronic kidney disease is defined as abnormalities of kidney structure or function, present 
for more than 3 months.  It can be classified according to the cause, GFR category, and 
albuminuria category, on the basis of their respective prognostic significance (KDIGO, 2012). 
There are 5 stages of CKD according to the GFR and evidence of structural or functional 
damage (Table 1-1). 
 
The GFR cannot be directly measured but instead is indirectly quantified using clearance of a 
filtration marker into urine. As the reference standard, the GFR can be accurately measured 
using the clearance of intravenously administered radioisotopes such as 51Cr-
ethylenediaminetetraacetic acid (51Cr-EDTA) (Martensson et al., 1998). More commonly, in 
clinical practice an estimated GFR (eGFR) is derived from measurement of endogenous 
serum creatinine and a number of equations are available. The Cockcroft-Gault equation was 
the first of these to be adopted after validation against 24-hour urinary creatinine clearance 
(Cockcroft and Gault, 1976), although it is no longer recommended because it systematically 
overestimates GFR. This relates to tubular creatinine secretion as well as the inclusion of 
weight as a variable, which in the presence of obesity and fluid overload is a poor reflection 
of lean body mass (Stevens et al., 2006). More commonly, eGFR is now calculated using 
either the Modification of Diet in Renal Disease (MDRD) equation or the Chronic Kidney 
Disease Epidemiology Collaboration (CKD-EPI) formula (Levey et al., 2009). Whilst both these 
methods calculate eGFR using the same 4 variables (age, race, gender and serum creatinine), 
it has been suggested that the CKD-EPI formula more accurately reflects measured GFR, 
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particularly in subjects with near-normal levels of renal function (GFR >60 ml/min/1.73m2) 
(Michels et al., 2010). Nevertheless, the accuracy of eGFR remains limited by its dependence 
on muscle mass and dietary protein intake. Cystatin C is a cationic cysteine proteinase, 
produced by all cells at a constant rate which is freely filtered by the glomerulus and almost 
completely reabsorbed and degraded by the proximal tubule (Stevens et al., 2006). The 
recent addition of cystatin C to that of serum creatinine to determine eGFR gives further 
improved accuracy and moreover, strengthens the association between the eGFR and the 
risks of death and end-stage renal disease (Shlipak et al., 2013). 
 
Data from the US National Health and Nutrition Examination Survey (NHANES) show the 
prevalence of CKD is both high and rising; over 13% of US citizens fulfil the National Kidney 
Foundation Dialysis Outcome Quality Initiative (NKF K/DOQI) criteria for stage 1 to 4 CKD 
(Coresh et al., 2007). Whilst this figure excludes patients with end stage renal disease (ESRD), 
a population associated with extreme cardiovascular risk, in public health terms the principal 
cardiovascular disease burden resides in early stage CKD which is over 50 times more 
prevalent (Figure 1-3), and affects up to 50% of community-dwelling subjects over the age of 
70 years (Coresh et al., 2003). 
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Table 1-1. Stages of Chronic Kidney Disease as Defined by KDIGO Guidelines. 
Stage  Description      GFR (ml/min/1.73m2) 
G1 Kidney damage* with normal or increased GFR ≥90 
G2 Kidney damage* with mildly decreased GFR 60-89 
G3 Moderately decreased GFR 30-59 
G4 Severely decreased GFR 15-29 
G5 Kidney failure <15 or dialysis 
*Evidence of functional or structural kidney abnormalities for ≥3 months. In the absence of evidence 
of kidney damage, neither GFR category G1 nor G2 fulfill the criteria for chronic kidney disease. 
Abbreviations: GFR, Glomerular Filtration Rate; KDIGO, Kidney Disease Improving Global Outcomes. 
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Figure 1-3. Estimated Prevalence of Chronic Kidney Disease in Adults in the United States according 
to the Third National Health and Examination Survey (NHANES III).  
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1.4. Chronic Kidney Disease and Cardiovascular Risk 
 
Chronic kidney disease (CKD) is a major but poorly recognised and under-treated risk factor 
for cardiovascular disease (Best et al., 2004). Numerous observational studies have 
demonstrated the excess cardiovascular risk associated with CKD (Go et al., 2004, Schiffrin et 
al., 2007, Van Biesen et al., 2007, Mccullough et al., 2007, Kurth et al., 2009, Di Angelantonio 
et al., 2010, Matsushita et al., 2010). In a study of over a million US adults in whom serum 
creatinine was measured between 1996 and 2000, there was an independent, graded 
inverse relationship between eGFR at levels <60 ml/min/1.73m2 and the risk of adverse 
cardiovascular events (Go et al., 2004). Although there is a consensus from international 
organisations (The National Kidney Foundation Kidney Disease Outcomes Quality Initiative 
(NKF K/DOQI) and Kidney Disease: Improving Global Outcomes (KDIGO)) that individuals with 
a GFR <60 ml/min/1.73m2 are at increased risk of cardiovascular morbidity and mortality, 
(Eknoyan et al., 2004, KDIGO, 2012), whether it is appropriate to dichotomize patients based 
on this “threshold” is questionable. Many studies have simply used subjects with an eGFR of 
>60 ml/min/1.73m2 as their reference population when considering cardiovascular risk. A 
more recent meta-analysis involving over a million participants taken from general 
population cohorts found all cause and cardiovascular mortality began rising at an eGFR of 
<75 ml/min/1.73m2 (Matsushita et al., 2010). The Belgian Inter-University Research on 
Nutrition and Health Population Study followed 8,913 apparently healthy participants for a 
total of 10 years (Van Biesen et al., 2007). The results suggested excess cardiovascular 
mortality began even earlier at an eGFR of <90 mL/min/1.73m2, a level commonly regarded 
as indicating near normal renal function. The cardiovascular mortality risk increased linearly 
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by 8% for every 10 mL/min/1.73m2 fall in eGFR. This is a potentially very important finding 
given the high prevalence of eGFR values in this range, particularly in the elderly in whom 
the loss of renal function has hitherto been regarded as benign. 
 
Several studies have also shown a graded relationship with cardiovascular risk and the level 
of albuminuria (Klausen et al., 2004, Arnlov et al., 2005, Matsushita et al., 2010). In the 
general population, even low levels of urinary albumin excretion, below the current 
diagnostic threshold for microalbuminuria, have been shown to predict future cardiovascular 
events including death, independent of other “traditional” cardiac risk factors (Klausen et al., 
2004, Arnlov et al., 2005). This finding was recently confirmed by a CKD Prognosis 
Consortium meta-analysis where urinary albumin : creatinine ratio (ACR) was independently 
associated with adjusted risk of all cause and cardiovascular mortality with a log linear 
relationship but there was no evidence of the threshold effect which has been postulated for 
GFR (Matsushita et al., 2010). Indeed, the hazard ratio for all cause and cardiovascular 
mortality is already doubled within the ACR range of 0.3 – 3.0 mg/mmol, a level which is not 
detected by standard urinary dipsticks and has often been considered innocuous. 
Furthermore, the risks of cardiovascular and all cause mortality appear to be independently 
and multiplicatively associated with eGFR and albuminuria (Matsushita et al., 2010). 
Proteinuria is also associated with progression of renal disease (Jafar et al., 2003) and may 
even play a causal role through toxicity to tubular epithelial cells (Hostetter et al., 1981). 
Albuminuria is likely to be more than just a passive biomarker of cardiovascular disease 
making it an attractive target for risk reduction therapy. The PREVEND group have shown 
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that treating normotensive microalbuminuric individuals with an angiotensin-converting 
enzyme inhibitor resulted in a significant reduction in urinary albumin excretion and was also 
associated with a trend in reducing cardiovascular events compared to placebo (Asselbergs 
et al., 2004). 
  
 14 
 
1.5. Pathophysiology of Cardiovascular Disease in Chronic Kidney Disease 
 
The importance of detecting early stage CKD has been emphasised of late because it offers 
the potential to prevent or delay its progression and reduce the risk of cardiovascular 
disease on a global scale (NICE, 2015). The development of cardiovascular risk reduction 
therapies is however, hindered by the fact that whilst the epidemiological association 
between CKD and cardiovascular disease is strong, the underlying pathophysiological 
mechanisms remain ill-defined. There is abundant evidence suggesting that modification of 
“conventional” atherosclerotic risk factors in CKD does not improve cardiovascular outcomes 
to the same degree that would be expected for the general population. First, although in 
CKD there is a clustering of classical risk factors such as hypertension and diabetes mellitus, 
they perform very poorly in the prediction of cardiovascular risk in this population, 
particularly in late stage CKD (Coresh et al., 1998). Indeed, in ESRD there is an inverse 
relationship between cardiovascular event rates and risk factors such as total cholesterol, 
obesity and even blood pressure. These paradoxical associations may, at least in part, be 
explained by “reverse causality”, a feature of chronic disease malnutrition-inflammation 
syndromes (Kalantar-Zadeh et al., 2003). Second, epidemiological studies suggest that whilst 
roughly 40% of all deaths in patients with ESRD are cardiovascular in origin, the majority of 
these deaths are attributable to sudden cardiac death, arrhythmia or congestive heart 
failure (Figure 1-4) with relatively few from atherosclerotic events such as myocardial 
infarction (USRDS, 2011). Heart failure is a major cause of morbidity and mortality in both 
early stage CKD and ESRD with incident rates 3-4 times higher than in non-CKD subjects 
(Foley et al., 2005). Thus, it is widely held that it is not atheromatous coronary artery disease 
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but myocardial disease - LV hypertrophy with fibrosis and diastolic dysfunction, often 
accompanied by systolic dysfunction - that is the principal cause of cardiovascular death and 
disease in CKD.  The prevalence of LV hypertrophy is increased from the earliest stages of 
progressive renal disease and reaches over 70% in patients with ESRD (Stewart et al., 2005, 
Mark et al., 2006). Recent cardiac magnetic resonance imaging (MRI) data reported from the 
Birmingham Cardio-Renal Group demonstrate that a process of diffuse LV fibrosis begins in 
early stage CKD which is associated with important functional changes including 
abnormalities of regional systolic and diastolic ventricular function (Edwards et al., 2015). 
The result from the SHARP (Study of Heart And Renal Protection) trial of lipid lowering 
therapy in CKD, in which LDL reduction was associated with a significant decrease in major 
atherosclerotic events, but no reduction in total vascular mortality (Baigent et al., 2011) is 
consistent with this paradigm. These data are similar to those seen in lipid lowering trials in 
heart failure (Kjekshus et al., 2007); in both disease processes the majority of deaths appear 
to result from pump failure or arrhythmia as opposed to coronary events (USRDS, 2011). 
 
1.5.1. Atheroma in Chronic Kidney Disease 
 
Examination of the arterial system of patients with CKD reveals two distinct but overlapping 
arterial pathologies: atherosclerosis and arteriosclerosis (Edwards et al., 2006). Whilst 
atherosclerosis is primarily an intimal disease, patchy in distribution and occurring 
preferentially in medium-sized conduit arteries, arteriosclerosis is a diffuse disease of the 
media which leads to increased arterial stiffness (see Section 1.5.2). The morphological 
characteristics of atheroma in patients with CKD are distinct and include increased plaque 
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calcification and increased intimal and medial thickness (Schwarz et al., 2000). The 
prevalence of atheromatous disease in CKD is high, although it is not clear whether this is a 
direct result of renal dysfunction or the clustering of risk factors such as hypertension, 
diabetes and inflammation which invariably accompany CKD. A study of carotid intima-
media thickness (IMT) from Finland showed a fourfold greater plaque score in CKD patients 
(pre-dialysis, dialysis and post transplant) compared to healthy controls (Leskinen et al., 
2003). In a Canadian study, compared to a reference control group the adjusted relative risk 
of myocardial infarction was 1.4 in patients with non-diabetic CKD and 2.7 in diabetic stage 3 
and 4 CKD compared to 2.0 for diabetes and 3.8 for subjects with previous myocardial 
infarction (Tonelli et al., 2012). When severe proteinuria was present, however, the relative 
risk of myocardial infarction in non-diabetic CKD equalled that of the diabetic population.  
There is also an increased prevalence of peripheral and cerebral vascular disease in CKD 
according to data from the US Renal Data System (Figure 1-5), though it must be 
remembered that these data are not controlled for co-morbidities such as diabetes and 
hypertension, known to be strongly associated with atheroma (Usrds, 2011). There is clear 
evidence of an adverse interaction between CKD and major atherosclerotic events; 
outcomes after acute coronary syndrome and stroke are much worse in CKD than in the 
general population (Macwalter et al., 2002, Hanna et al., 2011, Saltzman et al., 2011, Kumai 
et al., 2012). For instance, in ST elevation myocardial infarction, patients on dialysis (treated 
in the pre-primary angioplasty era) had a one year mortality rate of almost 60% with a one 
year cardiac mortality of 41% (Herzog et al., 1998). 
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Figure 1-4. Causes of Death in Prevalent US Dialysis Patients. 
Data are taken from 2007-2009. AMI; acute myocardial infarction; CHF, congestive heart failure; CVA, 
cerebrovascular accident. Figure is reproduced from Ch. 4 of the US Renal Data System annual report 
(2011). 
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Figure 1-5. Cardiovascular Disease Prevalence Rates (%) by CKD Stage For Common Cardiovascular 
Diseases. 
CKD, chronic kidney disease; CVA, cerebrovascular accident; MI, myocardial infarction; PVD, 
peripheral vascular disease; TIA, transient ischaemic attack. Figure reproduced from Ch. 4 of the US 
Renal Data System report (2011).  
 19 
 
1.5.2. Arteriosclerosis in Chronic Kidney Disease 
 
Arteriosclerosis is characterised by thickening and calcification of the medial arterial layer 
and is a hallmark feature of arterial disease in CKD.  Medial calcification is concentric and 
does not extend into the arterial lumen unless there is co-existent atheroma. Increased 
collagen content, hyperplasia and hypertrophy of the vascular smooth muscle cells cause 
wall thickening which in combination with calcification results in increased arterial stiffness 
(Edwards et al., 2006). Although associations exist between the degree of arterial stiffness 
and atheromatous plaque burden (Van Popele et al., 2001), studies have failed to 
demonstrate a significant influence of traditional atherosclerotic risk factors on the 
development of arteriosclerosis (Cecelja and Chowienczyk, 2009), suggesting that alternative 
factors drive this process. There appears to be at least some degree of mechanistic overlap, 
however, as endothelial dysfunction (ED) and reduced NO bioavailability have been shown 
to contribute to arterial stiffening (Schmitt et al., 2005). Increased arterial stiffening appears 
to play a central role in the causation of cardiovascular disease in CKD.  The strong 
association between arterial stiffening and mortality in ESRD was demonstrated over 10 
years ago by London and colleagues (Guerin et al., 2001, Blacher et al., 1999, Blacher et al., 
1998). Recent UK data (National Institute for Cardiovascular Outcomes Research) have 
demonstrated increased mortality after  transcatheter aortic valve implantation in those 
subjects with an eGFR <45 ml/min/1.73m2 (Ferro et al., 2015). These outcomes may in part, 
reflect the increased aortic calcification associated with worsening renal function (Chue et 
al., 2012b), which could predispose CKD subjects to peri-procedural complications such as 
paravalvular leak, aortic dissection and stroke. Whilst the process of arterial stiffening 
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appears to begin during early stage CKD, the prognostic significance of arterial stiffness in 
this specific population remains uncertain (Edwards et al., 2008a, Briet et al., 2006).  
 
Before the pathophysiological effects of arterial stiffening can be fully appreciated, an 
understanding of the normal physiology of the aorta and large arteries is essential.  Their 
major functions are not only to deliver blood around the body but to buffer the oscillatory 
changes in blood pressure that result from intermittent ventricular ejection. The highly 
distensible arterial system ensures that most tissues receive near steady flow with no 
exposure to peak systolic pressures; this mechanism is so efficient that there is almost no 
drop in peripheral mean arterial pressure compared to the ascending aorta (Avolio et al., 
2009). Loss of arterial distensibility results in a more rigid aorta that is less able to 
accommodate the volume of blood ejected by the left ventricle, resulting in greater pressure 
augmentation in systole and higher pulse pressures (Davies et al., 2008). An often cited 
additional explanation for the elevated systolic pressure that accompanies an increase in 
arterial stiffness is that of an earlier return of reflected waves of ventricular contraction from 
distal arterial branch points (London et al., 1992, Latham et al., 1985). In healthy compliant 
arteries reflected waves were believed to return to the ascending aorta in diastole, 
augmenting diastolic pressure and coronary blood flow; in older and stiffer arteries, the 
reflected waves were thought to return earlier in systole increasing ventricular afterload and 
augmenting systolic and pulse pressures. Although an attractive hypothesis, there is now 
abundant evidence showing that reflected waves arrive in systole irrespective of age (Baksi 
et al., 2009). These data together with information available from techniques that separate 
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reflected waves from the reservoir pressure strongly suggest that the “cushioning effect” or 
Windkessel model appears to be the more important physiological explanation (Wang et al., 
2003). In any case, as arterial stiffness increases, a loss in arterial distensibility exposes the 
myocardium, brain and kidneys to higher systolic pressures and greater pressure fluctuations 
resulting in myocardial, cerebral and renal microvascular damage and an increased risk of 
heart failure, arrhythmia, stroke and further renal impairment (Figure 1-6) (O'Rourke and 
Safar, 2005, Moody et al., 2013). Whilst higher systolic pressure increases LV afterload, 
lower diastolic pressure reduces diastolic coronary perfusion, promoting ischaemia and 
placing greater reliance on systolic coronary perfusion (London et al., 1996, Saeki et al., 
1995). 
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Figure 1-6. Proposed Mechanistic Pathways for Arterial and Myocardial Disease in Chronic Kidney 
Disease. 
Abbreviations: ADMA, asymmetric dimethylarginine; AGEs, advanced glycation endproducts; AOPP, 
advanced oxidation protein products; apoA-I, apolipoprotein AI; apoC-III, apolipoprotein CIII; C1TP, 
carboxy-terminal telopeptide; CaxPO4, calcium-phosphate product; CKD, chronic kidney disease; CRP, 
C-reactive protein; EN-RAGE, extracellular newly identified RAGE-binding protein; FGF-23, fibroblast 
growth factor-23; HDL, high-density lipoprotein; IL-6, interleukin-6; LV, left ventricular; MMP, matrix 
metalloproteinases; MPO, myeloperoxidase; oxLDL, oxidised low-density lipoprotein; NT-pro-BNP, N-
terminal fragment pro-B-type natriuretic peptide; PIIINP, Procollagen III N-Terminal Propeptide; PP, 
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pulse pressure; PTH, parathyroid hormone; PTX3, pentraxin-3; RAAS, renin-angiotensin-aldosterone 
system; ROS, reactive oxygen species; TG, triglycerides; TGF-β1, transforming growth factor-beta1; 
TIMP, tissue inhibitors of metalloproteinases; TNF-α, tumour necrosis factor-alpha; sTWEAK, soluble 
tumour necrosis factor-like weak inducer of apoptosis; Vit D, 1,25 dihydroxyvitamin D.  
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1.5.3. Arterial-Ventricular Interaction in Chronic Kidney Disease 
 
The central role of arterial stiffening has also focussed attention on the interaction between 
the left ventricle and arterial tree; termed arterial-ventricular interaction.  In health, cardiac 
function is physiologically matched or coupled with arterial function to ensure maximum 
cardiac work and efficiency (Chen et al., 1998). This coupling is most commonly investigated 
and quantified by the measurement of arterial and ventricular elastances, either invasively 
with conductance catheters or non-invasively using echocardiographic parameters. LV 
systolic elastance (Ees) is a measure of chamber stiffness at end systole and arterial 
elastance (Ea) is a measure of net ventricular afterload (incorporating resistance, pulsaltile 
load and blood pressure) determined by the ratio of end-systolic pressure to stroke volume. 
When LV function is normal, the coupling ratio is generally between 0.7 and 1.0 (Ea is 
smaller than Ees) so that work efficiency is maximised but stroke work is sub-maximal for a 
given preload. With systolic dysfunction, Ees falls so that in mild dysfunction, the ventricle 
performs at maximum stroke work.  When the heart is coupled to a stiff vascular system, the 
heart must increase systolic stiffness (Ees) to maintain cardiac metabolic efficiency ensuring 
transfer of blood to the arterial tree without excessive changes in pressure.  Thus the 
arterial-ventricular coupling ratio is maintained but both Ea and Ees are considerably 
elevated. These compensatory adaptations maintain cardiac performance with enhanced 
contractility at rest, but at a price: cardiac reserve is reduced, diastolic function is impaired 
and the cardiovascular responses to alterations in pressure and volume load are blunted 
leading to haemodynamic instability and a susceptibility to “flash” pulmonary oedema (Chen 
et al., 1998). 
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The abnormalities of arterial and LV function which are so highly prevalent in ESRD may 
begin in early stage CKD.  In a population-based study of 742 individuals, mildly reduced 
eGFR was significantly associated with greater LV mass in a process dependent upon 
increased arterial stiffness (Henry et al., 2005). In a cross-sectional study of patients with 
stage 2 and 3 CKD, the Birmingham Cardio-Renal Group found delayed ventricular relaxation, 
increased LV systolic and end diastolic stiffness and elevated left atrial volumes compared to 
healthy matched controls (Edwards et al., 2008a). Arterial elastance was also elevated such 
that the arterial-ventricular coupling ratio was preserved.  This suggests that the two 
processes occur in parallel and is consistent with the theory that aortic stiffness drives the 
development of LV stiffness in CKD (Edwards et al., 2008a). This pattern, similar to that 
found in heart failure with preserved ejection fraction (Edwards et al., 2008b), suggests that 
early stage CKD is likely to be associated with reduced cardiovascular reserve and increased 
haemodynamic instability, although further work is required in this area. The level of GFR at 
which arterial stiffening begins to increase is not clear but elevated pulse wave velocity 
(PWV), the current reference standard marker of aortic stiffness, is already evident in stage 2 
CKD (Wang et al., 2005). A stepwise increase in PWV corresponding with advancing stages of 
CKD suggests that arterial stiffness increases as a graded relationship with declining GFR. 
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1.6. Mechanisms of Arterial Stiffening and Left Ventricular Hypertrophy in Chronic 
Kidney Disease 
 
Understanding the potential mechanisms underlying increased arterial stiffness in CKD is 
important, particularly if we are to begin devising strategies to prevent or reverse this 
pathophysiology. Arterial stiffening is a result of both functional and structural abnormalities 
of the arterial wall. Endothelial dysfunction provides a dynamic component that may be 
amenable to treatment with conventional agents such as statins, antihypertensives and 
novel treatments that increase nitric oxide bioavailability. The structural vascular changes of 
CKD are however likely to prove harder to reverse. The various potential molecular causes of 
arteriosclerosis in CKD are summarised in Table 1-3. Recent work has highlighted the 
importance of both aldosterone and disordered bone mineral metabolism in the causation 
of arterial stiffness in CKD. Preventive therapy is available for both factors; such treatment 
might reduce arterial stiffness and prevent many of the pathological cardiovascular changes 
seen in CKD including LV hypertrophy and fibrosis. Reduction of arterial stiffness is an 
attractive target for it has the potential to slow the decline in renal function and thereby 
interrupt the spiralling progression of renal and vascular disease (Figure 1-6). 
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Table 1-2. Key Human Studies Investigating Molecular Mechanisms of Atherosclerosis in Chronic Kidney Disease. 
Factor/Mechanism Study population Study type Study outcomes Reference 
Endothelial dysfunction 
Reduced NO  Plasma creatinine Cross-sectional   Whole body basal NO production (determined by in vivo arginine-to-citrulline (Wever et al., 1999) 
 Secondary to reduced 770±250μmol/L (n=33)   conversion) was reduced compared to healthy controls.  
 eNOS activity, increased   
 ADMA and peroxynitrite Non-diabetic CKD stages Cross-sectional  Abnormal FMD demonstrated in early stage CKD compared to healthy (Thambyrajah et al., 2000) 
 formation  2-4 (n=106)  controls.   
 
ADMA  Non-diabetic CKD Cross-sectional Increase in ADMA associated with primary chronic renal disease (Kielstein et al., 2002) 
 Endogenous inhibitor of  (IgA nephropathy and  at an early stage, even when GFR was within the normal range.  
 eNOS principally excreted    ADPKD) (n=60) 
 by the kidney, decreases NO  
 bioavailability   CKD stage 5 on HD Prospective cohort When combined, ADMA and CRP levels predicted the progression of carotid (Zoccali et al., 2002) 
    (n=90)  IMT on a multivariate regression analysis. 
    
   CKD, GFR 31±15  Prospective cohort Plasma ADMA levels inversely correlated with GFR and predicted progression (Ravani et al., 2005) 
   ml/min/1.73m
2
 (n=131)  to ESRD and all-cause mortality. 
 
   T1DM with diabetic Prospective cohort ADMA levels predicted fatal and nonfatal CV events as well as progression  (Lajer et al., 2008) 
   nephropathy, GFR 76±34  of renal dysfunction over a median of 11.3 years. 
   ml/min/1.73m
2
 (n=397) 
 
EMP   CKD stage 5 (n=76)  Cross-sectional Increased numbers of circulating EMP correlated with reduced FMD and (Amabile et al., 2005) 
 Vesicles shed from the plasma    increased arterial stiffness determined by aortic PWV. 
 membrane in response to    
 endothelial cell injury/activation CKD stage 5 (n=64)  Cross-sectional Circulating apoptotic EMPs and VEGF were significantly higher in HD patients (Merino et al., 2010) 
       compared with non-dialysis CKD patients and those patients on PD. Serum 
      VEGF levels were significantly elevated in CKD compared with healthy controls.    
    
Angiogenic factors 
VEGF   CKD stage 5 on HD Prospective cohort Increased VEGF levels were associated with LV systolic dysfunction (reduced (Mallamaci et al., 2008) 
 Cytokine involved in endothelial (n=228)  fractional shortening of LV midwall) and mortality in HD patients. 
 proliferation, migration, tube 
 formation, and induces eNOS 
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sVEGFR-1 (or sFlt-1)   CKD stage 5 on HD (n=185) Prospective cohort A high level of sVEGFR-1 predicted all cause mortality over a median duration  (Guo et al., 2009) 
 An endogenous antagonist for     of 31 months. 
 VEGF and a negative regulator 
 of post-ischaemic angiogenesis CKD stage 3-5 (n=186) Cross-sectional Levels of sVEGFR-1 were higher in CKD patients compared with healthy controls. (Di Marco et al., 2009) 
          
EPC   CKD stage 5 on HD (n=74) Cross-sectional Lower EPC numbers were demonstrated which correlated with endothelial (Choi et al., 2004) 
 Circulating, bone-marrow      dysfunction and Framingham’s risk factor score. 
 derived cells involved in      
 endothelial cell regeneration  Early-moderate CKD, eGFR Cross-sectional Reduction in EPC demonstrated even in early stage CKD with increase in  (Jie et al., 2010) 
    37±19ml/min/1.73m
2
  VEGF levels and smooth progenitor cells with increasing renal dysfunction. 
    (n=82)   
    
   CKD stage 5 on HD (n=265) Prospective cohort The number of functionally active EPCs predicted adverse CV events  (Lorenzen et al., 2010) 
      over a median follow up of 36 months.    
 
Uraemic toxins 
p-cresylsulphate   Non-diabetic CKD stage 5  Prospective cohort p-cresylsulphate, indirectly quantified as p-cresol, was associated with all cause (Meijers et al., 2008) 
 End-product of phenol  on HD (n=175)   mortality and CVD after a mean follow up of 56 months. 
 metabolism, uraemic   
 retention solute  CKD stages 2-5 (n=139) Prospective cohort Total and free p-cresylsulphate were inversely correlated with renal function (Liabeuf et al., 2010) 
        and were significantly associated with vascular calcification. Free 
       p-cresylsulphate predicted overall and CV death over a mean of 25 months. 
 
Oxidative stress 
MPO   CKD stage 5 on HD (n=356) Prospective cohort Serum MPO levels correlated with levels of markers of inflammation (CRP, IL-6, (Kalantar-Zadeh et al., 2006) 
Enzyme that uses H2O2 to oxidise    TNF-alpha, CRP) and overall mortality over a median duration of 26 months.      
tyrosine  to tyrosyl radical which 
cross-links proteins 
      
AOPP   Non-diabetic CKD,  Prospective cohort AOPP, CRP and fibrinogen levels independently predicted incident vasculo- (Descamps-Latscha et al., 2005)
 Carried by oxidized plasma  20-40 ml/min (n=80)   occlusive atherosclerotic CV events over a median follow up of 7 years.    
 proteins, especially albumin 
 
oxLDL   CKD stages 3-5 (n=44) Cross-sectional Endothelial function determined using plethysmography was related to (Annuk et al., 2005)
 Chemotactic to monocytes,    intracellular oxidative stress in patients with CKD.  
 activates collagenases, promotes 
 apoptosis of endothelial cells   
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Homocysteine   CRIB study, CKD stages 1-5  Cross-sectional Among CKD patients with prevalent LVH (21%) and vascular disease (34%), (Wheeler et al., 2003)
 A non-protein amino acid  CrCl 6 to 105 mL/min  those with more severe renal impairment had higher plasma homocysteine 
 synthesised from methionine (n=369)   levels. 
 
Coagulation/fibrinolysis 
vWF   Hoorn study, population- Prospective cohort eGFR was inversely associated with vWF and VCAM-1 which predicted CV  (Stam et al., 2006) 
 Large plasma glycoprotein,  based study (n=613)   mortality over a median follow-up of 12.5 years. 
 produced by endothelial cells  
 and megakaryoctyes, binds to  Non-diabetic CKD stages  Cross-sectional  Abnormal FMD and increased vWF was demonstrated in early stage CKD  (Thambyrajah et al., 2000) 
 Factor VIII/collagen/platelet GpIb 2-4 (n=106)   compared with healthy controls. 
 
Fibrinogen   ARIC and CHS studies Prospective cohort Levels of fibrinogen, albumin, TG and CRP predicted composite CV events in   (Weiner et al., 2008) 
 Soluble plasma glycoprotein, eGFR 51±9ml/min/1.73m
2
  an adult general population cohort over median duration of 108 months. 
 produced in the liver, converted (n=1,678) 
 by thrombin into fibrin 
    CKD stages 3-4 (n=128) Prospective cohort Elevated fibrinogen independently predicted all cause mortality stage 3-4 CKD. (Goicoechea et al., 2008) 
        
Inflammation 
TNF-alpha   Pre-dialysis and dialysis Cross-sectional Raised circulating levels of TNF-alpha, IL-6 and CRP were associated with  (Bolton et al., 2001) 
 Cytokine involved in acute phase CKD (n=87)   reduced FMD compared with controls.    
 reaction, produced chiefly by 
 activated macrophages 
       
CRP   Pre-dialysis CKD, CrCl Cross-sectional During stepwise multivariate analysis, adjusting for age and gender, CRP  (Stenvinkel et al., 1999) 
 Acute phase response protein,  7+/-1 ml/min (n=109)  remained associated with an increased carotid intima-media area.  
 member of the pentraxin    
 superfamily   CKD stage 5, HD  Prospective cohort A synergistic effect of proinflammatory cytokines (CRP, IL-6, IL-8, albumin) (Panichi et al., 2008)  
    (n=757)   was demonstrated in predicting all cause and CV mortality over 30 months. 
 
   MDRD study, CKD  Prospective cohort High CRP independently predicted all cause and CV mortality over a median of  (Menon et al., 2005) 
   stages 3-4 (n=697)   125 months. 
 
IL-6   CKD stage 5 on dialysis Prospective cohort IL-6 was a stronger predictor of all cause and CV mortality than CRP over an (Tripepi et al., 2005) 
 Inflammatory cytokine, key (n=217)   average duration of 41 months. 
 factor in the acute phase   
 response  CKD stage 5 on dialysis Prospective cohort In a stepwise multiple regression model, IL-6 predicted changes in the (Stenvinkel et al., 2002) 
   (n=45)   carotid-intima media area independently of traditional risk factors.  
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PTX3   CKD stages 3-4 (n=71) Prospective cohort  In a post hoc analysis, PTX3 positively correlated with CV events and mortality. (Tong et al., 2007)  
 Member of the pentraxin  
 superfamily, released by   CKD stage 5, dialysis and Cross-sectional PTX3 levels were significantly higher in patients with a history of coronary  (Boehme et al., 2007) 
 monocytes, fibroblasts and non-dialysis (n=132)   artery disease and peripheral artery disease as well as those on HD.   
 endothelial cells  
 
sTWEAK    
 Binds to Fn14 receptor to induce Non-diabetic, non-dialysis Prospective cohort PTX3 and carotid IMT increased, whereas FMD and sTWEAK decreased with (Yilmaz et al., 2011a) 
 expression of cell adhesion  CKD stages 1-5 (n=257)  worsening renal function. sTWEAK levels predicted mortality after a median  
 molecules and cytokines,      of 39 months independent of traditional risk factors and FMD. 
 downregulated in atheroma     
         
    CKD stage 5 on chronic HD Cross-sectional Serum sTWEAK concentrations were lower in HD patients compared with  (Kralisch et al., 2008) 
    (n=120)   controls and lowest in patients with both ESRD and T2DM.   
  
 
CD14++ & CD16+ monocytes Non-dialysis CKD patients Prospective cohort CD14(++)CD16(+) monocytes were independently associated with CV events (Rogacev et al., 2011) 
 “Pro-inflammatory” monocyte (n=119)   over a median of 4.9 years. 
 subset  
 
AGEs   Diabetic and non-diabetic  Cross-sectional Levels of AGE peptides inversely  correlated with creatinine clearance and (Makita et al., 1991) 
 Product of irreversible   CKD (n=27)   were elevated in patients with diabetes. 
 covalent cross-linking of       
 collagen and elastin with  CKD stage 5 on HD (n=312) Prospective cohort Total serum fluorescent AGEs were 3-fold higher compared to healthy (Schwedler et al., 2002) 
 carbohydrates or carbonyls    controls although were associated with better survival over 32 months.    
 
sRAGE and EN-RAGE (S100A12) CKD stage 5 on HD (n=234) Prospective cohort sRAGE and EN-RAGE levels were significantly elevated compared to healthy  (Nakashima et al., 2010) 
 The soluble receptor of AGE and     controls. EN-RAGE, but not sRAGE, was independently and positively associated 
 its proinflammatory ligand     with CV mortality over a median follow up of 41 months.    
   
Abbreviations: ADMA, asymmetric dimethylarginine; AGEs, advanced glycation endproducts; ADPKD, adult polycystic kidney disease; AOPP, advanced oxidation protein products; ARIC, 
Atherosclerosis Risk in Communities; CD, cluster of differentiation; CHS, Cardiovascular Health Study; CKD, chronic kidney disease; CrCl, creatinine clearance; CRIB, Chronic Renal Impairment in 
Birmingham study; CRP, C-reactive protein; CV, cardiovascular; CVD, cardiovascular disease; EMP, endothelial microparticle; EN-RAGE, extracellular newly identified RAGE-binding protein; EPC, 
endothelial progenitor cell; ESRD, end-stage renal disease; sFlt-1, soluble fms-like tyrosine kinase-1; FMD, flow mediated dilatation; Fn14, fibroblast growth factor-inducible 14; eGFR, estimated 
glomerular filtration rate; Gp1b, glycoprotein 1b; HD, haemodialysis; H2O2, hydrogen peroxide; IL-6, interleukin-6; IL-8, interleukin-8; IMT, intima-media thickness; LV, left ventricular; LVH, left 
ventricular hypertrophy; MDRD, Modification of Diet in Renal Disease; MPO, myeloperoxidase, eNOS, endothelial nitric oxide synthase; NO, nitric oxide; oxLDL, oxidised low-density lipoprotein; PD, 
peritoneal dialysis; PTX3, pentraxin-3; PWV, pulse wave velocity; sRAGE, soluble receptor for advanced glycation endproducts; TNF-alpha, tumour necrosis factor-alpha; sTWEAK, soluble tumour 
necrosis factor-like weak inducer of apoptosis; T1DM, type 1 diabetes mellitus; T2DM, type 2 diabetes mellitus; VCAM; vascular cell adhesion molecule-1; sVEGFR-1, soluble vascular endothelial 
growth factor receptor-1; VEGF, vascular endothelial growth factor; vWF, von Willebrand factor. 
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Table 1-3. Key Human Studies Investigating Molecular Mechanisms of Arteriosclerosis in Chronic Kidney Disease. 
 
Factor/Mechanism Study population Study type Study outcomes Reference 
Vascular calcification 
Ca, PO4, PTH  CaNPREDDICT study Retrospective Mortality was associated with higher PO4, higher PTH and reduced Vitamin D (Levin et al., 2008)     
 Key mediators of bone CKD stage 4 (n=4,321)
   
over a median follow up of 31 months. 
 metabolism and vascular       
 calcification MESA study, CKD Cross-sectional Modest elevation of PO4 (even within the normal reference range) was (Adeney et al., 2009) 
   stage 3 (n=439)     associated with a greater prevalence of coronary, aortic and valvular 
         calcification, independent of PTH, vitamin D and traditional risk factors. 
      
  CKD stage 5 on HD  Prospective cohort Elevated serum PO4, Ca x PO4 product and PTH product was strongly  (Ganesh et al., 2001) 
   (n=12,833)       associated with cardiac mortality (especially sudden cardiac death) over 2 years. 
 
   Non-diabetic CKD    Cross-sectional Serum PO4 was independently associated with LV mass.  (Chue et al., 2012a) 
   stages 2-4 (n=208) 
 
Vitamin D   CKD stage 5 on HD  Case control Decreased levels of 25-(OH)D and 1,25-(OH)2D3 were associated with increased  (Wolf et al., 2007)  
 The kidney converts 25-(OH)D  (n=1,000)      all cause mortality within 90 days of starting dialysis. 
 to its active hormonal form  
 1,25-(OH)2D3   PRIMO study, CKD  Randomised Forty-eight weeks’ therapy with active vitamin D did not reduce LV mass on  (Thadhani et al., 2012) 
    stages 3-4 (n=227)  controlled trial cardiac MRI or improve LV diastolic function on echocardiography.   
    
FGF-23   CKD stage 5 on HD (n=219)  Prospective cohort High FGF-23 levels were associated with all cause mortality and vascular  (Jean et al., 2009) 
 Secreted by osteoblasts and       calcification independent of serum phosphate. 
 osteocytes, regulates levels of  
 phosphate and 1,25-(OH)2D3 Pre-dialysis CKD (n=149) Prospective cohort Elevated FGF-23 predicted CV events over a mean follow up of 5 years. (Seiler et al., 2010) 
  
   CKD stages 2-3 (n=177) Cross-sectional FGF-23 was independently associated with Gensini score, a measure of (Kanbay et al., 2010)  
        coronary atheroma. 
 
   CRIC study, CKD (n=411)  Prospective cohort Baseline FGF-23 levels independently predicted new onset LVH on   (Faul et al., 2011) 
   eGFR 20-70ml/min/1.73m
2
  echocardiography at 2.9 ± 0.5 years. 
    
α-Klotho   CKD stage 5 (n=21)    Cross-sectional Western blot showed reduced vascular Klotho protein expression associated   (Lim et al., 2012) 
 A cofactor for FGF-23 and         with extensive medial calcification in explanted human renal and epigastric 
 an endogenous inhibitor of       arteries. 
 vascular calcification          
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Fetuin-A  CKD stage 5 on HD  Cross-sectional Lower levels of fetuin-A were associated with CV and all cause mortality over (Ketteler et al., 2003) 
 Inhibitor of mineralisation, (n=312)     32 months.     
 downregulated in the acute    
 phase response         
      
OPG   CKD stage 5 on HD   Prospective cohort Increased OPG levels were associated with progression of aortic calcification (Nitta et al., 2003) 
 Member of the TNF receptor (n=26)      over a mean period of 5 years. 
 superfamily, osteoclastogenesis        
 inhibitory factor   CKD stage 5 on HD   Prospective cohort Elevated OPG levels predicted CV and all cause mortality over 2 years.  (Morena et al., 2006) 
    (n=185)    
 
Collagen/Fibrosis  
PIIINP   CRIB II study, CKD  Randomised PIIINP levels were increased in CKD in association with LV diastolic dysfunction;  (Edwards et al., 2010)
 Circulating biomarker of  stages 2-4 (n=112)  controlled trial this increase was attenuated by 40 weeks treatment with spironolactone.    
 collagen synthesis, degradation         
 product of type III collagen         
        
C1TP    RRI-CKD study, CKD    Cross-sectional Both PIIINP and C1TP values were significantly higher in more advanced  (Dellegrottaglie et al., 2011) 
 Marker of type I collagen   stages 3-5 (n=242)      stages of CKD. PIIINP was associated with PWV.      
 degradation              
        
Renin-angiotensin-aldosterone system 
Angiotensin II   CKD stage 5 on HD Prospective cohort Blood pressure lowering with an ACEI in combination with decreased PWV  (Guerin et al., 2001) 
 Vasoconstrictor, promotes  (n=150)   was associated with reduced all cause and CV mortality.    
 inflammation by stimulating   
 VSMC to generate oxygen  CRIB II study, CKD Randomised  The addition of spironolactone to ACEI/ARB treatment significantly reduced  (Edwards et al., 2009)  
 free radicals, induces   stages 2-4 (n=112) controlled trial PWV and LV mass.  
 VSMC hypertrophy and    
 collagen synthesis 
 
Endothelial dysfunction, Oxidative stress and Inflammation 
Please refer to Table 1-2. 
Abbreviations: ACEI, angiotensin-converting-enzyme inhibitor; ARB, angiotensin receptor blocker; Ca, calcium; CaNPREDDICT, Canadian study of prediction of risk and evolution to dialysis, death and 
interim cardiovascular events over time; CKD, chronic kidney disease; CV, cardiovascular; CRIB II; chronic renal impairment in Birmingham study II; C1TP, carboxy-terminal telopeptide; 25-(OH)D, 25-
hydroxyvitamin D (calcifidiol); 1,25(OH)2D3, 1,25-dihydroxyvitamin D3 (calcifitriol); FGF-23, fibroblast growth factor-23; HD, haemodialysis; LV, left ventricular; MESA, multi-ethnic study of 
atherosclerosis; OPG, osteoprotegerin; PIIINP, Procollagen III N-Terminal Propeptide; PO4, phosphate, PRIMO, Paricalcitol Capsules Benefits in Renal Failure Induced Cardiac Morbidity in Subjects 
With Chronic Kidney Disease Stage 3/4; PTH, parathyroid hormone; PWV; pulse wave velocity; RRI; Renal Research Institute; VSMC, vascular smooth muscle cell.
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1.6.1. Endothelial Dysfunction 
 
The vascular endothelium is recognised as having multiple, complex functions which regulate 
vascular tone, thrombosis, haemostasis, permeability and cell adhesion. It releases 
vasodilatory substances such as nitric oxide (NO), prostacyclin, C-type natriuretic peptide 
and endothelium-derived hyperpolarizing factor, as well as vasoconstrictors including 
endothelin-1 (ET-1), angiotensin II and thromboxane A2 (Endemann and Schiffrin, 2004). 
Endothelial dysfunction or, more correctly “endothelial activation”, is considered a key 
initiating step in atherogenesis (Table 1-2) and also contributes to arterial stiffening (Table 
1-3). Indeed, ED due to chronic inflammation and oxidative stress is thought to be an early 
and important feature of CKD (Schiffrin et al., 2007). It has been implicated as one of the 
chief pathophysiological mechanisms contributing to the association of cardiovascular 
disease and CKD (Stam et al., 2006) and may, in part, explain the strength of the graded 
correlation between worsening renal function and increasing cardiovascular risk (Schiffrin et 
al., 2007, Go et al., 2004).  
 
Measuring endothelial function in carefully defined cohorts of subjects with CKD offers 
promise as a method to examine the pathogenesis of atheroma in CKD. There remains 
however, a lack of clinical studies examining ED in subjects specifically with reduced GFR, 
particularly in those with early-stage CKD. Where data on ED in CKD does exist, reports are 
often conflicting. Early studies using flow-mediated-dilatation and circulating biomarkers 
suggested that patients with early stage CKD had deranged endothelial function 
(Thambyrajah et al., 2000, Stam et al., 2006, Bolton et al., 2001). More recent work has 
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suggested that this may have been due to the inclusion of patients with other risk factors 
such as hypertension, vasculitis, smoking and even established vascular disease, and that if 
these factors are excluded as far as possible, endothelial function is abnormal only in more 
advanced (stages 4 and 5) CKD (Lilitkarntakul et al., 2011). This inference is however, difficult 
to reconcile with the evidence that early stage CKD patients have multiple factors known to 
cause ED such as inflammation, oxidative stress, increased circulating asymmetrical 
dimethylarginine (ADMA) and RAAS activation (Moody et al., 2012b, Yilmaz et al., 2009, 
Yilmaz et al., 2010b). The precise relationship between GFR and ED remains to be elucidated 
and many potential mechanisms are still under investigation (Table 1-2 and Table 1-3).  
 
Abnormalities in vascular endothelial function amongst patients with CKD were originally 
described in patients with ESRD maintained on dialysis. In a cross-sectional analysis, 
endothelium-dependent, but not endothelium-independent, vasodilatation of the brachial 
artery was markedly reduced in 28 chronic haemodialysis subjects compared with 28 healthy 
controls (Van Guldener et al., 1997). The same investigators then showed FMD was similarly 
reduced in a group of peritoneal dialysis patients compared with age-matched controls (Van 
Guldener et al., 1998). A later cross-sectional study demonstrated both lower FMD and 
endothelium-independent dilatation in 114 chronic haemodialysis patients compared with 
49 age- and sex-matched controls (Yildiz et al., 2003). Flow-mediated-dilatation was 
independently associated with LV mass index, suggesting ED might cause decreased 
elasticity of the arterial vasculature and contribute to the development of LV hypertrophy. 
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Subsequent studies have also demonstrated the presence of ED in patients with ESRD 
(Luksha et al., 2011). 
 
The first published study to include early-stage CKD patients in an assessment of endothelial 
function involved measurement of FMD by ultrasound assessment of the brachial artery in 
80 non-diabetic CKD patients (eGFR 14 – 54 ml/min/1.73m2); FMD was significantly reduced 
compared with 26 normal controls (median (interquartile range), 2.6% (0.7 to 4.8%) vs. 6.5% 
(4.8 to 8.3%); p < 0.001) (Thambyrajah et al., 2000). There was no significant difference in 
FMD between GFR quartiles (1st quartile median GFR 49 (46 to 54); 4th quartile median GFR 
16 (14 to 18)), however, suggesting that ED occurs early in the course of renal disease. 
Similar findings were reported by another UK group who compared endothelial function in 
patients with angina, patients with pre-dialysis CKD (creatinine clearance <50 ml/min) and 
those on dialysis with healthy controls (Bolton et al., 2001). Flow-mediated-dilatation was 
severely reduced in all groups compared to controls (patients with both pre-dialysis and 
dialysis dependent CKD had similar values to those with angina) whilst endothelial-
independent dilatation was preserved in each group. Circulating levels of inflammatory 
cytokines (IL-6 and TNF-alpha), C-reactive protein and VCAM-1 were elevated in pre-dialysis 
patients compared with controls.  
 
In the Hoorn population cohort study, a series of biomarkers of ED were measured at 
baseline in 613 subjects aged 50 to 75 years in whom renal function was only mildly 
impaired (mean eGFR 68 ± 12 ml/min/1.73m2) (Stam et al., 2006). Estimated GFR was 
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inversely associated with soluble VCAM-1, von Willebrand Factor (vWF) and urinary ACR but 
not markers of inflammation. Over a median follow up period of 12.5 years, sixty-seven 
individuals from the original cohort died from cardiovascular causes. The relative risks (95% 
CI) of cardiovascular and all-cause mortality associated with a decrease of 5 ml/min/1.73m2 
of eGFR were 1.22 (1.09 to 1.36) and 1.12 (1.05 to 1.20), respectively. After adjustment for 
biomarkers of endothelial function, the strength of this association was markedly 
attenuated.   
 
The concept that ED is present even in patients with minor renal dysfunction and contributes 
to increased cardiovascular risk, was further supported by a large prospective cohort study 
(Yilmaz et al., 2011b). In 304 non-dialysis outpatients attending renal clinics, uniformly 
distributed across stages 1-5 CKD, a cross-sectional analysis showed highly sensitive C-
reactive protein (hsCRP) and carotid IMT had a graded inverse relationship with eGFR, whilst 
FMD decreased with declining renal function. After a median follow-up of 42 months, FMD 
was shown to predict adverse cardiovascular outcomes even after adjustment for age, sex, 
blood pressure, total cholesterol, eGFR, diabetes, and medical history of cardiovascular 
disease at baseline. In a Cox regression model containing FMD, hsCRP and carotid IMT, both 
FMD and hsCRP but not IMT were significant predictors of adverse cardiovascular events. 
The authors concluded the clinical use of FMD is preferred over IMT measurements to 
monitor early-stage CKD patients at risk. Nonetheless, there is abdundant evidence 
supporting carotid IMT as an important prognostic indicator. Indeed, a series of paediatric 
studies used carotid IMT as a surrogate marker of ED, demonstrating increases in as early as 
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stage 2 CKD and often within the first decade of life (Litwin and Niemirska, 2009, Litwin et 
al., 2008). Likewise, in an adult cross-sectional study of 38 pre-dialysis (stage 3 to 4 CKD), 18 
haemodialysis and 22 kidney-transplant patients, FMD was impaired whilst CRP and IMT 
were increased when compared with controls (Recio-Mayoral et al., 2011). There was a 
significant positive correlation between eGFR and FMD although in pre-dialysis patients, 
there was only a non significant trend towards impaired FMD (predialysis 3.2% vs. controls 
5.6 %). 
 
Endothelial dysfunction is a prerequisite for atherogenesis. Disruption of signalling of 
endothelium-derived relaxing factors occurs at an early stage in atherosclerosis and 
precedes development of lipid streaks and plaques (Schiffrin et al., 2007). Progressive 
deterioration of renal function in CKD is associated with the accumulation of uraemic toxins 
(Table 1-4) which may stimulate oxidative stress and inflammation, and in turn contribute to 
ED and progression of atheroma. Dyslipidaemia associated with CKD also contributes to the 
inflammatory response in renal failure with changes in blood-lipid composition (Schiffrin et 
al., 2007). Cardiovascular calcification in CKD patients is more prevalent, progressive, 
extensive and severe compared with the non-CKD population, and results from both 
disturbed mineral metabolism (see Section 1.6.3) and a complex, active process of 
osteogenesis in vascular smooth muscle cells (VSMCs) (Chue et al., 2010). 
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Table 1-4. Potential Uraemia-related Risk Factors Predicting Cardiovascular Disease or Outcome in 
Patients with Chronic Kidney Disease. 
Category of risk factor Biomarkers 
Endothelial dysfunction ADMA, EMP, PTX3, VCAM, EPC, albuminuria, 
vWF 
Inflammation  IL-6, IL-18, S-albumin, WBC, fibrinogen 
hyaluronan TNF-α, MPO, CRP, PTX3, PAI-1  
Oxidative Stress MPO, oxLDL, AOPP, homocysteine 
Protein-energy wasting serum albumin, serum creatinine, prealbumin 
Uraemic toxins S-creatinine, p-cresylsulphate 
Vascular calcification PO4, Ca, Mg, PTH, fetuin-A, OPG, OPN, FGF-23 
Sympatho-activation Norepinephrine 
Coagualtion/fibrinolysis disorders Fibrinogen, vWF 
Adipokines Adiponectin, visfatin, leptin 
 
Subclinical hypothyroidism “low T3 condition” fT3, T3 
 
Insulin resistance HOMA, AGEs 
 
Cardiac NT-pro-BNP, Troponin T 
 
Anaemia Haemoglobin 
 
Abbreviations: ADMA, asymmetric dimethylarginine; AGEs, advanced glycation end-products; AOPP, 
advanced oxidation protein products; CKD, chronic kidney disease; CRP, C-reactive protein; EMP, 
endothelial cell-derived microparticle; EPC, endothelial progenitor cell; FGF-23, fibroblast growth 
factor 23; HOMA, homeostasis model assessment method; IL, interleukin; MPO, myeloperoxidase; 
OPG, osteoprotegerin; OPN, osteopontin; oxLDL, oxidized low-density lipoprotein; PAI-1, 
plasminogen activator inhibitor 1; PTH, parathyroid hormone; PTX3, pentraxin-3; NT-pro-BNP, N-
terminal pro-brain natriuretic peptide; T3, triiodothyronine; TNF-α, tumour necrosis factor-α; vWF, 
von Willebrand factor; VCAM, vascular cell adhesion molecule; WBC, white blood cell count. (Moody 
et al., 2012b).  
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Endothelial dysfunction also contributes to arteriosclerosis, a disease affecting the media of 
large and middle sized arteries with an increased calcification, an increased collagen : elastin 
ratio, and hyperplasia and hypertrophy of VSMCs (see Section 1.5.2). Whilst increased 
arterial stiffness is caused primarily by structural changes, there appears to also be an 
important major functional contribution from the vascular endothelium. Marked increases in 
arterial stiffness as measured by PWV have been demonstrated in response to NOS 
inhibitors, with reductions in response to exogenous NO donors (Chue et al., 2010).  
 
The potential pathophysiological mechanisms responsible for ED in CKD are diverse and a 
more detailed account of these biological mechanisms is available elsewhere (Endemann 
and Schiffrin, 2004, Stenvinkel et al., 2008). A list of proposed mediators is given in Table 1-4. 
Systemic inflammation and oxidative stress are almost universal in CKD and result in ED by 
decreasing the bioavailablity of NO via reductions in nitric oxide synthase (NOS) activity and 
the production of peroxynitrite, a cytotoxic oxidant which leads to oxidation of LDL and 
uncoupling of endothelial NOS (eNOS) (Endemann and Schiffrin, 2004). There is also growing 
evidence to support a role for ADMA, a product of protein turnover and potent endogenous 
inhibitor of eNOS (Endemann and Schiffrin, 2004). Plasma ADMA levels are elevated in CKD 
because the kidney is the principal organ for excretion of ADMA and there is reduced activity 
of the enzyme dimethylarginine dimethylaminohydrolase. Increased ADMA levels are 
strongly associated with ED, carotid IMT, concentric LV hypertrophy and LV dysfunction 
(Endemann and Schiffrin, 2004). Higher ADMA levels have also been shown to predict faster 
rates of decline in GFR in subjects with early-moderate CKD as well as overall mortality 
(Endemann and Schiffrin, 2004). Numerous other uraemic toxins have been implicated in 
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causing adverse changes in endothelial function including the protein-bound solute p-cresol. 
More recently, its conjugate p-cresylsulphate, the principal end product of phenol 
metabolism, has emerged as the primary culprit for toxicity; it predicts mortality in ESRD and 
triggers an increase in endothelial microparticle release (Liabeuf et al., 2010).  
 
A number of studies have examined interventions aimed at improving endothelial function 
in CKD although results have been disappointing. Most trials have been small-scale and 
many have lacked a control group. In a small, unblinded, uncontrolled study of ESRD 
patients, administration of soy proteins improved endothelial function and decreased ADMA 
levels (Cupisti et al., 2007). A reduction in ADMA has also been reported in a small but 
randomized study of lipoic acid in 50 patients with ESRD (Chang et al., 2007). Whilst a 
reduction in ADMA levels also occurred following statin therapy in patients with 
hypercholesterolaemia (Lu et al., 2004), no such effect was seen in the Antioxidant Therapy 
in Chronic Renal Insufficiency (ATIC) study of patients with stage 2-4 CKD (Nanayakkara et 
al., 2009). This randomized double blind controlled trial did, however, demonstrate 
increased FMD, reduced carotid IMT and reduced urinary albumin excretion after 18 months 
of a regimen including pravastatin, vitamin E supplementation and homocysteine-lowering 
therapy (Nanayakkara et al., 2007). Statins have also been shown to improve FMD in non-
diabetic patients undergoing peritoneal dialysis (Han et al., 2011) and may exert pleiotropic 
effects by increasing the number of circulating EPC (Tousoulis et al., 2011). In contrast, a 
randomised double blind controlled study of children with stage 3-4 CKD failed to show any 
improvement in FMD after 8 weeks of atorvastatin (Mackie et al., 2010). A randomized, 
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double blind placebo controlled study including both non-diabetic and diabetic patients with 
CKD stage 3-4 showed short-term rosiglitazone therapy reduced vWF but had no effect on 
FMD or arterial stiffness (Chan et al., 2011). 
 
 
1.6.2. The Renin-Angiotensin-Aldosterone System 
 
It is unclear as to the exact mechanism but there appears to be RAAS activation in CKD which 
has deleterious effects on the cardiovascular system as a result of the actions of both 
angiotensin II and aldosterone (Brown, 2008, Quarles, 2013). Elevated aldosterone levels are 
the result of two mechanisms;  aldosterone “escape” describes inappropriately elevated 
plasma levels relative to salt and fluid overload (Struthers, 2004) while aldosterone 
“breakthrough” refers to persistently high levels despite treatment with ACE inhibitors and 
angiotensin receptor blockers (Schrier, 2010). It is now well recognised that aldosterone, 
probably produced locally as well as by the adrenal cortex, exerts injurious actions directly 
on the myocardium and vasculature. Aldosterone mediated oxidative stress and 
inflammation result in structural fibrotic change within the arterial wall and myocardium 
(Brown, 2008). These features may result from both genomic actions via mineralocortcoid 
receptor (MR) activation and non genomic actions. The adverse inflammatory effects of 
aldosterone are powerfully potentiated and may be dependent upon the presence of 
sodium excess. The combination of high levels of aldosterone and sodium overload is 
unusual as aldosterone production is usually suppressed by sodium overload but 
aldosterone “escape” is a characteristic of both heart failure (in which mineralocorticoid 
 42 
 
receptor blockers (MRB) have proven efficacy (Zannad et al., 2011, Pitt et al., 1999)) and CKD 
(Struthers, 2004).  
 
Aldosterone causes a range of other adverse vascular effects including ED, autonomic 
dysfunction, vasoconstriction and hypertension (Farquharson and Struthers, 2000, Funder, 
2010). Aldosterone decreases endothelial NO by increasing NADPH oxidase activity and 
generation of reactive oxygen species (Struthers and Macdonald, 2004). In a rabbit model, 
aldosterone decreased tetrahydrobiopterin, an important cofactor for eNOS activity and NO 
production, whilst the MRB eplerenone improved tetrahydrobiopterin levels and restored 
NO synthesis (Rajagopalan et al., 2002). Angiotensin II infusion in rats caused ED by oxidant 
stress from the stimulation of NADPH oxidase and uncoupling eNOS (Lobysheva et al., 2011). 
All of these deleterious actions, including inflammation and fibrosis, occur in the 
myocardium and in the kidney itself thereby causing further glomerular injury and setting up 
a toxic feed-forward loop of renal and vascular damage (Del Vecchio et al., 2007). 
 
Aldosterone and angiotensin II have also been associated with adverse LV geometry in small 
cross-sectional studies of patients with reduced GFR resulting from essential arterial 
hypertension (Muscholl et al., 1998, Nakahara et al., 2007). In a large community-based 
sample of 2119 Framingham Offspring Study participants, increased aldosterone-to-renin 
ratio independently predicted both concentric and eccentric hypertrophy in multivariable 
models (Velagaleti et al., 2008). Taken together, these data support a major role for RAAS 
activation in adverse LV remodelling.   
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Myography studies have shown that RAAS blockade in hypertensive type 2 diabetic patients 
with an ACE inhibitor or an angiotensin II receptor blocker (ARB) restored endothelial 
function and improved resistance artery remodelling (Rizzoni et al., 2001, Savoia et al., 
2006). This effect was thought to be independent of blood pressure since beta-1 
adrenoreceptor blockade with a similar degree of blood pressure lowering did not have an 
effect on endothelium-dependent vasodilatation. In subtotally nephrectomised rats, MRB 
therapy reduces arterial stiffness (Lacolley et al., 2002) as well as proteinuria and LV 
hypertrophy (Greene et al., 1996). These animal data are consistent with the theory that 
RAAS inhibition reduces risk at least in part, via a blood pressure independent mechanism. 
 
In further support of this paradigm, a recent study involving hypertensive diabetic patients 
with stage 1 CKD (24-h protein excretion ≥ 500 mg/d, systolic blood pressure ≥ 140 mmHg 
and/or diastolic blood pressure ≥ 90 mmHg) showed that treatment with valsartan improved 
FMD and normalized proteinuria, PTX3, and TWEAK (Yilmaz et al., 2010a) although the study 
was uncontrolled. In a similar longitudinal study of diabetic patients, the same investigators 
showed a beneficial effect of ramipril on FMD and proteinuria, accompanied by a reduction 
in levels of ADMA (Yilmaz et al., 2010b). Finally, in a study of 150 patients with CKD stage 5D 
given ACE inhibitor therapy over an average of 4 years, mortality benefit was only evident in 
those subjects with reduced PWV and absent in those subjects with unchanged PWV despite 
similar reductions in blood pressure (Guerin et al., 2001). 
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In patients with reduced GFR in association with chronic heart failure, the addition of a MRB 
to an ACE inhibitor improved endothelial function as measured by the vasodilator response 
to acetylcholine (Farquharson and Struthers, 2000). Several studies of CKD patients have 
shown spironolactone also reduces proteinuria (Struthers and Macdonald, 2004), and slows 
the progression of carotid IMT (Vukusich et al., 2010). Possible mechanisms of action of 
MRBs on endothelial function include reduced concentration of macrophage oxidized LDL 
cholesterol, increased NO bioavailability, up-regulation of endothelial-dependent 
vasodilators such as prostacyclin and endothelium-derived hyperpolarising factor, 
attenuation of angiotensin I-mediated vasoconstriction and improved endothelial signalling 
pathways leading to NO synthase synthesis (Struthers and Macdonald, 2004). 
 
The use of MRB therapy prevents many of the adverse effects of aldosterone both in vitro 
and in live animal studies (Luther et al., 2012) suggesting that providing these agents can be 
tolerated without serious hyperkalaemia in patients with CKD, they may be able to prevent 
or even reverse arterial stiffening and LV hypertrophy and fibrosis.  In a preliminary proof of 
concept study of patients with early-moderate CKD, the effects of spironolactone on PWV 
(determined by SphygmoCor) and LV mass (determined by cardiac MRI) were compared with 
placebo (Edwards et al., 2009). After 40 weeks, significant reductions in both PWV and LV 
mass were observed in the spironolactone group. Adverse effects such as hyperkalaemia 
were very infrequent suggesting that treatment is safe so long as appropriate monitoring is 
in place (Edwards et al., 2012). Further work is currently underway in the SPIRO-CKD study 
(EudraCT: 2013-002636-25) with the aim of confirming safety and to clarify the degree to 
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which these improvements in LV and arterial function were specific to MR blockade or 
secondary to blood pressure reduction. 
 
Data are beginning to emerge on the effects RAAS blockade on hard outcomes in CKD.  A 
meta-analysis of RAAS blockade either by an ACE inhibitor or ARB in CKD demonstrated a 
significant reduction in cardiovascular events and incident rate of heart failure compared to 
placebo, although no survival benefit was observed (Balamuthusamy et al., 2008). More 
recently, in a 3-year randomized trial of 309 haemodiaysis patients, subjects randomized to 
receive 25 mg spironolactone had a reduction in the composite primary outcome of 
cardiovascular death or hospitalization from cardiovascular cause compared to placebo 
(Matsumoto et al., 2014). There is now a call for larger studies such as the BARACK D 
(Benefits of Aldosterone Receptor Antagonism in Chronic Kidney Disease) trial to confirm the 
efficacy of MRB agents in CKD patients (Hill et al., 2014). 
 
1.6.3. Vitamin D, Parathyroid Hormone and Fibroblast Growth Factor-23  
 
Two of the key hormones involved in the regulation of calcium and phosphate homeostasis 
are parathyroid hormone (PTH) and fibroblast growth factor-23 (FGF-23). In response to 
hypocalcaemia or a phosphate load, PTH is secreted by the parathyroid glands serving to 
increase renal calcium reabsorption and increase phosphate excretion. Parathyroid hormone 
also raises the plasma calcium level by releasing calcium from the bones and stimulates the 
renal enzyme 1-α-hydroxylase to increase levels of the active form of vitamin D (1,25-
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dihydroxvitamin D) thereby promoting gastrointestinal absorption of phosphate and 
calcium. Fibroblast growth factor-23 is a phosphatonin hormone secreted primarily by 
osteocytes in bone in response to increased serum phosphate levels. It serves to reduce the 
expression and activity of Na/Pi co-transporters in the proximal renal tubules (Shimada et 
al., 2004), lowers serum levels of 1,25-dihydroxyvitamin D by inhibiting renal expression of 1-
α-hydroxylase (Saito et al., 2003), and suppresses synthesis of PTH (Martin et al., 2012a). It 
also stimulates expression of the catabolic enzyme 24-hydroxylase, resulting in reduced 
gastrointestinal phosphate absorption (Saito et al., 2003). The renal tubular effects of FGF-23 
are mediated by FGF receptors (chiefly FGFR-1); the interaction between FGF-23 and FGFR-1 
is facilitated by α-Klotho, a transmembrane protein co-receptor which increases the binding 
affinity of FGF-23 (Martin et al., 2012a, Urakawa et al., 2006). 
 
As well as having effects on the “classical” PTH target organs (the kidney, gut and bone), it 
appears that PTH may also have direct biological actions on the heart (Bro and Olgaard, 
1997). This is inferred from the presence of PTH receptors in the myocardium and further, 
the induction of cardiomyocyte hypertrophy with PTH in vitro (Schluter and Piper, 1998). 
Parathyroid hormone is recognised to stimulate the protein kinase C pathway, which has 
been implicated in the hypertrophy of cardiomyocytes (Ferreira et al., 2011). There are also 
clinical data supporting PTH as a key mediator in the development of left ventricular 
hypertrophy. Parathyroid hormone was originally proposed as a potential mediator of LVH 
among patients with ESRD and secondary hyperparathyroidism (Harnett et al., 1988). 
Perhaps the strongest evidence for PTH having a causal role in the development of LV 
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hypertrophy is available from an elegant case-control study of patients with primary 
hyperparathyroidism; at baseline there was a high prevalence of LV hypertrophy that 
significantly improved following parathyroidectomy without an accompanying change in 
mean blood pressure (Piovesan et al., 1999). This relationship is also evident among 
community-dwelling subjects in whom serum PTH levels are independently associated with 
higher LV mass (Saleh et al., 2003). In the Cardiovascular Health Study, 25-hydroxyvitamin D 
deficiency in conjunction with elevated concentrations of PTH observed in elderly patients 
with early-moderate CKD were associated with adverse cardiovascular events over 14 years 
of follow up (Kestenbaum et al., 2011). Whilst deficiency in 25-OHD deficiency was 
associated with myocardial infarction and mortality, PTH excess was associated with incident 
heart failure, a finding supported by the data which links PTH to adverse LV remodelling. 
Parathyroid hormone may also accelerate cardiovascular calcification, including 
mineralisation of the aortic valve (Hekimian et al., 2013). Most recently, it has been shown 
that those subjects with CKD post aortic valve replacement (eGFR <60 ml/min/1.73m2) were 
more likely to have insufficient levels of 25-hydroxyvitamin D together with increased 
circulating levels of PTH (Laflamme et al., 2014). Once again, the elevated PTH in these 
subjects was independently associated with LV mass. 
 
There has also been increasing interest in the potential role of FGF-23 as a novel 
cardiovascular risk marker. Increased circulating levels of FGF-23 predict decline in renal 
function in community-based individuals (Rebholz et al., 2015). Moreover, FGF-23 levels are 
independently associated with the incident rate of atrial fibrillation (Mathew et al., 2014), 
heart failure, coronary heart disease, and cardiovascular and all-cause mortality (Lutsey et 
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al., 2014, Ix et al., 2012). However, the proposed mechanisms by which FGF-23 is linked to 
these adverse outcomes are contentious. There is powerful evidence from translational 
work that elevated FGF-23 has a direct causal role in the pathogenesis of LV hypertrophy 
(Faul et al., 2011). In an ethnically diverse cohort of 3,070 participants with CKD enrolled in 
the Chronic Renal Insufficiency Cohort (CRIC) study, circulating FGF-23 levels were increased 
in CKD and independently associated with LVH. In the same report, it was demonstrated in 
vitro that FGF-23 directly induces pathological hypertrophy of isolated cardiomyocytes and t 
in vivo that mice injected with either intraventricular or intravenous injection of FGF-23 
develop significantly more LV hypertrophy compared with vehicle-injected mice. Left 
ventricular hypertrophy was evident in α-Klotho-deficient mice, an accepted animal model 
for constitutively elevated FGF-23 levels. Furthermore, the klotho heterozygotes manifested 
FGF-23 levels and LV remodelling that were intermediate between those of wild-type and 
klotho-deficient mice. Finally, it was shown in the 5/6 nephrectomy rat model of CKD that 
pharmacological inhibition of FGFR with PD173074 attenuated the severity of LV 
hypertrophy without a reduction in blood pressure. 
 
Despite this robust series of experiments, the exact cellular mechanism for the adverse LV 
remodelling associated with increased FGF-23 remains contentious because α-Klotho has not 
been found in the myocardium (Faul et al., 2011). Another potential explanation is that FGF-
23 activates FGFR/α-Klotho co-receptors in the kidney, which indirectly leads to LV 
hypertrophy and cardiovascular mortality through RAAS activation (Quarles, 2013). In 
keeping with this theory, FGF-23 appears to be a potent inhibitor of angiotensin converting 
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enzyme-2 expression in the kidney (Dai et al., 2012), thereby preventing degradation of 
angiotensin I and II. This complex feedback system is further influenced by 1,25-
dihydroxyvitamin D, which itself inhibits renin gene transcription and blocks RAAS but also 
stimulates FGF-23 production in bone (Simpson et al., 2007). Thus, the action of 1,25-
dihydroxyvitamin D causing increased circulating levels of FGF-23 but inhibiting RAAS might 
have contradictory effects on the myocardium; this may explain the results of the PRIMO 
study in which calcitriol treatment (1,25-dihydroxyvitamin D) had no significant effect on LV 
remodelling (P = 0.06) (Thadhani et al., 2012). Furthermore, there are data from in vivo 
animal models showing angiotensin II suppresses renal α-Klotho expression and that α-
Klotho overexpression can mitigate angiotensin II–induced proteinuria (Mitani et al., 2002). 
Finally, in klotho-hypomorphic (kl/kl) mice, aldosterone directly stimulated vascular 
calcification by inducing Pit-1-dependent phosphate transport in vascular smooth muscle 
cells via direct activation of the MR receptor (Voelkl et al., 2013). In this model of α-Klotho 
deficiency, spironolactone increased life span in association with reduced vascular 
calcification lending further support to the notion that MRB therapy confers vascular 
protection at least in part, via blood pressure independent effects. 
 
In simple terms, the increased afterload caused by arterial calcification and stiffening 
together with hypertension should lead to LV hypertrophy. In truth, however, this concept 
maybe a gross over-simplification; the pathophysiology behind the development of LV 
hypertrophy and vascular calcification in relation to bone mineral disturbances in CKD 
(Chronic Kidney Disease–Mineral and Bone Disorder (CKD-MBD)) is undoubtedly complex, 
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and this is reflected by refractoriness to current therapies. Indeed, the recent results from 
clinical trials aimed at improving cardiovascular endpoints by correcting disturbances in 
mineral metabolism have thus far proved disappointing (Thadhani et al., 2012, Chertow et 
al., 2012, Chue et al., 2013b). A multifaceted strategy that includes targeting the proximate 
pathogenic factors such as PTH, FGF-23 and aldosterone may offer greater potential to 
improve cardiovascular outcomes in CKD. 
 
 
1.6.4. Erythropoietin and Anaemia 
 
Anaemia in CKD is typically normocytic, normochromic, and hypoproliferative (Babitt and 
Lin, 2012). Although generally normal or slightly increased in anaemia of CKD,  EPO levels are 
considered inappropriately low relative to the degree of anaemia, because similarly anaemic 
patients with normal kidney function have 10–100 times higher EPO levels (Mcgonigle et al., 
1984, Garcia et al., 1982). As well as the relative EPO deficiency, there are a number of other 
factors which contribute to anaemia of CKD including shortened erythrocyte survival, the 
presence of uraemic-induced inhibitors of erythropoiesis, and disordered iron homeostasis 
(Babitt and Lin, 2012).  
 
The effects of anaemia on the development of LV hypertrophy are well established in 
subjects with ESRD. In chronic anaemia, prolonged volume and fluid overload and increased 
cardiac work lead to progressive cardiac enlargement and LVH (Parfrey et al., 1996, Harnett 
et al., 1988). The extent of adverse left ventricular remodelling progresses in parallel with 
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changes in haemoglobin level (London, 2001). Importantly, the effects of chronic anaemia on 
the LV may not be limited to subjects with ESRD. In a prospective study of 246 patients with 
mild-moderate CKD and a baseline prevalence of LV hypertrophy of 36%, a 12-month decline 
in haemoglobin level independently predicted the increase in LV mass index measured using 
two-dimensional-targeted M-mode echocardiography (Levin et al., 1999). 
 
Early data from small-scale observational studies suggested that the correction of anaemia 
with EPO decreased cardiac output and heart rate, and might induce at least a partial 
regression of LV mass and delay the development of LV dilatation (Foley et al., 2000, Pascual 
et al., 1991). In subsequent randomized controlled trials however, the use of EPO stimulating 
agents have not been shown to reduce adverse outcomes associated with anaemia, such as 
mortality, nonfatal cardiovascular events, hospitalizations, and progression of kidney disease 
(Kdoqi, 2006). Moreover, recent trials in both haemodialysis and predialysis CKD patients 
demonstrate an increased risk of death, adverse cardiovascular events, and stroke by 
administering EPO stimulating agents to target haemoglobin levels >110 g/L (Pfeffer et al., 
2009, Singh et al., 2006, Besarab et al., 1998, Parfrey et al., 2005).  Similarly, in a meta-
analysis of 1731 ESRD and anaemic CKD subjects, conventional haemoglobin targets for EPO 
therapy of >100 g/L were associated with a reduction in LV mass index, but a target level of 
>120 g/L did not have a beneficial impact on adverse LV remodelling (Parfrey et al., 2009). 
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1.6.5. Uric acid 
 
Uric acid is generated during the metabolism of nucleotides and adenosine triphosphate 
(ATP) and represents the end-product of purine metabolism in humans, which is produced 
chiefly in the liver and intestines, but also by the endothelium, skeletal muscle and the 
kidneys (Kanbay et al., 2013). Under normal physiological conditions, two-thirds of the uric 
acid produced is excreted via the kidneys with one third eliminated via the biliary tract. In 
the kidney, urate is filtered readily by the glomerulus and then reabsorbed by the proximal 
tubules. The exact details of urate transport are poorly elucidated but it appears that, the 
efficiency with which the kidney reabsorbs urate contributes to hyperuricaemia. A number 
of factors play a role in elevating uric acid levels in CKD including the reduced GFR, frequent 
use of diuretics, increased renal vascular resistance, and co-existent insulin resistance (Jalal 
et al., 2013).   
 
Uric acid has a number of deleterious cellular actions which could explain the association 
between hyperuricaemia and adverse cardiovascular and renal outcomes. It is accepted that 
entry of uric acid into the cell induces oxidative stress and this is mediated by its direct 
reactions with superoxide and peroxynitrite (Sautin et al., 2007, Kuzkaya et al., 2005). This 
process generates several radicals, including the aminocarbonyl radical and the 
triuretcarbonyl radical (Imaram et al., 2010), as well as intermediates with alkylating activity 
(Gersch et al., 2008). Uric acid has also been implicated in the development of ED. Numerous 
studies show that the presence of intracellular uric acid is associated with a reduction in 
nitric oxide bioavailability via a number of pathways, including blocking uptake of L-arginine, 
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stimulating L-arginine degradation via arginase, and the scavenging of nitric oxide by uric 
acid or from uric acid generated oxidants (Kanbay et al., 2013). Treatment with L-arginine in 
rats blocks the adverse effects of hyperuricaemia on systemic hypertension and prevents 
preglomerular arteriolopathy. (Sanchez-Lozada et al., 2007). There is also evidence that uric 
acid may have a role in both systemic and intrarenal RAAS activation. In a renal histology 
study of the remnant kidney rat model of progressive renal failure, levels of uric acid were 
associated with the percentage of renin positive juxtaglomerular cells (Kang et al., 2001). 
 
Observational data have consistently demonstrated higher uric acid levels are associated 
with a greater risk of ischaemic heart disease, elevated blood pressure, and an adverse 
cardiovascular risk profile (Fang and Alderman, 2000, Liese et al., 1999, Sundstrom et al., 
2005, Bos et al., 2006). It remains possible however, that these findings result from 
unmeasured confounding or the phenomenon of reverse causality, whereby preclinical 
arteriosclerosis might lead to increased circulating levels of urate before a diagnosis of 
hypertension or LV hypertrophy is made. In a recent Mendelian randomisation analysis that 
used variation in the SLC2A9 gene (solute carrier family 2, facilitated glucose transporter 
member 9) as an instrument for uric acid (Vitart et al., 2008), there was no strong evidence 
for causal associations between uric acid and ischaemic heart disease or blood pressure 
among the 58702 participants assessed (Palmer et al., 2013).  
 
Nonetheless, evidence is emerging albeit from small interventional studies, that uric acid 
may represent a true cardiovascular risk factor and play a causal role in the pathogenesis of 
cardiovascular disease. Lowering uric acid levels with allopurinol reduced both office and 
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ambulatory blood pressure in hyperuricaemic adolescents with newly diagnosed 
hypertension (Feig and Johnson, 2003). A subsequent unblinded study performed in adult 
subjects with asymptomatic hyperuricaemia demonstrated only small benefits of allopurinol 
on blood pressure but improved endothelial function and eGFR after just 4 months of 
treatment (Kanbay et al., 2011). In a post hoc analysis of the RENAAL (Reduction of 
Endpoints in Non-insulin dependent diabetes mellitus with the Angiotensin II Antagonist 
Losartan) study it was suggested that one fifth of the protective renoprotective effect of 
losartan among patients with diabetic nephropathy could be attributed to the decrease in 
serum uric acid levels (Miao et al., 2011). Finally, in a randomised double-blind placebo-
controlled trial of CKD stage 3 patients with LV hypertrophy, lowering uric acid with a 
xanthine oxidase inhibitor resulted in a significant reduction in LV mass as measured by 
cardiac MRI but had no effect on blood pressure, implying that uric acid may have direct 
adverse effects on myocardial structure (Kao et al., 2011). After 9 months of treatment, 
there were also accompanying improvements in augmentation index (AIx) on pulse wave 
analysis and endothelial function as determined by FMD. Larger randomised studies are 
warranted to confirm these preliminary findings but the fact that uric acid levels can already 
be effectively and safely modified in CKD with low doses of allopurinol is encouraging. 
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1.7. Limitations to Studies of Cardiovascular Disease in Chronic Kidney Disease 
 
Lower estimated glomerular filtration rate (eGFR) has been consistently associated with an 
increased risk of major vascular events and death and a recent meta-analysis suggests that if 
this relationship is causal, up to one fifth of vascular events among those over 70 years could 
be attributed to reduced renal function (Mafham et al., 2011). Yet despite the wealth of 
evidence associating reduced GFR with an elevated cardiovascular risk, it is difficult to prove 
causality. Cross-sectional studies of CKD are almost invariably confounded by factors such as 
the underlying disease (e.g. hypertension, diabetes mellitus, systemic vasculitis) and the 
harmful sequelae of CKD which include hypertension, anaemia and inflammation. Thus, it 
remains possible that renal disease itself does not cause cardiovascular disease and merely 
represents a clustering of cardiovascular risk factors. A prospective longitudinal study of 
subjects who develop a decline in GFR and or albuminuria is required to examine the effects 
of new onset renal dysfunction on the cardiovascular system. In human studies this is 
difficult because the duration of kidney disease is seldom evident at the time of 
presentation. Kidney donors, however, provide a near ideal experimental model as they are 
a healthy population, screened to exclude confounding co-morbidity, in whom renal function 
declines suddenly at a known time point. Two thirds of donors will fall into the category of 
stage 3 CKD after donation (Moody et al., 2012a) and whilst initial survival data have been 
largely reassuring (Segev et al., 2010, Fehrman-Ekholm et al., 1997), a small adverse 
cardiovascular influence cannot be excluded because donors are “super-selected” for health 
and, therefore, have better predicted cardiovascular risk than healthy control populations. 
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1.8. Living Kidney Donors 
1.8.1. Current Status of Living Donor Kidney Transplantation 
 
Renal transplantation is the optimal treatment for patients with ESRD but demand continues 
to exceed the supply of cadaveric organs. This has led to a substantial growth in the practice 
of living kidney donation such that every year more than 27,000 adult  subjects worldwide 
elect to donate a kidney (Horvat et al., 2009). In the UK, there has been an increase in the 
number of annual living donor kidney transplants (Table 1-5); in 2012-13, living donations 
represented 36% of the total kidney transplant programme (NHSBT, 2013). Similarly, in the 
US and Canada, the number of living donor kidney operations performed has doubled over 
the last decade and accounts for over 40% of all kidney transplants (Knoll, 2008). This 
increased activity can be attributed to a number of factors including: improved patient 
education (BTS, 2005), recognition of its cost-effectiveness (Laupacis et al., 1996, Baltzan et 
al., 1997), use of minimally invasive laparoscopic nephrectomy reducing donor morbidity 
(Chin et al., 2009), evidence that pre-emptive transplants performed from living kidney 
donors have better graft survival than those from cadaveric donors (Meier-Kriesche and 
Kaplan, 2002) and the acceptance that outcomes from living genetically unrelated donors 
are equivalent to traditional genetically related donations (Terasaki et al., 1995). Another 
key aspect has been the surge in the number of non-directed altruistic donors. In 2012-13, of 
the 1,068 people receiving a living donor kidney transplant in the UK, 76 were from altruistic 
living donors (NHSBT, 2013). 
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Table 1-5. UK Living Donor Kidney Transplantation. 
Year     N 
2007-08     804 
2008-09     903 
2009-10     1,037 
2010-11     1,045 
2011-12     1,009 
2012-13     1,068 
Data from www.uktransplant.org.uk (2013) 
 
The criteria for “fitness” to undergo donor nephrectomy were initially very strict in an 
attempt to minimise both operative and long-term risks in subjects undergoing surgery for 
no personal physical benefit. Subjects were intensively screened prior to surgery so that 
kidney donors comprised a super fit population with lower levels of co-morbidity and 
cardiovascular risk than the general population. Recently however, with an ever growing 
waiting list for kidney transplantation, exclusion criteria for living donors have become more 
relaxed. Centres are now accepting subjects with a lower GFR than may have been 
considered appropriate in the past in addition to older age groups, those with controlled 
hypertension, and those with raised body mass index (Bia et al., 1995, Knoll, 2008). Indeed, 
nearly a fifth of all living kidney donors (199 out of 1068; 18%) proceeding to nephrectomy 
last year in the UK were aged over 60 years (NHSBT, 2013). The potential long-term renal 
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and cardiovascular effects of kidney donation may be most relevant to these donors with 
higher cardiovascular risk profiles. 
 
1.8.2. Renal Function after Kidney Donation 
 
Glomerular filtration rate. Uninephrectomy is associated with an acute 50% reduction in GFR 
followed by an improvement to about 70% of baseline within 2-3 weeks secondary to 
glomerular hypertrophy and hyperfiltration in the remaining kidney (Krohn et al., 1966, 
Anderson et al., 1991). Long-term longitudinal studies comparing early and late post 
donation GFR have found no evidence of a further decline in mean function over periods of 
between 10 and 30 years (Saran et al., 1997). In a meta-analysis of 48 cross-sectional studies 
involving over 3,000 patients and 1,703 controls, uninephrectomy was associated with a 
reduction in GFR of 17.1 ml/min/1.73m2 (95% CI -20.2 to -14.0 ml/min/1.73m2) that tended 
to improve slightly with each 10 years of follow-up (Garg et al., 2006). These findings are 
difficult to interpret as GFR was measured by a variety of methods including creatinine 
clearance by timed collection and estimated values derived from serum creatinine 
concentration, both of which are known to be inaccurate particularly at the modestly sub-
normal GFR levels expected post-donation (Poggio et al., 2005, Barri et al., 2010, Tan et al., 
2010). Ibrahim measured GFR by iohexol clearance in a randomly selected sample of 255 
donors at a mean of 12 years after donation and found a mean GFR of 63.7 +/- 11.9 
ml/min/1.73m2, 76% of the estimated level at the time of donation (Ibrahim et al., 2009). 
Fifteen percent of donors fulfilled criteria for stage 3 CKD although in no case was the value 
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<30 ml/min/1.73m2. In a recent study using 125I-iothalamate GFR, a more accurate 
assessment of renal function, the overall prevalence of stage 3 CKD in 196 donors at 3 
months after nephrectomy was higher at 27%; this proportion was heavily age dependent, 
however, with only 10% of donors under 30 years falling into this category but 91% of those 
aged 60–69 years (Barri et al., 2010). The figures for stage 3 CKD according to eGFR are even 
higher (Figure 1-7) and it should be remembered the graded association between CKD and 
cardiovascular risk emerged from observational studies which used eGFR as their index of 
renal function. These data are supported by my own analysis of 71 donors transplanted in 
2009 at Queen Elizabeth Hospital, Birmingham (Moody et al., 2012a). Despite a mean 
baseline iGFR of 100 ml/min/1.73m2  using 51Cr-EDTA clearance and a mean donor age of 
only 47 years, 65% had an eGFR <60 ml/min/1.73m2 at 3–12 months post-nephrectomy 
(Figure 1-8). 
 
The risk of developing CKD of any category after donation is dependent upon race and age. 
In a large US study of health outcomes after kidney donation (Lentine et al., 2010), older age 
at donation was associated with an increased risk of 4% per year of age of “medically coded” 
CKD. Black and Hispanic donors were approximately twice as likely to develop CKD after 
nephrectomy as white donors. Of more concern was the finding that black donors were at 
increased risk of progressing to ESRD over 20 years with an incidence of nearly 1% (2 out of 
271) compared to <0.5% in Hispanics and 0% in whites. However, in the largest US study of 
donors to date, a difference in the cumulative incidence of ESRD was observed in both black 
and white donors (Muzaale et al., 2014). Black donors had an estimated risk of 75 per 10,000 
at 15 years after donation compared with 24 per 10,000 black nondonors; the risk in white 
eGFR (ml/min/1.73m2) 
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donors was estimated at 23 per 10,000 versus 0 per 10,000 white nondonors. Thus, there 
was a significant increased relative risk of developing ESRD following live kidney donation 
although the magnitude of the absolute risk increase was small, even among black donors.  
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Figure 1-7. Percentage Proportion of Stage 3 Chronic Kidney Disease in Living Kidney Donors 3 
Months Post-Nephrectomy According To Age and Method Used for GFR Measurement. 
(Barri et al., 2010) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1-8. Living Donor Estimated Glomerular Filtration Rate at 3–12 Months Post-Nephrectomy. 
(Moody et al., 2012a)  
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Proteinuria.  A number of studies have demonstrated an increase in protein excretion 
following kidney donation. In a meta-analysis of 48 studies involving 5,048 donors, at an 
average of 7 years after donation, the average 24-h urinary protein excretion was 154 
mg/day (above the upper limit of normal protein excretion; see Table 1-6) (Garg et al., 2006). 
The pooled incidence of clinical proteinuria (>300 mg/day) was 12% and compared to 
controls, the pooled risk of microalbuminuria was increased at 3.9 (relative risk 3.9, 95% CI 
1.2 to 12.6). The effect of normal ageing was investigated by analysing 3 studies with 
controls involving 129 donors and 59 controls. At an average of 11 years after donation, 24-h 
urinary protein was higher in donors compared to controls (147 vs. 83 mg/day). This 
difference increased with time from donation suggesting a progressive effect. Higher levels 
of proteinuria are seen in donors with hypertension (Gossmann et al., 2005, Hakim et al., 
1984, Chavers et al., 1985) and males appear to be at greater risk than females (Furchgott 
and Zawadzki, 1980). More recently, Ibrahim et al. reported that in 255 donors selected 
randomly from 3,698 nephrectomies performed at the University of Minnesota between 
1963 and 2007, 11.5% had microalbuminuria and 1.2% had macroalbuminuria at a mean of 
12.2 years after donation (Ibrahim et al., 2009). There was a log linear increase in ACR with 
time following donation although in the absence of a control group, it was not possible to 
distinguish this from an effect of ageing. 
  
No. 
Living 
Kidney 
Donors 
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Table 1-6. Equivalents for 24 h Urinary Albumin and Protein Excretion, Albumin : Creatinine Ratio 
(ACR) and Protein : Creatinine ratio (PCR).  
Albuminuria*                                                 Proteinuria** 
   ACR 24 h urinary   PCR 24 h urinary 
mg/g; albumin mg/g; protein 
(mg/mmol)  (mg/24 h) (mg/mmol) (mg/24 h) 
 
30 (3.4) 30 150 (17.0) 150 
 
300 (33.9)  300 500 (56.8) 500 
 
 700 (79.5)   700  1000 (113.0) 1000 
 
*Microalbuminuria is defined as a 24 h albumin excretion rate of 30-300 mg/24 h (ACR > 3.0 
mg/mmol). Macroalbuminuria is defined as a 24 h albumin excretion rate of >300 mg/24 h (ACR > 
30 mg/mmol) **There is no consistent definition for proteinuria. The upper limit of normal 
protein excretion is usually defined as a 24 h urinary protein of 150 mg/24 h (PCR 15 mg/mmol). 
To convert mg/g to mg/mmol multiply by 0.113. Data adapted from www.nice.org.uk/CG73  
 
1.8.3. Risk of Hypertension after Kidney Donation 
 
A meta-analysis of 48  studies from 28 countries (11 prospective, 37 retrospective) examined 
blood pressure changes following kidney donation in 5,145 donors (Boudville et al., 2006). 
Roughly a third of the donors had incomplete follow-up data and only 10 of the studies 
selected had a control group with comparable age, sex and ethnicity. Most individual reports 
failed to detect a statistically significant change in blood pressure but were almost certainly 
underpowered. The pooled estimates, however, did show that compared to controls, systolic 
blood pressure increased by 5 mmHg and diastolic blood pressure by 4 mmHg at 
approximately 10 years after donation. The Norwegian Living Donor Registry of 256 donors 
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also demonstrated an increase in systolic blood pressure of about 5 mmHg at 5 years after 
nephrectomy, and an increased prevalence of hypertension at 27% compared to 3% before 
donation (Mjoen et al., 2010). Similarly, a retrospective cohort study of 1,278 donors 
showed an increase in diagnosed hypertension compared to controls (16.3% vs. 11.9%, 
hazard ratio 1.4, 95% CI 1.2-1.7) at a mean of 6.2 years  (Garg et al., 2008). The same study 
also noted that donors were seen more often by their primary care physicians, raising the 
possibility that the increased prevalence might have been due to increased monitoring. In 
the University of Minnesota study, mean “office” systolic blood pressure in the 255 patients 
following nephrectomy was 122 mmHg, significantly lower than an age matched control 
population (Ibrahim et al., 2009). The prevalence of hypertension requiring drug therapy was 
25%, not significantly different from the figure of 29% in the control population. A 
longitudinal study of 75 donors followed over 10 years did show an increased prevalence of 
hypertension in donors when compared with age/sex matched data from epidemiological 
studies of the general population (Saran et al., 1997). The prevalence of hypertension was 
36% at an initial visit 1–21 years after donation increasing to 75%. This effect was especially 
strong in those donors over the age of 55 years. It appears that baseline blood pressure 
influences the magnitude of the observed increase in blood pressure in donors. Higher pre-
donation blood pressure, even that regarded as being within normal limits, is associated 
with higher rates of hypertension post-donation (Ludmer et al., 1986, Rizvi et al., 2005). 
Older age at donation is also associated with an increased risk of post-donation hypertension 
with an effect size of 6% per year (Lentine et al., 2010). In a recent retrospective Canadian 
cohort study published in the New England Journal of Medicine, gestational hypertension or 
preeclampsia were reported to be more common in living kidney donors than in nondonors 
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with comparable baseline health (11% vs. 5%; odds ratio, 2.4) although there were no 
reports of maternal death, stillbirth, or neonatal death among the 131 donors (Garg et al., 
2015). In the general population, it is accepted that subjects with a history of preeclampsia 
are at a significantly heightened risk for cardiovascular disease (Ahmed et al., 2014) and this 
might in part, relate to the development of left ventricular dysfunction, as evidenced by 
impaired myocardial longitudinal strain (Shahul et al., 2012).  
 
The well recognised racial disparities which affect the development and progression of 
hypertension in the general population are also evident among living kidney donors. In a 
large retrospective study of 4,650 donors the prevalence of hypertension at 5 years from 
donation varied from 13.9% in young white women to 47.9% in black men over 50 years of 
age (Lentine et al., 2010). At a median of 7 years, the risk of hypertension in black and 
Hispanic donors was greater than that of white donors with an adjusted hazard ratio of 1.52. 
The risk of hypertension in Hispanics exceeded control values from NHANES data and there 
was a similar trend in black donors that could not be accounted for by socioeconomic 
factors. These data are further supported by a study demonstrating hypertension in as many 
as 41% of black donors at a mean follow up of 7 years post-nephrectomy (Nogueira et al., 
2009). In a single centre retrospective cohort study, hypertension was diagnosed more 
frequently among 38 indigenous North American donors compared with 76 randomly 
selected white donor controls (NA 42% vs. white 19%, p=0.02) (Storsley et al., 2010). 
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1.8.4. Risk of Diabetes Mellitus after Kidney Donation 
 
To date, there is no evidence to confirm an increased risk of developing type 2 diabetes 
mellitus (T2DM) in humans following kidney donation. No effect on insulin resistance was 
detected in an uncontrolled observational cohort study of 58 living donors at 6 months post-
donation (Prasad et al., 2008). In a retrospective survey of 3,777 kidney donors at a mean of 
18 years after donation, 154 of the 2,954 respondents (6%) had developed T2DM (Ibrahim et 
al., 2010). This proportion is roughly equivalent to that observed in the general population 
suggesting it probably represents an effect of ageing but the lack of control group might 
have concealed an excess risk associated with donation. Those who did develop T2DM were 
more likely to have hypertension (70.8% vs. 36.2%, p = 0.005) and proteinuria (18.8% vs. 
3.9%, p < 0.0001) but had a similar eGFR when compared to matched controls. As for the 
general population, risk factors associated with an increased risk of developing T2DM post 
donation include male gender and body mass index >30 kg/m2 at baseline. Black, Hispanic 
(Ibrahim et al., 2010) and native North American donors (Storsley et al., 2010) also appear to 
be at increased risk of developing T2DM following nephrectomy compared with white 
donors. 
 
1.8.5. Other Cardiovascular Consequences of Kidney Donation 
 
Two cross-sectional studies have examined PWV in kidney donors (Bahous et al., 2006, 
Abhayaratna et al., 2010), a well-validated measure of arterial function that is independently 
predictive of cardiovascular mortality in a range of populations including hypertension and 
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CKD (Laurent et al., 2006). Increased arterial stiffness in CKD is believed to play a central role 
in promoting the adverse changes in cardiac structure and function which predispose to an 
increased risk of cardiovascular death. Its mechanistic importance is discussed in section 
1.5.2 and has also been reviewed in detail elsewhere (Moody et al., 2013). Aortic PWV was 
found to be significantly higher in 101 donors at a mean of 111 ± 42 months post-
nephrectomy relative to a healthy volunteer group, even after adjustment for age, sex, and 
blood pressure (Bahous et al., 2006). The second study of 40 living kidney donors included 
echocardiographic assessment at an average of 7 years post-nephrectomy (Abhayaratna et 
al., 2010). When compared with controls, donation was associated with increased PWV as 
well as increased LV relative wall thickness and left atrial size. 
 
In a retrospective cross-sectional study, echocardiography was used to determine LV mass 
among patients with CKD stage 2-3 and compared to a group of healthy subjects with a 
similarly reduced iGFR as a consequence of renal donation (Rugale et al., 2013). The LVM 
index among patients with early-stage CKD was higher than in donors and associated with 
lower haematocrit, an increased plasma renin activity and higher aldosterone levels. A more 
recent longitudinal study of 45 normotensive healthy donor subjects, reported that 
increased baseline carotid-femoral PWV measured using the SphygmoCor system was 
associated with decreased post donation compensatory hyperfiltration independent of age, 
blood pressure and baseline GFR (Fesler et al., 2015). There was no significant change in 
PWV or office blood pressure at 12 months post-donation although it is notable that the 
study was not blinded and lacked a control group. 
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There is some weak evidence from two other small longitudinal cohort studies that the 
reduction in GFR accompanying nephrectomy is also associated with ED (Rossi et al., 2014, 
Yilmaz et al., 2014). A progressive reduction in endothelium dependent (FMD) and 
independent (glyceryl trinitrate (GTN)) brachial reactivity was observed in 42 living donors 
over the 2 years following nephrectomy, together with sustained increases in uraemic toxins 
including indoxyl sulfate and p-cresyl sulphate. An increase in the carotid IMT was also 
observed at 2 years. However, the magnitude of the absolute change in both these 
functional and structural parameters was small and comparable to that which has been 
observed with “normal” ageing (Howard et al., 1993, Celermajer et al., 1994). Similarly, in a 
study including 38 living kidney donors, FMD was significantly reduced at 3 and 12 months as 
compared to baseline and associated with increases in mean serum IL-6, ADMA and VCAM 
levels (Yilmaz et al., 2014). In keeping with these findings, significant increases in ADMA and 
FGF-23 at 6 months post-donation were reported in a longitudinal study involving 34 living 
kidney donors, although no change in blood pressure was demonstrated (Huan et al., 2013). 
However, it is notable that all of the aforementioned cohort studies have lacked a control 
group, and so it becomes difficult to draw any firm conclusions from these data. 
 
To date, only one other prospective, controlled pathophysiological study of human kidney 
donors exists (Kasiske et al., 2013). For each donor in this study, healthy siblings with 2 
kidneys were originally recruited as the “ideal” controls. After one year however, only 23 
pairs had enrolled despite the involvement of 7 US transplant centres and therefore, the 
inclusion criteria for controls were relaxed to include any healthy individual who 
theoretically could have been a donor. It was not until 2013 that the study released its first 
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report (seven years after its inception), which reflects the difficulty in executing large scale 
prospective controlled studies of living kidney donors. In the 203 pairs that completed a 6 
month follow up visit, there was a 23% increase in PTH in donors compared with controls, as 
well as an increase in uric acid, and a small but significant reduction in haemoglobin. All of 
these serological indices have been associated with adverse LV remodelling and increased 
arterial stiffness (Laflamme et al., 2014, Kao et al., 2011, Levin et al., 1999), although no 
assessment of large artery or LV structure and function was undertaken.  
 
1.8.6. Animal Studies Assessing the Cardiovascular Effects of Uninephrectomy 
 
There are limited animal studies addressing the effects of reduced renal function on the 
cardiovascular system but those data which are available are in keeping with the literature in 
humans. Investigators have shown that subtotal nephrectomy causing severe renal 
dysfunction causes major abnormalities of cardiovascular structure and function (Sviglerova 
et al., 2010). Burnett Jr. and co-authors have shown that even mildly reduced renal function 
caused by unilateral nephrectomy in Wistar rats resulted in increased myocardial collagen 
content and induced changes in LV gene profiles in the absence of hypertension (Martin et 
al., 2008). In the same model, the investigators have since shown that uninephrectomy is 
associated with a persistent increase in LV mass and myocardial fibrosis when compared 
with Sham control at 4 and 16 weeks (Martin et al., 2012b). Cardiac fibrosis was significantly 
associated with urinary protein excretion, and increases in circulating aldosterone and 
plasma BNP, together with impairment of both systolic and diastolic function demonstrated 
by strain echocardiography. Animal work has also suggested that kidney donation might be 
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associated with an increased risk of type 2 diabetes mellitus (T2DM). Sprague-Dawley rats 
develop glucose intolerance and islet beta cell loss 8 months after uninephrectomy (Sui et 
al., 2007).  
 
1.8.7. Survival and Health Status after Kidney Donation 
 
 
In general, the results of existing long-term follow up studies suggest that far from suffering 
an increased risk of early mortality, kidney donors have an excellent prognosis (Figure 1-9). A 
number of previous large single centre studies provide reassurance that nephrectomy does 
not adversely affect donor survival. Indeed, a widely quoted Swedish study which followed 
the health status of 430 kidney donors between 1964 and 1994, suggested that donors tend 
to live longer than the general population (Fehrman-Ekholm et al., 1997). A case series of 
601 Japanese subjects donating a kidney between 1970 and 2006, found a 20-year survival 
rate of 86%, which was more or less equivalent to that reported by Fehrman-Ekholm et al. 
(Okamoto et al., 2009). Similarly, Ibrahim and colleagues from the University of Minnesota 
found no significant difference in survival between 3,698 donors who donated kidneys 
between 1963 and 2007 and a NHANES cohort matched for age, sex and race (Ibrahim et al., 
2009). At 30 years, these proportions were 83% versus 76%, and at 40 years, they were 50% 
in donors versus 56% in controls. In addition, this study randomly selected 255 donors from 
its sample and measured various health and quality of life outcomes as well as iohexol GFR 
measurements, demonstrating that compared with age-, sex-, race-, and body mass index–
matched controls, donor outcomes were not inferior. The above reports are limited 
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however, by the fact that they are all single centre studies with racial homogeneity among 
donors. 
 
 
Figure 1-9. Studies Examining Living Kidney Donor Survival. 
Combined survival donor estimates are based on Kaplan-Meier curves from the individual studies. 
(Reule et al., 2013) 
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Nevertheless, these results are in agreement with a large scale registry study of over 80,000 
US donors between 1994 and 2009 with a median follow up period of over 6 years, in which 
the mortality of live kidney donors was slightly lower than that of matched controls from the 
NHANES III cohort (Segev et al., 2010). In this study, admirable efforts were made to identify 
a suitable control population that closely matched the relatively healthy status of kidney 
donors. Quality of life was better than population norms and co-existent health problems 
were not significantly different.  
 
1.8.8. Limitations to Studies of Cardiovascular Disease in Living Kidney Donors 
 
The general lack of excess morbidity and mortality amongst kidney donors represents a 
paradox in the face of strong evidence from epidemiological studies which show a clear and 
graded association between reduced GFR and cardiovascular risk (Mahmoodi et al., 2012, 
Fox et al., 2012, Matsushita et al., 2010). If the relationship between GFR and cardiovascular 
risk is causative, a 30% lower eGFR confers a 20% – 30% higher risk of major vascular events 
and all-cause mortality (Mafham et al., 2011), yet there is an equivalent decline in GFR 
accompanying the reduction in glomerular mass after nephrectomy (Barri et al., 2010). This 
discrepancy may be explained by residual confounding related to difficulties in identifying an 
equivalent control group to kidney donors. Prior to selection for transplantation, potential 
donors undergo intensive health screening and because the finding of almost all disease 
states (apart from mild hypertension) leads to exclusion from donation they are not 
representative of the general population. Indeed, based on accepted living kidney donor 
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exclusion criteria, more than half of the NHANES cohort would have been ineligible as 
donors (Segev et al., 2010, Ibrahim et al., 2009). In the absence of detailed physiological 
assessments, epidemiological donor studies will continue to suffer a selection bias with 
residual confounding arising from unrecognized medical problems in the nondonor group. 
For instance, the Canadian Donor Nephrectomy Outcomes Research Network have 
published extensively using a “universal healthcare administrative database” as their 
baseline data source for nondonor controls, although these data were heavily reliant on 
community subjects rating their own health and lacked information on blood pressure, 
serological indices or imaging parameters (Garg et al., 2015, Garg et al., 2012, Moody and 
Townend, 2014, Moody et al., 2012c). Further confounding may arise from the fact that 
donors are well motivated often making substantial healthy lifestyle modifications both 
before and after surgery. It is noteworthy that thus far, with the exception of two recent US 
reports (Segev et al., 2010, Muzaale et al., 2014), virtually all studies of kidney donors are 
either retrospective or have low inclusion rates making them heavily subject to selection and 
follow-up biases. 
 
Elevated blood pressure is a key risk factor for cardiovascular disease accounting for 
approximately 8 million premature deaths per year worldwide (Lawes et al., 2008). If it is 
confirmed that nephrectomy for kidney transplantation increases the risk of developing 
hypertension (Boudville et al., 2006, Moody et al., 2014b), kidney donors would be the only 
group of patients yet studied, in which a rise in blood pressure has not been accompanied by 
an increase in mortality. In the general population, even a 2 mmHg increase in systolic blood 
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pressure confers a long-term increase in mortality from stroke and cardiovascular disease of 
10% and 7%, respectively (Lewington et al., 2002). Thus, it is likely that either the data on 
blood pressure or on morbidity and mortality in kidney donors are incorrect. 
 
Despite initially reassuring findings from a Norwegian registry study (Mjoen et al., 2012), 
after an extended median follow up of 15.1 years, it was suggested for the first time that 
there may be a small increase in the risk of cardiovascular events in donors compared to 
controls (Mjoen et al., 2013). The selection process for identifying nondonor controls in this 
study was however subject to question (Mjoen et al., 2013, Moody and Townend, 2014). A 
significant difference in the mean age between donors and controls of almost 10 years (46.0 
± 11.5 yr vs. 37.6 ± 11.7 yr) may have contributed to the increased cardiovascular death rate 
observed in donors despite adjusting for age in the survival analyses. Furthermore, this 
report was also limited by the lack of information on renal function in the nondonor 
controls. 
 
It remains possible that the cross-sectional studies which imply reduced eGFR causes 
cardiovascular disease have drawn wrong conclusions because of residual confounding by 
disease states that tend to co-exist with CKD (e.g. diabetes, hypertension), which have not 
been adequately corrected for by the investigators. Further, since age is a factor in the 
calculation of eGFR using the MDRD formula, these two entities are inextricably linked. It is 
conceivable, therefore, that the epidemiological association of CKD with cardiovascular 
disease is at least, in part, an effect of increasing age (Lindeman et al., 1985, Moynihan et al., 
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2013). Employing accurate measures of GFR using isotopic methods would allow further 
qualification of the level of reduced renal function at which excess cardiovascular risk begins 
and also help distinguish the effects of reduced renal function from those of ageing. 
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1.9. Summary 
 
In summary, there is strong cross-sectional evidence of an association between 
cardiovascular disease and CKD although proof that a reduction in GFR is a causative factor 
in cardiovascular disease remains lacking. Chronic kidney disease has a powerful clustering 
effect for other cardiovascular risk factors such as hypertension, diabetes, dyslipidaemia and 
inflammation and together these processes may confound this association as well as 
heighten the possibility of “reverse causality”.  Increasing rates of living kidney donation 
provide an ideal opportunity to examine the effects of an isolated reduction in renal function 
on the cardiovascular system, free from the confounding co-morbidity present in many 
patients with CKD. Although large scale retrospective studies have in the main revealed no 
evidence of excess mortality in kidney donors, adverse effects on cardiovascular health may 
be hidden by (1) the careful selection of healthy donors without diabetes and with low levels 
of hypertension and obesity relative to the general population, and (2) the inappropriate 
selection of nondonor controls with unrecognized medical disorders owing to inadequate 
screening. These factors could conceal an adverse impact of reduction in GFR upon 
cardiovascular parameters since resulting values could still be within those of a “normal” 
unselected control population. A prospective, controlled study examining hard outcomes in 
kidney donors would prove very challenging because of low event rates, making it expensive 
as well as taking a long time to report. An alternative is to undertake a detailed prospective 
pathophysiological study of living kidney donors with comparison against an appropriate 
control population, and with the ability to detect adverse effects on well-recognised 
surrogate markers of cardiovascular disease following a reduction in GFR.  
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1.10. Experimental Hypotheses 
 
The following a priori hypotheses were therefore proposed. A reduction in GFR 
accompanying surgical uninephrectomy in human living kidney donors is associated with 
adverse cardiac and vascular effects which include:  
(1) An increase in LV mass 
(2) An impairment in LV systolic and diastolic function  
(3) A blood pressure-independent increase in aortic stiffness (PWV) 
(4) An increase in central and peripheral blood pressure 
(5) An increase in biomarkers of inflammation, myocardial stretch and myocyte injury 
(6) A reduction in endothelial function measured by FMD 
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2. METHODS 
 
The following chapter describes in detail the techniques used for the forthcoming studies. 
Table 2-1 lists the major data collection methods employed and includes the key outcomes 
of interest.  
 
2.1. Cardiac Magnetic Resonance Imaging 
 
Cardiac MRI was performed using a 1.5-T scanner (Magnetom Verio, Siemens, Erlangen, 
Germany) (Figure 2-1). Serial contiguous short axis cines were piloted from the vertical long 
axis and horizontal long axis images of the left and right ventricles (ECG R-wave gated, 
steady-state free precession imaging (SSFP) [True-FISP]; matrix size 256 x 158, temporal 
resolution 40-50 ms, repetition time 3.2 ms, echo time 1.7 ms, flip angle 60°, slice thickness 
7 mm with 3 mm gap) in accordance with previously validated methodology (Maceira et al., 
2006). 
 
2.1.1. Left Ventricular Volumes, Function and Mass 
 
Cardiac MRI is the reference standard for the determination of ventricular mass, volumes 
and function and as compared with transthoracic echocardiography, has higher interstudy 
reproducibility, thereby reducing the number of participants required to adequately power 
studies such as those described in the following chapters (Grothues et al., 2002). 
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Table 2-1. Summary of Main Data Collection Methods and Outcomes of Interest. 
Outcome Method 
Primary outcome  
Left ventricular mass Images were acquired using 1.5T cardiac magnetic resonance 
   imaging (Magnetom Avanto, Siemens, Erlangen, Germany).  
   Analysis will be performed offline (Circle Cardiovascular  
   Imaging Software, cvi42, Vers. 4.2.1, Calgary, Canada). 
 
Secondary outcomes 
Aortic stiffness (aPWV) Aortic pulse wave velocity (SphygmoCor, AtCor Medical, 
   Sydney) were performed following 15 minutes of supine rest 
   using a high-fidelity micromanometer (SPC-301, Millar  
   Instruments, Texas). Path length is taken as sternal notch-to-
   femoral pulse distance minus sternal notch-to-carotid pulse 
   distance. 
 
Mean 24h ambulatory Mean blood pressure from the non-dominant arm using 
peripheral blood pressure a 24 hour monitoring system (Mobil-O-Graph NG, IEM, Stolberg). 
 Readings taken every 30 min during the day (08:00-22:00) and 
 every 60 min overnight. 
 
Office systolic and diastolic   Three separate measurements taken after at least 5 minutes of   
blood pressure seated rest using a BHS validated automated device, mean of 
  last two recorded. 
  
Augmentation index and A micromanometer (SPC-301, Millar Instruments, Texas) was 
central haemodynamics  used to flatten, but not occlude the radial artery using gentle 
 pressure. An averaged peripheral waveform and corresponding 
 central waveform will be generated after 11 seconds of data 
 capture. The central waveform will then be analysed to  
 determine augmentation index and central aortic pressures. 
 
Left ventricular systolic and   CMR-FT analysis of SSFP cine images was undertaken offline 
diastolic function by a single blinded observer (TomTec 2D, Cardiac Performance 
 Analysis, Munich, Germany). 
 
 Myocardial tagging (SPAMM) was performed and analysis 
 performed offline by a single blinded observer (CIMTag2D, 
 Auckland, NZ). 
 
  Transthoracic echocardiography was undertaken (iE33,  
  Philips, Eindhoven, Netherlands) and analysis performed  
  offline on an Xcelera workstation (Philips, Eindhoven,  
  Netherlands). 
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Endothelial function Magnetic resonance imaging (Magnetom Avanto, Siemens,  
  Erlangen, Germany) to calculate flow-mediated dilatation  
  as the proportional change in brachial artery area in response 
  to hyperaemia. Analysis will be performed offline using semi-
  automated contour tracking software (MATLAB R2008b,  
  MathWorks Inc., Massachusetts, USA). 
          
Renal function Isotopic GFR using the renal clearance of 51Cr-EDTA. 
 
Bloods Haemoglobin, creatinine, calcium, albumin, glucose, phosphate, 
  parathyroid hormone, hsTnT, hsCRP, NT-proBNP and uric acid. 
 
Urine Albumin: creatinine ratio 
 
Abbreviations: aPWV, aortic pulse wave velocity; BHS, British Hypertension Society; CMR-FT, cardiac 
magnetic resonance-feature tracking; EDTA, Ethylenediaminetetraacetic acid; GFR, glomerular 
filtration rate; hsCRP, highly sensitive C-reactive protein, hsTnT, highly sensitive Troponin T; LV, left 
ventricular; NT-proBNP, N-terminal prohormone of brain natriuretic peptide; SPAMM, spatial 
modulation of magnetization imaging; SSFP, steady state free precession; TDI, tissue doppler 
imaging. 
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Analysis was made off-line in a Core laboratory by a single observer (W.E.M.) blinded to 
subject donor/control status (Circle Cardiovascular Imaging Software, cvi42, Vers. 4.2.1, 
Calgary, Canada). Each cardiac MRI dataset was anonymised and saved under a unique 
random identifier blinded to the observer. Unblinding was performed at the end of the study 
once analysis had been completed for all study participants. 
 
Manual planimetry of the short axis epicardial and endocardial contours in end-diastole and 
end-systole was performed using standardised methods for determination of ventricular 
ejection fraction, volumes and mass (Maceira et al., 2006). The LV basal short axis slice was 
identified as the image containing at least 50% of circumferential myocardium in end-
diastole. Papillary muscles were included in the mass and excluded from volumetric 
analyses. Mass was calculated as end-diastolic epicardial − endocardial volume × 1.05. LV 
mass was indexed to body surface area using the Mosteller formula: BSA (m2) = √((weight 
(kg)×height (cm))/3600). Left ventricular hypertrophy was defined as LV mass >2SDs above 
the mean for age and sex (Maceira et al., 2006). The mass-to-volume ratio calculated as LV 
mass / LV end-diastolic volume, was used as an index of concentric LV remodelling (Zile et 
al., 2011, Cheng et al., 2009).  
 
To cross-check LV volumetric data, aortic forward flow measurements at the level of the 
pulmonary artery were performed along with assessment of right ventricular stroke volume 
by manual tracing of the right ventricular endocardial border in end-diastole and end-
systole. Values for LV volumes and mass were only accepted for subsequent analysis if all of 
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the following conditions had been satisfied: (1) LV stroke volume is within 10 mL of right 
ventricular stroke volume; (2) LV stroke volume is within 10 mL of the total aortic forward 
flow; and (3) LV end-diastolic and end-systolic masses are within 10% of each other. 
 
Assessment of intra-observer and inter-study reproducibility for the measurement of LV 
mass, volumes and function using cardiac MRI is described in detail in Chapter 3 (Moody et 
al., 2015). 
 
2.1.2. Assessment of Left Ventricular Systolic and Diastolic Function 
 
In addition to gross volumetric measures of systolic LV function (ejection fraction and stroke 
volume), both systolic and diastolic function were assessed using cardiac MRI measurement 
of myocardial deformation by feature tracking (TomTec 2D Cardiac Performance Analysis, 
Munich, Germany). A validation of this technique against dynamic tissue-tagging MRI, the 
reference standard non-invasive methodology for strain calculation, is described in detail in 
Chapter 4 (Moody et al., 2014a). A normal reference range for cardiac magnetic resonance-
feature tracking (CMR-FT) strain parameters has also recently been published using data 
from this study (Taylor et al., 2015). Briefly, the endocardial borders of the LV steady-state 
free-precession horizontal long-axis cine and mid LV short-axis cines were manually 
contoured in the end-diastolic frame. The software then automatically tracked the motion of 
related features adjacent to the endocardial border, such as the cavity-tissue boundary or 
individual tissue patterns, throughout the remainder of the cardiac cycle to produce 
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endocardial strain parameters. The average of the segmental strains from the short-axis 
view was computed as the global endocardial circumferential strain (GCS), and the average 
of segmental strains in the horizontal long-axis view was recorded as the global endocardial 
longitudinal strain (GLS). Global strain rate (SR) signals were also recorded during systole and 
early filling as peak systolic SR and early diastolic SR, respectively (Figure 2-2).  
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Figure 2-1. 1.5T Cardiac Magnetic Resonance Scanner Used to Perform Imaging in Subjects. 
 
 
Figure 2-2. Representative Circumferential Strain Rate Profile From Cardiac Magnetic Resonance-
Feature Tracking at the Mid Left Ventricular Level of a Healthy Control. 
This example demonstrates a typical strain rate pattern with S (systolic), E (early diastolic) and A (late 
diastolic) waves. The dotted white line represents the global subendocardial circumferential strain 
rate.  
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Longitudinal atrioventricular plane descent (AVPD) was also measured in the septum and 
lateral wall as the distance travelled by the respective annulus from end-diastole to end-
systole (Maceira et al., 2006). The biplane area-length method was used to assess left atrial 
volumes using the horizontal and vertical long axis images in end-systole: Volume = (0.848 x 
Area4ch x Area2ch)/ [(Length2ch + Length4ch)/2] (Hudsmith et al., 2007). The left atrial 
appendage was included but the pulmonary veins were excluded from area measurements.  
The longitudinal axis of the left atrium was defined by measuring the distance from the 
center of the mitral valve annulus to the posterior left atrial wall. 
 
In asymptomatic subjects without manifest heart disease at baseline, lower peak 
longitudinal atrial strain (PLAS) measured using CMR-FT, is an independent predictor of 
incident heart failure (Habibi et al., 2014). Left atrial function was therefore also assessed 
using CMR-FT, as previously described (Habibi et al., 2014). The software (TomTec 2D 
Cardiac Performance Analysis, Munich, Germany) generates longitudinal strain curves for 
each atrial wall segment from the horizontal and vertical long axis images. Global 
longitudinal atrial strain was generated by averaging all LA segmental values in each time 
frame. Global peak longitudinal atrial strain (PLAS) and pre-atrial contraction longitudinal 
strain (preA-S) were derived from the global longitudinal strain profile as shown in Figure 
2-3. 
 
Dynamic tissue-tagging MRI also allowed direct non-invasive assessment of regional systolic 
and diastolic function and is a previously validated technique (Yeon et al., 2001). Spatial 
modulation of magnetization was used to generate a uniform grid pattern with 8 mm tag 
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separation on the LV myocardium at three short axis sections (basal, mid and apex) and the 
horizontal long axis image using a fast filed echo multi-shot sequence (temporal resolution 30 
ms, repetition time 3.9 ms, echo time 1.7 ms, voxel size 1.99/2.04/8.00 mm3, flip angel 5°, tag 
grid angle 45° with slice thickness 8 mm and a minimum number of 15 phases per cardiac 
cycle) with prospective ECG gating, as previously described (Young et al., 1994). Blinded 
analysis was performed offline (SIMTAG, University of Auckland, New Zealand) for LV 
longitudinal and circumferential shortening as previously described (Young et al., 1994). 
 
 
 
Figure 2-3. Representative Left Atrial Longitudinal Strain Profile in a Healthy Control Subject. 
Abbreviations: PLAS, peak longitudinal atrial strain; preA-S, pre-atrial contraction longitudinal strain.  
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2.1.3. Aortic Distensibility 
 
Measurement of aortic distensibility using MRI has low intra-observer variability and good 
reproducibility (Forbat et al., 1995). Aortic distensibility was assessed at the ascending aorta, 
the proximal descending aorta at the level of the pulmonary artery (Figure 2-4), and the 
distal descending aorta at the level of the diaphragm on held end-expiration. Measurements 
were calculated using the previously validated formula (Chue et al., 2013a, Groenink et al., 
1998): 
 
Aortic distensibility = Δ aortic area / (minimum aortic area × pulse pressure) 
 
Peripheral blood pressure was measured synchronously, in triplicate, at the brachial artery 
at the time of scanning for determination of pulse pressure. The measurement of aortic 
cross-sectional area in systole and diastole was made off-line using automated in house 
software within Matlab 6.5© (MathWorks Inc., Massachusetts, USA) (Jackson et al., 2009). 
 
2.1.4. Endothelial Function 
 
The term “endothelial dysfunction” was originally coined to describe impaired endothelium-
dependent vasodilatation to specific stimuli such as acetylcholine (ACh) and bradykinin 
(Endemann and Schiffrin, 2004). A much wider definition of ED has now been accepted, 
encompassing the presence of a pro-inflammatory and pro-thrombotic state. Despite 
expansion of this term, the overwhelming majority of clinical investigators continue to use 
techniques employing endothelium-dependent vasodilatation as their index of ED. Ex vivo, 
 88 
 
using the small vessel myograph, an increasing number of studies have been performed using 
resistance arteries from human subcutaneous fat to assess endothelium-dependent relaxation 
(Endemann and Schiffrin, 2004). In vivo methods include strain-gauge plethysmography to 
measure changes in forearm blood flow during infusion of intra-arterial endothelial-
dependent and -independent vasodilators such as ACh and sodium nitroprusside (NO donor), 
respectively. Arguably, this remains the clinical “gold standard” (Wilkinson and Webb, 2001). 
The measurement of FMD of the brachial artery using ultrasound and more recently magnetic 
resonance imaging is less invasive and, although a process not completely dependent on the 
release of NO in response to increased shear stress (Joannides et al., 1995), has become 
increasingly prominent (Wiesmann et al., 2004, Celermajer et al., 1992). 
 
Flow mediated dilatation of the brachial artery was measured using MRI measurement of 
brachial artery area before and after 5 minutes of arterial occlusion and also following GTN 
control (400mcg, sub-lingual) (Wiesmann et al., 2004). Brachial artery measurements were 
performed off-line using semi-automated contour tracking software (MATLAB R2008b, 
MathWorks Inc., Massachusetts, USA; Figure 2-5). The FMD was calculated as the 
proportional change in cross-sectional area in response to hyperaemia (Jackson et al., 2009). 
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Figure 2-4. Measurement of Aortic Cross-Sectional Area Made Off-line Using Automated In-House 
Software Within Matlab 6.5© (MathWorks Inc., Massachusetts, USA). 
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Figure 2-5. Magnetic Resonance Assessment of Flow Mediated Dilatation at the Brachial Artery. 
Brachial artery cross-sectional area was measured off line within Matlab 6.5© (MathWorks Inc., 
Massachusetts, USA) at baseline, after functional hyperaemia and after 400 mcg glyceryl trinitrate 
control. 
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2.1.5. Assessment of Extracellular Volume Fraction 
 
Following a substantial amendment to the protocol, patients were also consented to receive 
intravenous gadolinium 0.15mmol/kg for the purpose of assessing the extracellular volume 
fraction (ECV). A SSFP single breath hold modified Look-Locker (MOLLI) inversion recovery 
sequence was used for T1 mapping in the LV basal and mid-ventricular short axis levels before 
and between 15-20 minutes after contrast administration (8mm slice with a 192 read-out 
matrix, 6/8 phase partial Fourier with 81% phase resolution, FOV 320 x 320, TR 2.4ms, TE 
1.01ms, 11 phases (3, 3, 5 scheme), total breath hold 17 R-R intervals). Late gadolinium 
enhancement imaging was performed 7-10 minutes after 0.15 mmol/Kg of gadolinium 
contrast bolus (Gadovist Bayer Health Care).  
 
Quantitative parametric T1 images were generated using Argus software (Siemens®) with 
manual contouring to define a region of interest (ROI) in the LV septum at basal and mid 
myocardial levels. Global native (non-contrast) myocardial T1 time (ms) was calculated from 
the averaged T1 times in the LV septum basal and mid ventricular regions of interest (ROI) 
before contrast administration and global ECV after contrast using validated formulae (Moon 
et al., 2013, Ugander et al., 2012): 
ECV = [ΔR1myocardium − ΔR1blood pool] * [1 – Hct] 
Hct refers to the haematocrit recorded on a venous blood sample at the time of scan, ΔR1 = 
1/T1 time post contrast – 1/T1 time pre contrast. Myocardial intracellular volume (ICV) was 
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also calculated as; 1-ECV providing a measure of cell volume which is important when 
interpreting the composition of the myocardium with LV hypertrophy (Moon et al., 2013). 
 
2.2. Assessment of Blood Pressure 
 
Office blood pressure was measured with the patient seated on 3 occasions using a validated 
automated device. The first measurement was made following at least 5 minutes of seated 
rest. Two further readings were made with at least one minute between each reading and 
the average of these was used for analysis. All measurements were made from the non-
dominant arm using the same cuff size between visits. Participants also underwent 24-h 
ambulatory blood pressure monitoring using a British Hypertension Society validated 
oscillometric recorder (Mobil-O-Graph NG, IEM, Stolberg, Germany) which provided data on 
both peripheral and central blood pressure (Wei et al., 2010, Weiss et al., 2012). 
 
2.3. Assessment of Arterial Stiffness 
2.3.1. Pulse Wave Velocity 
 
Aortic PWV is the current reference standard non-invasive technique for measuring aortic 
stiffness (Laurent et al., 2006). Subjects were studied in a quiet, temperature-controlled 
laboratory after 15 minutes of lying supine. Pulse wave velocity (SphygmoCor, AtCor 
Medical, Sydney) was determined by sequential acquisition of pressure waveforms from the 
carotid and femoral arteries by use of a micromanometer (SPC-301, Millar Instruments, TX, 
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USA; ) as previously described (Wilkinson et al., 1998, Frimodt-Moller et al., 2008). The path 
length was calculated by subtracting the distance between the sternal notch and the carotid 
recording site from the distance between the sternal notch and the femoral site. Transit time 
is calculated using the foot-to-foot method, which determines the time difference between 
the onset of the pulse wave at the carotid and femoral sites. The foot of the pulse wave was 
defined as the onset of the steep rise of the pulse wave at end diastole. Carotid and femoral 
arterial waveforms were sequentially recorded using the high fidelity micromanometer 
whilst an ECG was simultaneously obtained. A representative output is depicted in Figure 
2-6. 
 
Aortic PWV is a blood pressure-dependent variable and therefore PWV values were adjusted 
for mean arterial pressure as described previously (Ford et al., 2010).  Adjustment was made 
based on a linear regression of PWV with mean arterial pressure as the determinant. 
Unstandardised residuals derived from this regression model were added to the mean PWV 
to derive adjusted PWV (PWVadj). 
 
2.3.2. Pulse Wave Analysis 
 
Blood pressure measurement was performed in subjects lying supine before undertaking 
applanation tonometry to record high fidelity arterial pressure waveforms from which 
indices relating to large artery stiffness could be calculated. Central pressure waveforms 
were derived and analysed using the technique of pulse wave analysis as previously 
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described (Wilkinson et al., 1998, Savage et al., 2002). A micromanometer was used to 
flatten, but not occlude the radial artery using gentle pressure (Figure 2-7). An averaged 
peripheral waveform and corresponding central waveform was generated after 11 seconds 
of data capture. The central waveform was then analysed to determine the augmentation 
index (AIx: the difference between the second and first peaks of the central pressure 
waveform, expressed as a percentage of the pulse pressure and central aortic pressures 
(Figure 2-8). This method has been shown to be reproducible in both healthy subjects and in 
patients with CKD (Wilkinson et al., 1998, Savage et al., 2002). 
 
 
 
Figure 2-6. Representative Ouput From Pulse Wave Velocity.  
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Figure 2-7. Applanation Tonometry of the Radial Artery. 
 
 
Figure 2-8. Representative Output From Pulse Wave Analysis.  
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2.4. Assessment of Carotid-Intima Media Thickness 
 
Subjects were examined supine with the head rotated at 45 degrees. Right and left common 
carotid arteries were imaged using high resolution ultrasound (Philips iE33, L9-3 MHz linear 
array transducer) 1 cm proximal to the carotid bifurcation with images optimized to 
demonstrate the posterior wall intima-media in accordance with published guidelines 
(Touboul et al., 2012). Common carotid IMT was measured as the distance between lumen-
intima and media-adventitia interfaces using automated wall tracking software (IMT plug-in, 
QLAB). The mean of the right and left carotid measurements was used for analysis. 
 
2.5. Echocardiography 
 
A comprehensive transthoracic echocardiogram (iE33, Philips, Eindhoven, Netherlands) was 
performed at rest with the subject in the left lateral decubitus position by a single 
experienced sonographer (W.E.M.) using second harmonic imaging and an S5-1 multi-
frequency transducer. All parameters were measured in triplicate and averaged as per the 
American Society of Echocardiography guidelines (Schiller et al., 1989). Analysis was 
performed offline by a single blinded observer on an Xcelera workstation (Philips, 
Eindhoven, Netherlands). Ventricular dimensions, wall thickness, chamber volumes and 
stroke volume were determined using standard methods (Lang et al., 2005). Left ventricular 
diastolic function was determined using standard techniques (Nagueh et al., 2009). Peak 
systolic (s’), early diastolic (e’) and late diastolic (a’) mitral annular velocities were measured 
at end expiration with real time pulsed wave tissue Doppler (TDI) (Alam et al., 1999). 
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2.5.1. Calibrated Integrated Backscatter 
 
The ultrasonic reflectivity of tissue has long been used to non-invasively characterize 
myocardial tissue and is well validated against histologically quantitated collagen (Jellis et al., 
2010, Shapiro et al., 1984, Picano et al., 1990). A higher (less negative) calibrated integrated 
backscatter (cIBS) value is indicative of a greater amount of LV interstitial fibrosis. 
 
Measurements of tissue intensity were obtained offline from sample volumes placed within 
the pericardium, posterior wall, and anteroseptum from standard gray-scale 2-D parasternal 
long-axis view images. A fixed 5 x 5 mm region of interest was positioned in the mid- 
myocardium of the antero-septal and posterior walls of the LV and a fixed 2 x 2mm region of 
interest was positioned in the pericardium. A resultant integrated backscatter curve was 
derived with standard commercial software (QLAB, Philips, Eindhoven, Netherlands). 
Calibrated integrated backscatter was calculated by subtracting pericardial integrated 
backscatter intensity from the mean integrated backscatter intensity of the posterior wall 
and anteroseptum in end-diastole.  
 
2.6. Assessment of Renal Function 
 
Isotopic GFR (iGFR) studies were performed using the renal clearance of 51Cr-EDTA 
(Martensson et al., 1998) under the supervision of Dr. Christopher Boivin in the Nuclear 
Medicine Department at the Queen Elizabeth Hospital Birmingham. Venous blood samples 
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were drawn at 2, 3 and 4 hours after a single intravenous injection of the isotope. The CKD-
EPI equation was used to determine eGFRcr with serum creatinine recalibrated to be 
traceable to an isotope derived mass spectroscopy method (Levey et al., 2009). Urinary ACR 
was determined from a spot morning urine sample (Gansevoort et al., 2005). 
 
2.7. Biochemical Assays 
 
Highly sensitive Troponin T was measured by a sandwich principle immunoassay (cobas 8000 
modular analyzer, Roche Diagnostics, Burgess Hill), with a lower limit of detection of 5 ng/L 
and a 99th percentile value in apparently healthy individuals of 14 ng/L (Giannitsis et al., 
2010). Serum N-terminal pro B Natriuretic peptide was measured by sandwich immunoassay 
with magnetic particle separation and chemiluminescent detection (Roche Diagnostics, 
Burgess Hill) with a lower limit of detection of 0.6 pmol/L (Downie et al., 1999). Serum C-
reactive protein was measured using a highly sensitive assay by latex-enhanced 
nephelometry (Full Range CRP, SPAPLUS analyser, The Binding Site Group Ltd, Birmingham, 
UK). Plasma intact PTH was measured by a sandwich immunoassay method (Roche 
Diagnostics, reference range, 3.5-6.5 pmol/L). Plasma 25-hydroxyvitamin D was measured by 
liquid chromatomography tandem mass spectrometry.  Renin was measured using the Cis-
Bio immunoradiometric (IRMA) kit (Codolet, France) and aldosterone was determined by 
tandem mass spectrometry on an AB Sciex 6500 triple quad mass spectrometer coupled to a 
Shimadzu Nexera XR UPLC (Warrington, UK). Serum calcium, phosphate and uric acid were 
measured by standard automated methods. 
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Assays for high sensitive C-reactive protein and cystatin C were performed by Dr Lakhvir Assi 
at The Binding Site Group Ltd, Birmingham. Assays for N-terminal pro-brain natriuretic 
peptide were performed by Prof Leong Ng at Leicester Royal Infirmary. Assays for renin and 
aldosterone were performed by Dr Rachel Webster at the Queen Elizabeth Hospital 
Birmingham. 
 
 
2.8. Overview of Statistical Methodology 
 
All data presented in this thesis were analysed using SPSS version 21 (SPSS Inc., Chicago, 
Illinois, USA). Normality of data distribution for each variable was determined using the 
Kolmogorov-Smirnov test and normality plots. Normally distributed variables were 
presented as mean ± standard deviation and analysed using parametric tests. Any non-
normally distributed variables were log-transformed prior to analysis to achieve normality 
and the logs were analysed using parametric tests; such variables were quoted as median 
(interquartile range). If normality was not achieved with log transforming, non-parametric 
analyses were performed. Between-group comparisons were performed using independent 
t-tests (two groups) or a one-way analysis of variance (more than two groups). Within-group 
comparisons across different time points were assessed using paired samples t-tests. The 
primary analysis performed between-group comparisons across different time points using a 
repeated measures analysis of variance, with the time point (month 0 and month 12) as the 
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within-subjects factor and the group (donor, control) as the between-subjects factor, thus 
testing the difference in change over time between the two groups. To account for the effect 
of missing data, a further quantitative analysis was performed using a last observation 
carried forward principle. Independent predictors of changes in variables were determined 
using multivariable logistic regression. Generalised estimating equations were used to 
compare groups (donors, controls) for the likelihood of developing detectable variables over 
time (0 and 12 months). Linear regression analysis was performed to determine the 
relationship between continuous variables; parametric variables were assessed using 
Pearson’s correlation and any non-parametric variables assessed using Spearman’s 
correlation. Categorical variables were presented as frequency (percentage) and analysed 
using the chi-square test. A Type I error rate below 5% (P<0.05) was considered statistically 
significant. 
 
2.9. Regulatory Approvals and Authorisations 
 
Professor Jonathan N. Townend was the designated Principal Investigator for this study. This 
project did not constitute a Clinical Trial of an Investigational Medicinal Product (IMP) as 
defined by the EU Directive 2001/20/EC. The South Birmingham Research Ethics Committee 
granted approval for the human research studies described in this thesis (Ref: 10/H1207/70). 
The project was also given local Research and Development and Site Specific Assessment 
approval from University Hospitals Birmingham NHS Foundation Trust. The University 
Hospital Birmingham NHS Foundation Trust acted as sponsor (Ref. RRK3922). Approval from 
the Administration of Radioactive Substances Advisory Committee was given to authorise 
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use of 51Cr-EDTA for determination of isotopic GFR (Ref. RPC 290/1051/126569). University 
Hospital Coventry and Warwickshire agreed to act as a Participant Identification Centre (PIC). 
The study was conducted in accordance with the recommendations for physicians involved 
in research on human subjects adopted by the 18th World Medical Assembly, Helsinki 1964 
and later revisions. Informed written consent was sought prior to any study procedures 
being conducted. The study was supported by a British Heart Foundation Clinical Research 
Fellowship under Dr William Moody (FS/11/17/28700). The study was subject to inspection 
and audit by University Hospital Birmingham NHS Foundation Trust under their remit as 
sponsor and was found to adhere to Good Clinical Practice. 
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3. REPRODUCIBILITY OF LEFT VENTRICULAR MEASUREMENTS 
 
3.1. Background 
 
Cardiac MRI is considered the gold standard technique to monitor changes in LV dimensions 
and function in both congenital and acquired heart disease (Fratz et al., 2013, Hendel et al., 
2006). Reference ranges normalized for gender, age and body surface area help clinicians 
discriminate between normality and pathology (Hudsmith et al., 2005, Maceira et al., 2006), 
and by including assessments of short-term inter-study variability (test-retest after 1 week) 
can account for differences in LV measurements arising from physiological variation (load 
alterations and time of day effects). Most clinical imaging however, is repeated at much 
greater time intervals; physicians frequently monitor ventricular size and function in patients 
with valvular heart disease or cardiomyopathy on an annual basis, although there are no 
longitudinal cardiac MRI data quantifying the effect of biological and technical variability 
over this time frame. Without such information, it is difficult to determine what represents a 
clinically significant change, particularly when the observed difference is small. 
 In this study, we therefore sought to examine the within-subject changes in LV 
volumes, mass and ejection fraction (EF) using cardiac MRI over 12 months in subjects 
identified from the control arm of the CRIB-Donor study (see Chapter 5), a well-
characterized cohort of normal healthy adults. 
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3.2. Methods 
 
3.2.1. Patient Selection 
 
We retrospectively identified 42 healthy control subjects (45 ± 13 yr, male 43 %) who did not 
proceed to nephrectomy from the Chronic Renal Impairment in Birmingham – Donor study 
(CRIB-Donor, NCT01028703), the results of which are described in detail in Chapter 5. All 
subjects included in the current study had a 10-year risk of a cardiovascular event of < 7.5%, 
a normal exercise stress echocardiogram and normal haematology and biochemistry blood 
profiles (JBS3, 2014). Exclusion criteria included any of the following: a history of 
cardiovascular disease, including hypertension; diabetes; glucose intolerance; chronic kidney 
disease; or a first degree relative with a proven or potentially inheritable cardiac condition. 
 
3.2.2. Cardiac Magnetic Resonance Imaging  
 
The full cardiac MRI study protocol is described in detail in Section 2.1 and has been 
published elsewhere (Moody et al., 2014b). Briefly, subjects underwent cardiac MRI imaging 
(1.5 T Magnetom Verio, Siemens) at baseline and 12 months. Analysis of SSFP images was 
performed manually offline (Argus Software) by a single blinded observer (W.E.M., 5 years 
experience) for the assessment of LV ejection fraction (LVEF), LV end-diastolic volume 
(LVEDV), LV end-systolic volume (LVESV), and LV mass (LVM). The LV basal short axis slice 
was identified as the image containing at least 50% of circumferential myocardium in end-
diastole (Figure 3-1). Papillary muscles were included in the mass and excluded from 
volumetric analyses. 
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Figure 3-1. Example of the Offline Analysis Performed Using Argus Software on Left Ventricular Short 
Axis Steady State Free Precession Cine Images. 
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3.2.3. Reproducibility 
 
To assess intraobserver report variability, baseline studies were re-analyzed by the same 
observer 4 weeks later, blinded to the original data. A random subset of participants (n = 10) 
also underwent repeat imaging within 7 days to determine short-term interstudy 
reproducibility; both scans were analyzed by the same blinded observer. 
 
3.2.4. Statistical Analysis 
 
Data were analyzed using SPSS (v. 21, Chicago, IL). Data are expressed as mean ± SD, median 
(interquartile range) or frequency (%). The normality of distribution was determined using 
normality plots and the Kolmogorov-Smirnov test. The within-patient changes were 
compared with a Student’s paired t-test. The mean short-term change in LV parameters was 
compared with the mean 12-month change using an unpaired t-test. 
 Reliability was assessed using the intraclass correlation coefficient (ICC) with a model 
of absolute agreement; absolute measurement error was estimated by the standard error of 
measurement (SEM) and smallest detectable change (SDC) (Weir, 2005). The SEM is defined 
as SEM = SDd / √ 2, where SDd is the standard deviation of the mean difference between 
two measurements, and takes the amount of measurement error into consideration and 
quantifies the within-subject variability. The SDC is calculated as SDC = 1.96 x SEM x √2, 
where 1.96 corresponds to the 95% confidence interval and the square root of 2 is to adjust 
for sampling from two different measurements, and represents the 95% confidence that a 
change in the measurement exceeding this threshold is true and reliable and not just a 
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measurement error (Weir, 2005). For all statistical comparisons, P < 0.05 was considered 
significant. 
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3.3. Results 
 
The demographics and cardiovascular risk profiles of the healthy control subjects identified 
for this study are presented in Table 1. All subjects remained well with no clinical events 
over the 12 month study period. There were no significant changes in any LV parameter on 
repeat cardiac MRI at 12 months (Table 3-2). Moreover, the short-term interstudy biases 
(mean differences) were not significantly different from the long-term changes observed at 1 
year (LVEF, LVEDV, LVESV, LVM; P = 0.81, 0.63, 0.97, 0.72, respectively). On the basis of our 
interstudy reproducibility, the SDC for LVEF, LVEDV, LVESV and LVM, which could be 
recognized with 95% confidence are 6%, 13ml, 7ml and 6g, respectively (Table 3-3). 
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Table 3-1. Patient Characteristics. 
Patient variable N = 42 
Age (yr) 45 ± 13 
Gender (male:female) 18:24 
Height (m) 1.70 ± 0.90 
Weight (kg) 74.5 ± 11.5 
Body mass index (kg/m2) 26.2 ± 4.0  
Office systolic blood pressure (mmHg) 120.7 ± 11.7 
Office diastolic blood pressure (mmHg) 74.1 ± 8.4 
Cardiovascular medications 0 (0) 
Hemoglobin (g/L) 135.2 ± 10.2 
eGFR <60 ml/min/1.73m2 0 (0) 
Fasting cholesterol (mg/dL) 191.4 ± 40.2 
Fasting glucose (mg/dL) 
Urinary ACR (μg/mg) 
84.4 ± 7.2 
0.89 (0.89 – 2.65) 
10 yr cardiovascular risk < 7.5%* 42 (100) 
Data are expressed as mean ± SD, median (interquartile range) or frequency (%). Dividing the 
urinary ACR by 8.84 converts the units from μg/mg to mg/mmol. ACR, albumin : creatinine ration; 
eGFR, estimated glomerular filtration rate. 
*Calculated using the JBS-3 heart risk calculator available at www.jbs3risk.com 
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Table 3-2. Annual Change in Left Ventricular Ejection Fraction, Volumes and Mass. 
Parameter Month 0 Month 12 Mean difference p 
LVEF (%) 70.3 ± 6.9 71.2 ± 6.4 0.9 ± 4.3 0.18 
LVEDV (mL) 121.2 ± 28.2 121.3 ± 26.9 0.1 ± 10.4 0.91 
LVESV (mL) 37.0 ± 14.7 35.8 ± 13.7 -1.2 ± 6.6 0.26 
LVM (g) 111.4 ± 31.7 109.5 ± 32.0 -2.0 ± 8.6 0.14 
Data are mean ± SD. Changes in LV parameters compared using a paired Student’s t test. 
Abbreviations: LVEF, left ventricular ejection fraction; LVEDV, left ventricular end diastolic volume; 
LVESV, left ventricular end systolic volume; LVM, left ventricular mass. 
 
 
Table 3-3. Intraobserver and Short-Term Interstudy Variability Using Cardiac Magnetic Resonance in 
Normal Healthy Adults. 
Parameter Variability 
Mean 
difference 
p 
Limits of 
agreement 
ICC (95% CI) SDC 
  LVEF (%) 
Intraobserver 
Interstudy 
1.00 ± 1.27  
0.57 ± 2.94 
0.11 
0.63 
-1.48 to 3.48 
-5.19 to 6.33 
0.99 (0.94 to 1.00) 
0.93 (0.62 to 1.00) 
- 
5.8 
LVEDV (mL) 
Intraobserver 
Interstudy 
0.67 ± 3.62 
-1.57 ± 6.47 
0.67 
0.43 
-6.43 to 7.77 
-14.25 to 11.11 
0.99 (0.95 to 1.00) 
0.99 (0.97 to 1.00) 
- 
12.7 
LVESV (mL) 
Intraobserver 
Interstudy 
-0.83 ± 2.79 
-1.29 ± 3.65 
0.50 
0.37 
-6.30 to 4.64 
-8.44 to 5.86 
0.99 (0.93 to 1.00) 
0.98 (0.91 to 1.00) 
- 
7.2 
LVM (g) 
Intraobserver 
Interstudy 
-0.33 ± 2.16 
-1.00 ± 3.03 
0.21 
0.50 
-4.56 to 3.90 
-6.94 to 4.94 
0.99 (0.95 to 1.00) 
0.98 (0.91 to 1.00) 
- 
5.9 
Data are mean ± SD. Changes in LV parameters compared using a paired Student’s t test. 
Abbreviations: ICC, intraclass correlation coefficient; SDC, smallest detectable change. All other 
abbreviations as in Table 3-2.  
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3.4. Discussion 
 
To our knowledge, this is the first longitudinal cardiac MRI study to perform a repeat annual 
assessment in individuals free of cardiovascular disease. The data presented herein suggest 
the effect healthy ageing at 1 year is negligible and need not be taken into account by 
clinicians when reporting cardiac MRI studies performed in patients over this time frame. 
 As for any imaging modality, cardiac MRI is subject to variability because of technical, 
procedural, observer, and biological factors (Iskandrian et al., 2014). The intrinsic variability 
of cardiac MRI becomes important in interpreting serial tests in both research (such as in the 
CRIB-Donor study), and in the clinical setting to be able to define a true pathological change 
in a given patient. Therefore, in order to calculate a SDC for each LV parameter, we opted to 
include an assessment of short-term interstudy reproducibility. Despite recent 
improvements in MRI scanner performance and pulse sequences, it has been over a decade 
since the test, re-test (interstudy) reproducibility of LV mass and volume measurements 
made in normal adult subjects using manual contouring has been reported (Grothues et al., 
2002, Moon et al., 2002). Our interstudy reproducibility was excellent which may in part 
reflect implementation of contemporary imaging hardware and potentially improved cine 
sequences. 
 For completeness, both relative and absolute indices of agreement are presented: 
ICC and SDC, respectively. However, when interpreting clinical tests it becomes more 
intuitive and appropriate to calculate a SDC because this index can account for both random 
and systematic error in measurements (Vaz et al., 2013). The SDC is based on a statistical 
computation and is distinct from the minimally clinically important difference (MCID) which 
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is set on clinical grounds and represents how large the change in an outcome should be, to 
be deemed clinically important. Establishing a MCID for LV parameters was beyond the 
scope of the current study.  
 All images in this study were acquired using a standardized imaging protocol on a 
single scanner at one center, conditions which might often be replicated in routine practice. 
Studies were also performed however, by the same technician and analysed by a single 
trained observer which may approximate less to standard clinical circumstances. 
Nevertheless, this scenario provides the optimal setting to maximize test-retest reliability 
and derive the lowest achievable SDC for respective LV parameters. It should also be 
remembered that as an index of test-retest reliability, the ICC is affected by the 
characteristics of the individuals being tested and will therefore likely be higher in this 
healthy cohort as compared to diseased populations (Moon et al., 2002). Indeed, these 
results may be less generalisable to patients with heart disease where the reliability of SSFP 
cine imaging may be hampered by gating issues (e.g. atrial fibrillation or frequent ectopy) or 
the inability to perform adequate breath holds (e.g. heart failure). 
 The current study was not designed or indeed powered, to examine changes in LV 
structure or function due to “normal” ageing; cross-sectional data provided from the Multi-
Ethnic Study of Atherosclerosis study suggest that LV mass decreases incrementally with 
increasing age by -0.3 g per year (Cheng et al., 2009). By contrast, the novelty of the current 
study lies in its longitudinal design which has enabled an assessment of within-subject 
variability of LV functional metrics over a 12 month period. Importantly, the data presented 
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herein demonstrate that in health, the size of any change to the LV observed at 1 year is not 
significantly different in magnitude to the respective SDC. 
 
In conclusion, the results of this study have demonstrated high reproducibility for the 
measurements of LV mass and function. These findings support the hypothesis that 
measured differences in the LV are due to “real” changes in the cardiovascular system. By 
emphasising the reproducibility and reliability of cardiac MRI data, these data have 
particular importance for the interpretation of routine clinical reports, as well as longitudinal 
research studies presented in this thesis (Chapter 5, CRIB-Donor study). In patients 
undergoing repeat annual assessment by cardiac MRI, even small changes in LV function, 
size and mass (which are greater than the SDC for the given parameter) may be attributable 
to disease progression and/or a treatment response. 
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4. VALIDATION OF CARDIAC MAGNETIC RESONANCE FEATURE-TRACKING 
METHODOLOGY FOR THE ASSESSMENT OF MYOCARDIAL STRAIN 
 
4.1. Introduction 
 
Myocardial strain is a sensitive measure of regional and global LV contractile function (Mor-
Avi et al., 2011).  Recognising abnormal strain allows the early detection of subtle LV 
dysfunction which precedes decreases in ejection fraction in conditions such as dilated 
cardiomyopathy (DCM) (Poterucha et al., 2012, Hankiewicz et al., 2008).  Early identification 
of myocardial dysfunction is important for clinical risk stratification, prompt initiation of 
treatment and guides therapeutic decision-making (Donal et al., 2012).  We recently used 
dynamic tissue-tagging cardiac MRI to identify improvements in longitudinal strain 
parameters following treatment with spironolactone in patients with early-stage chronic 
kidney disease (Edwards et al., 2010). 
 
Myocardial tagging by cardiac MRI has been widely accepted as the reference standard non-
invasive imaging technique for quantifying strain after validation against sonomicrometry in 
dogs (Yeon et al., 2001) and non-homogenous strain phantoms (Young et al., 1993).  Most 
MR tagging techniques create a visible pattern of magnetisation saturation in a grid or with 
parallel lines on the magnitude reconstructed images which are then analysed, e.g. spatial 
modulation of magnetization (SPAMM), or by extracting information about myocardial tags 
in k-space, e.g. harmonic phase (HARP) (Young et al., 2012b).  All tagging pulse sequences 
have at least one disadvantage which may include tag fading, low signal to noise ratio, long 
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acquisition times requiring prolonged breath-holds, limited availability of validated post-
processing software and protracted retrospective analysis.  Moreover, each tagging 
technique requires the acquisition of additional sequences to those which are routinely 
performed, a factor limiting clinical applicability. 
 
Cardiac magnetic resonance feature-tracking analysis offers a fast and practical method to 
calculate strain from routinely acquired SSFP cine images without the need to perform 
additional tagged sequences (Hor et al., 2011).  In a large study of boys with Duchenne 
muscular dystrophy, CMR-FT was proposed as an accurate method for measuring strain in a 
comparison with HARP although quantification was limited to average circumferential 
systolic strain in the mid-LV short axis slice (Hor et al., 2010).  Despite recent reports 
addressing inter-study (Morton et al., 2012), and inter and intra-observer variability for 
CMR-FT (Schuster et al., 2011b, Schuster et al., 2011a), there has been no attempt to 
validate this technique for diastolic SR calculation against a reference standard myocardial 
tagging analysis (Harrild et al., 2012).  Furthermore, according to one previous study the 
CMR-FT framework cannot yet be reliably extended to assess long axis function (Augustine 
et al., 2013).  Therefore, the aim of the current study was to compare CMR-FT with SPAMM 
tissue tagging for the computation of longitudinal and circumferential systolic and diastolic 
strain measures in a group of healthy adult controls and patients with DCM. 
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4.2. Methods 
 
This study was approved by the West Midlands Research Ethics Committee and carried out 
in accordance with the principles of the Declaration of Helsinki.  All patients provided 
informed written consent. 
 
4.2.1. Study Population 
 
Control subjects.  Normal healthy adults were prospectively identified from CRIB-Donor, a 
study which aimed to examine the effects of living kidney donation on cardiovascular 
structure and function (Chapter 5).  The current UK exclusion criteria for living kidney 
donation are given in Table 5-2. Prior to nephrectomy, all potential kidney donors that 
underwent normal baseline cardiac MR studies from March 2011 to June 2012 were 
included as healthy controls. Control subjects also had normal 12-lead electrocardiography, 
stress echocardiography and routine haematology and biochemistry profiles. 
 
DCM subjects.  Patients with DCM were prospectively identified as part of a detailed 
pathophysiological study assessing the effects of myocardial fibrosis on cardiac mechanics 
(REC: 12/WM/0157).  The diagnosis of idiopathic DCM was made on the basis of LV 
dilatation and systolic dysfunction in the absence of valvular heart disease, congenital heart 
disease and ischaemic heart disease sufficient to cause ventricular impairment, following 
gadolinium contrast-enhanced cardiac MRI (Assomull et al., 2006), and normal coronary 
angiography. 
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4.2.2. Imaging Protocol 
 
Cardiac MRI studies were conducted using a 1.5-T scanner (Magnetom Verio, Siemens, 
Erlangen, Germany). The time taken to acquire images for each patient was recorded. All 
cardiac magnetic resonance images were acquired by me with the assistance of Dr. Colin 
Chue, Dr. Richard Steeds, Dr. Nicola Edwards and Dr. Robin Taylor. 
Steady State Free Precession Cine Imaging. Vertical long axis (VLA) and horizontal long axis 
(HLA) SSFP cine imaging of the left and right ventricles was performed and these images 
were used to pilot the LV short axis stack as described in section 2.1 (Maceira et al., 2006). 
Myocardial tagging. As described in Section 2.1.2, three short axis tagged images at the LV 
base (mitral valve), middle (papillary muscle) and apex, as well as a HLA image were acquired 
using prospective electrocardiographic gating. Tagging was performed prior to the 
administration of gadolinium. 
 
4.2.3. Myocardial Strain and Strain Rate Analysis 
 
A timed off-line analysis was performed on tagged and SSFP images at identical slice 
positions by two independent blinded observers (R.J.T and W.E.M.; 4 and 5 years’ 
experience, respectively).  Both tagged and SSFP slices were reviewed by an independent 
expert (R.P.S; 13 years’ experience) and only high quality MR studies were included for 
analysis. 
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CIMTag dynamic tissue-tagging.  Tagged images were analyzed with CIMTag2D software 
(Cardiac Image Modelling, University of Auckland, Auckland, NZ).  An overview of the 
generalized analysis framework is depicted in Figure 1.  The model geometry was initialized 
in the first frame (end-diastole) using guide-point modelling (Young et al., 2000).  Briefly, 
guide points placed by the user on the endocardial and epicardial border of the LV in the 
end-diastolic frame were fitted by the model using linear least squares optimization, 
resulting in an initial segmentation of the LV with minimal user interaction (Figure 4-1a).  The 
reference model was then automatically warped to fit the tissue displacement map given by 
the SPAMM images.  The tissue displacement map was given from a nonrigid registration 
tracking procedure as previously described (Young et al., 2012b, Li et al., 2008, Li et al., 
2010).  Points were tracked from frame to frame using the incremental displacement maps.  
A texture map of model stripes was overlaid on the display to provide a graphical 
representation of the tracking result (Figure 4-1b).  The initial tag locations, spacing and 
orientation were automatically determined by interrogating the location of the harmonic 
peaks in the k-space data.  The user corrected any tracking errors by placing guide points on 
the texture map overlay, thereby interactively warping the model to provide a best fit 
between image tags and model stripes (Figure 4-1c).  The HLA image sequence was used to 
determine LV longitudinal strain and SR.   Left ventricular circumferential strain and SR were 
measured from the 3 short axis views.  Whole wall global peak systolic strain and SR values 
were obtained and subdivided according to wall thickness into respective thirds: 
subepicardium, midwall and subendocardium. 
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Figure 4-1. Overview of the Generalized CIMTag2D Analysis Framework. 
 
a) Guide points placed by the user on the endocardial and epicardial border of the LV in the first 
frame (end-diastole) were fitted by the model using linear least squares optimization, resulting in an 
initial segmentation of the LV with minimal user interaction and subsequent initialization of the finite 
element model in the first frame of the SPAMM sequence. 
b) Visual depiction of the tissue displacement map provided by non-rigid registration image tracking 
process at end-diastole. 
c) User corrected texture map overlay as seen after placing guide points in end-systole, thereby 
interactively warping the model to provide a best fit between image tags and model stripes. 
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CMR-FT analysis.  Diogenes CMR-FT software (TomTec Imaging Systems, Munich, Germany), 
a vector-based analysis tool, was used to perform subendocardial strain analysis in the 
corresponding SSFP images (Figure 4-2).  Endocardial borders were drawn manually in the 
end-diastolic frame for each image.  The CMR-FT software automatically propagated the 
contour and followed its features (brightness gradient at the tissue-cavity interface, 
dishomogeneties of the tissue, spatial coherence) throughout the remainder of the cardiac 
cycle.  Global measures of subendocardial longitudinal strain were derived from the HLA 
view.  Global subendocardial circumferential strain parameters were derived from the three 
short axis views.  As for tagging analysis, global diastolic SR signals were recorded during 
early filling.  CMR-FT segmental strain parameters were not extracted for comparison with 
tagging because a series of reports demonstrate high intra- and inter-observer variability for 
regional data (Kempny et al., 2012, Morton et al., 2012, Schuster et al., 2011a, Schuster et 
al., 2011b). 
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Figure 4-2. Acquisition of Circumferential Strain with FT Software in a Normal Subject. 
 
The endocardial contour of a midventricular SSFP image is drawn manually. The first segment is 
always set in the anterior septum for consistency. 
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4.2.4. Left Ventricular Function, Volumes, Mass and Wall Thickness 
 
Analysis of LV function, volume and LV mass was performed offline (Argus Software, 
Siemens, Erlangen, Germany) as described in Section 2.1.1. Left ventricular wall thickness 
was also measured in the short axis in each of the six segments of the mid LV according to 
the AHA standardized model, and at the identical slice position from which mid LV 
circumferential strain parameters were derived. 
 
4.2.5. Statistical Analysis 
 
Data are presented as mean ± standard deviation, median (interquartile range) or frequency 
(percentage).  Data distribution for continuous variables was assessed using normality plots 
and the Kolmogorov-Smirnov test.  Non-parametric data were log-transformed prior to 
analysis to achieve normality.  Individual strain and SR values obtained using the two 
different methods were compared using the Bland-Altman technique and Pearson’s 
correlation.  A Spearman’s rank correlation of the differences with the means of parameters 
derived from FT and CIMTag was performed.  The mean strain parameters derived from the 
two techniques were compared using paired t tests if normally distributed.  Continuous 
variables from controls and DCM patients were compared using independent t tests.  An 
ANOVA with repeated measures with a Greenhouse-Geisser correction was used to compare 
differences in tagging derived strain parameters across the 3 myocardial layers.  Statistical 
analysis was performed using SPSS v21.  A type I error rate <5% (p<0.05) was considered 
statistically significant.  
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4.2.6. Variability of CIMTag2D and CMR-FT Strain Measurements 
 
Inter-observer and intra-observer variability assessments were performed using a paired t 
test and reported as a bias (mean difference) and standard deviation (SD). The coefficient of 
variability, defined as the SD of the differences divided by their mean, and the ICC for 
absolute agreement were also calculated (Grothues et al., 2002). 
 
4.3. Results 
 
4.3.1. Study Population 
 
A total of 45 subjects were identified (35 controls, 10 DCM); age was 44 ± 14 years.  Baseline 
characteristics are shown in Table 4-1.  Compared with healthy controls, DCM patients were 
older (58 ± 14 vs. 41 ± 12 years, p<0.01) and had higher body weight (87 ± 17 vs. 77 ± 11 kg, 
p<0.01).  No other demographic data were significantly different. 
 
All participants completed the full imaging protocol.  Two controls were however, excluded 
from the imaging analysis because of poor tagging imaging quality due to breathing artefacts 
(n = 1) and electrocardiogram gating issues (n=1); these participants were therefore only 
included in volumetric and LV mass assessments.  All SSFP images were of excellent image 
quality and compatible with CMR-FT software. 
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Table 4-1. Baseline Characteristics of the Study Population. 
Baseline characteristics 
Controls 
(n= 35) 
DCM 
(n= 10) 
Overall 
(n=45) 
Age (years) 41 ± 12 58 ± 14* 44 ± 14 
Male gender (%) 26 (62) 6 (60) 32 (63) 
Ethnicity 
  Caucasian (%) 
  Asian (%) 
  Afro-Caribbean (%) 
 
36 (90) 8 (80) 45 (88) 
3 (8) 1 (10) 4 (8) 
1 (2) 1 (10) 2 (4) 
Weight (kg) 77 ± 11 87 ± 17* 79 ± 13 
Heart rate (bpm) 66 ± 10 70 ± 10 67 ± 10 
Systolic blood pressure (mmHg) 120 ± 11 112 ± 14** 119 ± 12 
Diastolic blood pressure (mmHg) 72 ± 6 72 ± 11 72 ± 7 
Left ventricular ejection fraction (%) 71 ± 6 33 ± 15† 69 (64 – 74)‡ 
End-diastolic volume (mL) 124 ± 25 205 ± 51† 137 ± 43 
End-systolic volume (mL) 37 ± 13 140 ± 60† 39 (30 – 59) 
Stroke volume (mL) 87 ± 14 64 ± 21† 84 ± 17 
Left ventricular mass (g) 122 ± 27 161 ± 21 123 (106 – 141) 
Left ventricular mass index (g/m2) 64 ± 11 82 ± 20 64 (59 – 73) 
Late gadolinium enhancement result - All negative - 
Data are mean ± standard deviation, frequency (percentage) or median (interquartile range). DCM, 
dilated cardiomyopathy. *p<0.01;  **p<0.05;  †p<0.001 (compared with controls using an independent 
two-tailed Student’s t test). ‡ Range of left ventricular ejection fraction for overall cohort was 19-79%. 
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4.3.2. Myocardial Strain and Strain Rate Analysis 
 
A detailed summary of the statistical comparison of FT versus tagging for all global strain and 
SR parameters is presented in Table 4-2. 
 
Global longitudinal strain (Ell).  Tagged imaging revealed a transmural longitudinal strain 
gradient; there was a progressive increase in longitudinal deformation from the 
subepicardium through the midwall and into the subendocardium (p<0.001; Figure 4-3).  In 
an analysis of all subjects, CMR-FT peak systolic global longitudinal strain (Ell) correlated 
most strongly with CIMTag Ell values derived from tagging of the subendocardium (r=0.70, 
p<0.001; Figure 4-4a).  A Bland Altman plot (Figure 4-4b) demonstrates agreement but with 
a small systematic overestimation from CMR-FT (-18.1 ± 5.0% vs. -16.7 ± 4.8%, bias 1.3 ± 
3.8%, p=0.03).  Whilst in DCM patients mean peak global Ell values were not significantly 
different between the two techniques (-9.7 ± 4.5% vs. -8.8 ± 3.9%, p=0.44), among healthy 
controls there was a small but significant difference in Ell values derived from CMR-FT versus 
tagged imaging (-19.5 ± 3.5% vs. -18.0 ± 3.5%, p=0.04; Figure 4-5). 
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Table 4-2. Comparison of CMR-FT versus Tagging Derived Global Strain and Strain Rate Parameters 
for the Overall Cohort, in Healthy Controls and in Dilated Cardiomyopathy Subjects. 
HEALTHY CONTROLS (n=35) 
 
Feature 
Tracking 
Tagging whole 
Wall 
Tagging sub- 
epicardium 
Tagging mid 
wall 
Tagging sub-
endocardium 
Long axis function (HLA) 
Peak systolic longitudinal E 
     
  Mean value ± SD (%) -19.5 ± 3.5 -18.0 ± 3.5 -15.9 ± 3.0  -17.7 ± 3.2  -18.0 ± 3.5 
    p-value* - 0.01  <0.001 0.002 0.04 
  Pearson’s correlation coefficient - 0.29 0.25  0.27  0.35 
    p-value** - 0.09  0.15 0.11 0.04 
  Bias ± SD (%) - 2.51 ± 4.0  3.6 ± 4.0 3.6 ± 4.0 1.42 ± 4.0  
Peak systolic longitudinal SR      
  Mean value ± SD (1/s) -1.12 ± 0.22 -0.95 ± 0.24 -0.90 ± 0.23 -0.97 ± 0.24 -1.03 ± 0.26 
    p-value* - 0.001 <0.001 0.002 0.07 
  Pearson’s correlation coefficient - 0.27 0.27 0.27 0.31 
    p-value** - 0.12 0.12 0.11 0.06 
  Bias ± SD (1/s) - 0.17 ± 0.28 0.22 ± 0.27 0.16 ± 0.28 0.09 ± 0.28 
Early diastolic longitudinal SR      
  Mean value ± SD (1/s) 1.19 ± 3.5 0.69 ± 0.30 0.67 ± 0.30 0.70 ± 0.30 0.72 ± 0.30 
    p-value* - <0.001 <0.001 <0.001 <0.001 
  Pearson’s correlation coefficient - 0.20 0.22 0.19 0.19 
    p-value** - 0.25 0.20 0.27 0.27 
  Bias ± SD (1/s) - -0.50 ± 0.40 -0.51 ± 0.40 -0.49 ± 0.40 -0.47 ± 0.40 
Short axis function (mid LV) 
Peak systolic circumferential E 
     
  Mean value ± SD (%) -24.8 ± 2.9 -18.6 ± 2.5 -12.9 ± 2.0 -18.3 ± 2.6 -24.9 ± 3.0 
    p-value* - <0.001 <0.001 <0.001 0.90 
  Pearson’s correlation coefficient - 0.15 0.02 0.10 0.26 
    p-value** - 0.39 0.92 0.55 0.13 
  Bias ± SD (%) - 6.2 ± 3.5 11.9 ± 3.5 6.6 ± 3.7 -0.08 ± 4.0 
Peak systolic circumferential SR      
  Mean value ± SD (1/s) -1.48 ± 0.27 -1.01 ± 0.18 -0.72 ± 0.13 -0.98 ± 0.18 -1.34 ± 0.31 
    p-value* - <0.001 <0.001 <0.001 0.02 
  Pearson’s correlation coefficient - 0.22 0.01 0.18 0.28 
    p-value** - 0.21 0.99 0.31 0.09 
  Bias ± SD (1/s) - 0.48 ± 0.29 0.76 ± 0.30 0.50 ± 0.30 0.14 ± 0.06 
Early diastolic circumferential SR      
  Mean value ± SD (1/s) 1.34 ± 0.32 0.79 ± 0.16 0.48 ± 0.11 0.76 ± 0.16 1.15 ± 0.24 
    p-value* - <0.001 <0.001 <0.001 0.001 
  Pearson’s correlation coefficient - 0.53 0.44 0.52 0.45 
    p-value** - 0.001 <0.01 0.001 <0.01 
Bias ± SD (1/s) - -0.55 ± 0.27 -0.85 ± 0.29 -0.58 ± 0.28 -0.19 ± 0.30 
 
 
DILATED CARDIOMYOPATHY (n=10) 
 
 
    
Long axis function (HLA) 
Peak systolic longitudinal E 
     
  Mean value ± SD (%) -9.7 ± 4.7 -8.2 ± 3.5 -7.6 ± 3.0 -8.3 ± 3.6 -8.8 ± 3.9 
    p-value* - 0.26 0.16 0.30 0.44 
 126 
 
  Pearson’s correlation coefficient - 0.77 0.73 0.75 0.80 
    p-value** - 0.08 0.10 0.09 0.05 
  Bias ± SD (%) - 1.5 ± 2.9 2.1 ± 3.1 1.4 ± 3.0 0.9 ± 2.7 
Peak systolic longitudinal SR      
  Mean value ± SD (1/s) -0.56 ± 0.19 -0.45 ± 0.19 -0.46 ± 0.15 -0.46 ± 0.19 -0.47 ± 0.23 
    p-value* - 0.04 0.16 0.05 0.08 
  Pearson’s correlation coefficient - 0.88 0.65 0.87 0.91 
    p-value** - 0.02 0.16 0.03 0.01 
  Bias ± SD (1/s) - 0.11 ± 0.10 0.10 ± 0.15 0.10 ± 0.10 0.09 ± 0.10 
Early diastolic longitudinal SR      
  Mean value ± SD (1/s) 0.49 ± 0.20 0.31 ± 0.22 0.28 ± 0.18 0.31 ± 0.23 0.35 ± 0.26 
    p-value* - 0.07 0.05 0.07 0.17 
  Pearson’s correlation coefficient - 0.57 0.45 0.59 0.60 
    p-value** - 0.24 0.38 0.22 0.21 
  Bias ± SD (1/s) - -0.19 ± 0.20 -0.22 ± 0.20 -0.19 ± 0.19 -0.14 ± 0.22 
Short axis function (mid LV) 
Peak systolic circumferential E 
     
  Mean value ± SD (%) -9.6 ± 4.8 -7.2 ± 2.4 -6.3 ± 1.8 -7.2 ± 2.2 -8.1 ± 1.9 
    p-value* - 0.15 0.07 0.15 0.36 
  Pearson’s correlation coefficient - 0.70 0.76 0.73 0.61 
    p-value** - 0.12 0.08 0.10 0.20 
  Bias ± SD (%) - 2.5 ± 3.5 3.3 ± 3.6 2.4 ± 3.5 1.6 ± 3.8 
Peak systolic circumferential SR      
  Mean value ± SD (1/s) -0.57 ± 0.23 -0.41 ± 0.10 -0.36 ± 0.09 -0.40 ± 0.10 -0.50 ± 0.23 
    p-value* - 0.06 0.04 0.05 0.37 
  Pearson’s correlation coefficient - 0.80 0.67 0.82 0.73 
    p-value** - 0.06 0.14 <0.05 0.10 
  Bias ± SD (1/s) - 0.16 ± 0.17 0.20 ± 0.19 0.17 ± 0.16 0.07 ± 0.17 
Early diastolic circumferential SR      
  Mean value ± SD (1/s) 0.48 ± 0.26 0.46 ± 0.20 0.30 ± 0.13 0.44 ± 0.20 0.63 ± 0.26 
    p-value* - 0.89 0.23 0.79 0.41 
  Pearson’s correlation coefficient - 0.18 0.20 0.20 0.20 
    p-value** - 0.73 0.71 0.71 0.71 
Bias ± SD (1/s) - -0.03 ± 0.36 -0.18 ± 0.32 -0.04 ± 0.36 0.15 ± 0.41 
E, Lagrangian strain; HLA, horizontal long axis; LV,left ventricle; SD, standard deviation; SR, strain rate 
*Feature tracking derived means compared with tagging measurements using a paired Student’s t 
test. **Using Pearson’s r, correlation coefficient. 
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Figure 4-3. Global Longitudinal Strain Measures Calculated From CMR-FT and a Targeted Tagging 
Analysis Across the Three Layers of the Myocardium. 
When using an ANOVA with repeated measures with a Greenhouse-Geisser correction, the mean 
scores for peak systolic global longitudinal strain across the 3 layers of the myocardium were 
statistically different (F(1.2, 49.9)=54.8, P<0.001). 
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Figure 4-4. (a) Pearson Correlation and (b) Bland Altman Plots Demonstrating Agreement for Peak 
Systolic Global Longitudinal Strain Calculation Using CMR-FT versus Tagging. 
Spearman’s rank correlation of the differences and the means was non-significant (ρ=0.078, 
P=0.625). 
a 
b 
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Figure 4-5. Comparison of CIMTag versus CMR-FT Derived Peak Systolic Global Longitudinal Strain 
Between Control and DCM subjects. 
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Longitudinal strain rate.  The subendocardial layer also had the highest values for peak 
systolic longitudinal SR derived from tagging (Table 4-2).  Among all participants, FT-peak 
systolic global longitudinal SR correlated with corresponding CIMTag derived measurements 
from the subendocardium (r=0.64, p<0.001; Figure 4-6a).  There was agreement between 
the two techniques for peak systolic global longitudinal SR values with a small tendency 
towards higher values from CMR-FT compared with tagging (-1.04 ± 0.29 1/s vs. -0.95 ± 0.32 
1/s, bias 0.09 ± 0.26 1/s, p=0.04; Figure 4-6b).  Although the correlation remained significant 
(r=0.42, p=0.007), the weakest agreement between the two techniques was for early 
diastolic global longitudinal SR (1.10 ± 0.40 1/s vs. 0.67 ± 0.32 1/s, bias -0.42 ± 0.40 1/s, 
p<0.001; Figure 4-7). 
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Figure 4-6. (a) Pearson Correlation and (b) Bland Altman Plots Demonstrating Agreement for Peak 
Systolic Global Longitudinal Strain Rate Calculation Using CMR-FT versus Tagging. 
Spearman’s rank correlation of the differences and the means was non-significant (ρ=0.196, 
P=0.213). 
a 
b 
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Figure 4-7. (a) Pearson Correlation and (b) Bland Altman Plots Demonstrating Agreement for Early 
Diastolic Global Longitudinal Strain Rate Calculation Using CMR-FT versus Tagging. 
Spearman’s rank correlation of the differences and the means was significant (ρ=-0.329, P=0.036) 
suggesting a proportional error with a downward trend.  
a 
b 
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Circumferential strain (Ecc).  Across all subjects, CMR-FT derived peak systolic global 
circumferential strain measurements at the mid LV slice were not significantly different from 
those calculated via tagging (Figure 4-8).  As with the long axis analysis, FT-Ecc values 
correlated most strongly with CIMTag-Ecc values derived from the subendocardium (r=0.83, 
p<0.001; Figure 4-9 and Figure 4-10a). A Bland-Altman plot shows close agreement between 
the two techniques across the entire cohort with neither systemic overestimation nor 
underestimation and a bias of only 0.2 ± 4.0% (-22.7 ± 6.2% vs. -22.5 ± 6.9%, p=0.80; Figure 
4-10b). 
 
 
 
 
Figure 4-8. Comparison of CIMTag versus CMR-FT Derived Peak Systolic Global Circumferential Strain 
between Control and DCM Subjects.  
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Figure 4-9. Global Circumferential Strain Measures Calculated from CMR-FT and a Targeted Tagging 
Analysis Across the Three Layers of the Myocardium. 
Using an ANOVA with repeated measures with a Greenhouse-Geisser correction, the mean scores for 
peak systolic global circumferential strain across the myocardium were statistically different (F(1.0, 
41.8)=218.4, P<0.001). 
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Figure 4-10. (a) Pearson Correlation and (b) Bland Altman Plots Demonstrating Agreement for Peak 
Systolic Global Circumferential Strain Calculation Using CMR-FT versus Tagging. 
Spearman’s rank correlation of the differences and the means was non-significant (ρ=0.292, P=0.06). 
a 
b 
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Measures of circumferential strain from the mid LV slice showed better agreement between 
CMR-FT and CIMTag compared with measures derived from the LV base and apex (Table 
4-3). Tagged imaging also showed a graded increase in circumferential shortening from the 
base towards the apex. 
 
Circumferential strain rate.  Among all participants, FT-peak systolic global circumferential SR 
correlated closely with corresponding CIMTag derived measurements from the 
subendocardium (r=0.69, p<0.001; Figure 4-11a). As for longitudinal SR, Bland-Altman 
analysis also showed agreement between the two techniques for calculation of peak systolic 
global circumferential SR (-1.35 ± 0.42 1/s vs. -1.22 ± 0.42 1/s, bias 0.13 ± 0.33 1/s; Figure 
4-11).  FT-early diastolic global circumferential SR also correlated with tagging derived values 
from the subendocardium (r=0.64, p<0.001; Figure 4-12a) and showed satisfactory 
agreement (1.21 ± 0.44 vs. 1.07 ± 0.30, bias -0.14 ± 0.34 1/s; Figure 4-12b). 
 
Influence of wall thickness. There was no significant difference between the mid LV 
ventricular wall thickness of DCM patients and healthy controls (7.2 ± 1.1 mm vs. 7.3 ± 1.0 
mm, p=0.7).  The limits of agreement for calculation of peak systolic circumferential strain in 
patients with DCM versus healthy controls were comparable (-7.76 to 7.92 % vs. -5.85 to 
9.05 %).  For calculation of peak systolic circumferential strain across the overall cohort, 
there was no association between ventricular wall thickness and the size of the bias relative 
to its mean value (r = -0.15, p=0.33).   
 137 
 
Table 4-3. Comparison of CMR-FT versus Tagging Derived Global Circumferential Strain in the Short Axis at the 
Apex and Base for the Overall Cohort. 
 Feature 
tracking 
Tagging 
whole wall 
Tagging sub 
epicardium 
Tagging mid 
wall 
Tagging sub 
endocardium 
Short axis function (base) 
Peak systolic circumferential E 
 
Mean value ± SD (%) -23.9 ± 6.4 -12.8 ± 4.1 -9.6 ± 2.8 -12.6 ± 4.0 -16.7 ± 5.9 
p-value* - <0.001 <0.001 <0.001 <0.001 
Pearson’s r - 0.63 0.52 0.64 0.63 
p-value** - <0.001 <0.001 <0.001 <0.001 
Bias ± SD (%) - 11.1 ± 5.0 14.4 ± 5.5 11.3 ± 4.9 7.3 ± 5.3 
Short axis function (apex) 
Peak systolic circumferential E 
 
Mean value ± SD (%) -26.2 ± 9.2 -18.5 ± 4.7 -12.7 ± 3.3 -18.2 ± 4.6 -24.9 ± 7.0 
p-value* - <0.001 <0.001 <0.001 0.27 
Pearson’s r - 0.56 0.39 0.56 0.59 
p-value** - <0.001 0.01 <0.001 <0.001 
Bias ± SD (%) - 7.7 ± 7.6 13.5 ± 8.5 7.9 ± 7.6 1.3 ± 7.6 
E, Lagrangian strain; SD, standard deviation. 
*FT derived means compared with tagging measurements using a paired Student’s t test. 
**Using Pearson’s r, correlation coefficient.
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Figure 4-11. (a) Pearson Correlation and (b) Bland Altman Plots Demonstrating Agreement for Peak 
Systolic Global Circumferential Strain Rate Calculation Using CMR-FT versus Tagging. 
Spearman’s rank correlation of the differences and the means was non-significant (ρ=-0.034, 
P=0.833).  
a 
b 
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Figure 4-12. (a) Pearson Correlation and (b) Bland Altman Plots Demonstrating Agreement for Early 
Diastolic Global Circumferential Strain Rate Calculation using CMR-FT versus Tagging. 
Spearman’s rank correlation of the differences and the means was significant (ρ=-0.315, P=0.045) 
suggesting a proportional error with a downwards trend.  
a 
b 
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Table 4-4 shows the large difference in post-processing time taken between the two 
techniques (5.9 ± 0.8 vs. 23.2 ± 3.5 min, p<0.001). 
 
 
Table 4-4. Time Taken for Image Acquisition and Post-processing Analysis. 
    Feature tracking Tagging 
SSFP acquisition time (min) 12.1 ± 3.4 12.1 ± 3.4 
SPAMM acquisition time (min) - 8.4 ± 2.3 
Post-processing time (min) 5.9 ± 0.8* 23.2 ± 3.5 
Data are mean ± SD. SSFP, steady-state free precession; SPAMM, spatial modulation of magnetization. 
*p<0.001 (means compared using a paired Student’s t test). 
 
 
4.3.3. Interobserver and Intraobserver Variability for Strain and Strain Rate  
 
Intraobserver and interobserver variability for CMR-FT analysis of peak systolic global 
longitudinal strain was small (bias -0.49 ± 1.83 % and 0.22 ± 1.13 %; respectively). The 
reproducibility of CMR-FT strain measurements compared favourably with CIMTag, 
particularly with respect to interobserver variability (Table 4-5 and Table 4-6). 
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Table 4-5. Intraobserver and Interobserver Variability for CMR-FT Derived Global Strain Parameters. 
Parameter Variability Bias ± SD p value Limits of Agreement 
Coefficient of 
Variation (%) 
Intra-class Correlation 
Coefficient (95% CI) 
Ell (%) Intraobserver 
Interobserver 
-0.49 ± 1.83 
0.22 ± 1.13 
0.29 
0.42 
-4.08 to 3.11 
-1.99 to 2.42 
7.68 
5.48 
0.88 (0.72 to 0.96) 
0.98 (0.94 to 0.99) 
SSRll (1/s) Intraobserver 
Interobserver 
0.02 ± 0.18 
0.02 ± 0.16 
0.70 
0.61 
-0.34 to 0.38 
-0.30 to 0.33 
17.89 
12.95 
0.89 (0.72 to 0.96) 
0.86 (0.67 to 0.95) 
DSRll (1/s) Intraobserver 
Interobserver 
0.05 ± 0.18 
0.01 ± 0.28 
0.27 
0.90 
-0.30 to 0.40 
-0.53 to 0.55 
14.84 
20.99 
0.85 (0.64 to 0.94) 
0.85 (0.63 to 0.94) 
Ecc (%) Intraobserver 
Interobserver 
-0.34 ± 0.87 
0.63 ± 1.29 
0.09 
0.06 
-2.05 to 1.36 
-1.90 to 3.16 
3.55 
4.95 
0.96 (0.90 to 0.99) 
0.93 (0.81 to 0.97) 
SSRcc (1/s) Intraobserver 
Interobserver 
-0.02 ± 0.08 
0.02 ± 0.11 
0.21 
0.56 
-0.18 to 0.13 
-0.20 to 0.23 
5.36 
6.68 
0.96 (0.90 to 0.98) 
0.94 (0.84 to 0.98) 
DSRcc (1/s) Intraobserver 
Interobserver 
0.00 ± 0.07 
-0.01 ± 0.11 
0.92 
0.63 
-0.13 to 0.13 
-0.24 to 0.21 
5.29 
7.82 
0.97 (0.93 to 0.99) 
0.96 (0.89 to 0.98) 
Ecc, Peak systolic global circumferential strain; Ell, Peak systolic global longitudinal strain; SSRcc, Peak systolic global circumferential strain rate; SSRll, Peak 
systolic global longitudinal strain rate; DSRcc, Early diastolic circumferential strain rate; DSRll, Early diastolic longitudinal strain rate. 
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Table 4-6.  Intraobserver and Interobserver Variability for Myocardial Tagging Derived Global Strain Parameters. 
Parameter Variability Bias ± SD p value Limits of Agreement 
Coefficient of 
Variation (%) 
Intra-class Correlation 
Coefficient (95% CI) 
Ell (%) Intraobserver 
Interobserver 
-0.47 ± 0.62 
-0.47 ± 2.02 
0.04 
0.49 
-1.68 to 0.74 
-4.42 to 3.49 
3.41 
11.44 
0.97 (0.83 to 0.99) 
0.75 (0.29 to 0.93) 
SSRll (1/s) Intraobserver 
Interobserver 
0.00 ± 0.06 
-0.01 ± 0.17 
0.91 
0.90 
-0.11 to 0.11 
-0.33 to 0.32 
6.64 
17.27 
1.00 (0.98 to 1.00) 
0.60 (-0.04 to 0.89) 
DSRll (1/s) Intraobserver 
Interobserver 
0.05 ± 0.10 
0.11 ± 0.20 
0.14 
0.12 
-0.14 to 0.24 
-0.28 to 0.49 
14.15 
31.59 
0.89 (0.62 to 0.97) 
0.45 (-0.11 to 0.82) 
Ecc (%) Intraobserver 
Interobserver 
-0.39 ± 1.22 
-0.53 ± 1.53 
0.39 
0.30 
-2.79 to 2.09 
-3.54 to 2.48 
4.79 
6.01 
0.92 (0.74 to 0.98) 
0.86 (0.56 to 0.96) 
SSRcc (1/s) Intraobserver 
Interobserver 
0.00 ± 0.06 
-0.02 ± 0.18 
0.92 
0.71 
-0.12 to 0.12 
-0.37 to 0.33 
4.63 
13.86 
0.95 (0.82 to 0.99) 
0.46 (-0.25 to 0.83) 
DSRcc (1/s) Intraobserver 
Interobserver 
0.03 ± 0.08 
0.09 ± 0.19 
0.25 
0.15 
-0.13 to 0.19 
-0.27 to 0.46 
7.38 
16.75 
0.95 (0.81 to 0.99) 
0.78 (0.36 to 0.94) 
Ecc, Peak systolic global circumferential strain; Ell, Peak systolic global longitudinal strain; SSRcc, Peak systolic global circumferential strain rate; SSRll, 
Peak systolic global longitudinal strain rate; DSRcc, Early diastolic circumferential strain rate; DSRll, Early diastolic longitudinal strain rate.
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4.4. Discussion 
 
In this study, we have principally compared a SSFP FT-based algorithm against a 
reference standard tagged image analysis (SPAMM) for the assessment of Lagrangian 
strain and SR.  This report builds upon recent validation work by including comparisons 
of 2D longitudinal and circumferential strain and SR during systole and diastole; only 
systolic strain parameters have previously been validated (Hor et al., 2010, Harrild et al., 
2012, Augustine et al., 2013).  We have compared the ability of the two techniques to 
accurately measure diastolic SR during early filling, a sensitive marker of LV diastolic 
dysfunction which is an important precursor of incident heart failure (Kane et al., 2011).  
On the basis of our analysis performed in the subendocardium and in the 
circumferential direction, CMR-FT could realistically be extended to the computation of 
early diastolic SR.  From a technical viewpoint, the current study benefits from having 
performed all sequences on a 1.5T MR scanner; a previous validation utilised a mix of 
acquisitions from 1.5T and 3T MR scanners (Hor et al., 2010). The validation described 
herein was also undertaken on corresponding SSFP and tagging images acquired from 
identical slice positions, a method which has not always been adopted (Hor et al., 2010).  
Finally, by performing a timed analysis, this report highlights that CMR-FT can generate 
strain data over four-times more rapidly than myocardial tagging and this has obvious 
clinical implications.  
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Our results contrast with a recent report from Augustine et al. which demonstrated that 
CMR-FT measurements of longitudinally directed strain showed poor agreement with 
tagging (Augustine et al., 2013).  There are a number of differences between the studies 
which could account for this discrepancy.  In our analysis, strain parameters derived 
from CMR-FT versus tagging were compared for all patients entered into the study, 
which included healthy subjects as well as those with DCM; the validation by Augustine 
was more modest and included only 20 healthy volunteers out of a total of 145 subjects 
(13.8%).  More importantly, Augustine et al. compared measurements of longitudinal 
strain derived from tagging across the whole myocardial wall with CMR-FT measures 
derived from the blood-tissue interface, which effectively select subendocardial 
deformation information.  In order to perform a valid comparison between the two 
techniques, it is imperative to measure strain from the equivalent myocardial layer, 
namely the subendocardium.  Indeed, the longitudinal myocardial fibres are principally 
located in the subendocardium (Geyer et al., 2010). For this reason, in our Bland-Altman 
analyses, we made the a priori decision to compare CMR-FT strain parameters with 
tagged subendocardial values, which likely explains the improved agreement between 
the two techniques reported in the current study. 
 
Results of the two methods for calculation of subendocardial strain measures are 
correlated and, with the exception of early diastolic longitudinal SR, Bland-Altman 
assessments displayed good agreement, although there are small differences in the 
measurements between techniques.  Some of the variability in CIMTag strain 
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measurements may relate to the requirement to manually contour both endocardial 
and epicardial borders, together with the need to make a visual assessment of the 
tissue displacement map before making corrections to provide a best fit between image 
tags and model stripes. In contrast, only endocardial contours were constructed in the 
CMR-FT platform in this study, after which the process was fully automated without an 
option to modify tracking. These differences may account for CIMTag measurements 
having poorer inter-observer variability as compared with CMR-FT as well as tagging 
post-processing taking considerably longer. Another potential disadvantage of SPAMM 
tagging, which may also contribute to increased variability in strain outputs, is the 
potential for image quality to be affected by changes in heart rate. Furthermore, 
measurement of strain throughout the cardiac cycle to include diastolic parameters is 
not always achievable with 1.5T MRI scanners because of loss of tags caused by T1 
relaxation (Edvardsen et al., 2006).  CMR-FT offers a potentially more robust calculation 
of diastolic strain data because it relies on standard cine images whose spatial 
resolution is not adversely affected by T1 relaxation.   
 
In general, the CMR-FT derived longitudinal strain and SR data were more variable than 
the circumferential data calculated from the short axis.  This may be due to difficulty 
tracking at the blood-tissue interface and a tendency to track the mitral valve 
apparatus.  In keeping with previous reports, circumferential strain showed the 
strongest agreement between the two techniques and was particularly robust for the 
mid-LV slice (Augustine et al., 2013, Hor et al., 2010).  At the LV apex, however, less 
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muscle is available for creating the tag grid upon which the guide point modelling for 
CIMTag is based which may have led to increased variability.  CMR-FT may lose some of 
its ability to track the features in each voxel at the tissue-cavity interface at the apex 
(where there is a potential for cavity obliteration in end-systole) which may also account 
for increased error.  The variability in circumferential strain at the LV base could be 
explained by a relative increase in the through plane motion typically observed at this 
level.  The extent to which this degree of variability in CMR-FT measurements might 
relate to clinical use requires further exploration. There is already evidence that regional 
assessment by CMR-FT may not be as robust as existing tagging modalities but the 
potential advantages in ease of acquisition and time for analysis suggest that this 
method of assessing global deformation could still be of clinical utility.  
 
This study has confirmed a transmural strain gradient which exists across the myocardial 
wall (Moore et al., 2000); both longitudinal and circumferential strain values from 
tagging increased from subepicardial through to subendocardial layers.  This likely 
explains the better agreement of CMR-FT with tagging values from the 
subendocardium.  It also offers a potential explanation for the reduced sensitivity and 
slightly higher strain values derived from CMR-FT.  The CMR-FT algorithm only tracked 
deformation at the endocardial border therefore potentially losing important trans-
mural information captured in tag grids that span the entire thickness of the ventricular 
wall.  Mechanistically, this is in keeping with the pathology of dilated cardiomyopathy, 
which is characterized by epicardial injury on ex vivo histopathology and demonstrable 
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in vivo with late post gadolinium imaging (Simonetti and Raman, 2010).   In this study, 
ventricular wall thickness was not significantly different between DCM and controls.  In 
DCM, the ventricles are dilated but often with normal ventricular wall thickness, 
imparting an appearance of thin ventricular walls (Maron et al., 2006). Nonetheless, in 
an analysis which included all study subjects, wall thickness did not appear to affect the 
agreement between strain measures calculated using CMR-FT and myocardial tagging. 
 
By design, this study did not attempt to validate regional measures because of ongoing 
concerns over the reproducibility of CMR-FT segmental data. CMR-FT applies 2D B-
mode tracking such that the motion components parallel to tissue boundaries 
responsible for segmental information are much more affected by noise compared to 
the perpendicular components from which global strain measures are derived. This 
relates to the gradients in backscatter amplitude being much higher between tissue and 
blood than within the myocardium. 
 
A number of limitations to the current study deserve mention. There were a 
comparatively low number of subjects included with pathology; however this cohort 
enabled a validated assessment of the CMR-FT based technique over a broad range of 
LV function.  Only subendocardial global measures of deformation could be measured 
on CMR-FT and a comprehensive assessment of SR during late diastolic filling was not 
possible because of constraints over temporal resolution and loss of tags.  Assessment 
of myocardial deformation by strain and SR is sensitive to differences in sampling rate.  
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Even though considerable effort was made to ensure all tagging sequences were 
acquired with more than 15 phases (and many over 20 phases), there will almost 
inevitably be a difference in temporal resolution between a prospectively-gated 
sequence and retrospectively-gated sequence, specifically when confined by the resting 
heart rate and breath-holding of the patient.  The issue of temporal resolution is such 
that whilst results may correlate, values recorded are unlikely to be the same – in a 
clinical situation, it would be important to compare results using the same method in 
any single patient.  All scans were performed on a 1.5T scanner for consistency, 
although employing a 3T scanner may have resulted in improved tag persistence.  
Finally, differences in breath-hold requirements may have contributed to variability 
between acquisitions. 
 
4.5. Conclusion 
 
In a study population with a wide range of LV function, CMR-FT systolic and diastolic 
global circumferental strain measures and systolic global longitudinal strain measured at 
the subendocardium show satisfactory agreement with corresponding values from 
tagged imaging.  The CMR-FT global algorithm is a reliable tool in the research arena 
and also offers the potential for clinical utility, because it can be performed without the 
need for additional imaging and lengthy post-processing. 
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5. CARDIOVASCULAR EFFECTS OF UNILATERAL NEPHRECTOMY IN HUMAN 
LIVING KIDNEY DONORS 
 
 
5.1. Hypothesis 
 
The CRIB (Chronic Renal Impairment in Birmingham) – Donor study was designed to test 
the hypothesis that compared to control subjects, the reduction in GFR in living kidney 
donors causes adverse structural and functional cardiovascular effects including LV 
remodelling coupled with increases in LV mass and increased aortic stiffness. 
 
5.2. Methods 
 
5.2.1. Study Design 
 
The CRIB-Donor protocol has been reported previously in detail (Moody et al., 2014b). 
The study had a prospective, longitudinal, parallel group, blinded end point design 
comparing living kidney donors with similarly healthy controls, and was conducted 
between March 2011 and July 2014. The study was approved by the West Midlands 
Research Ethics Committee (Ref: 10/H1207/70), adhered to the principles set out by the 
Declaration of Helsinki, and was registered with the U.S. National Institutes of Health 
database (NCT01769924). The conduct and reporting of this study was guided by the 
STROBE (Strengthening the Reporting of Observational Studies in Epidemiology) 
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Statement (Von Elm et al., 2007). Written informed consent was obtained from all 
subjects. 
 
5.2.2. Setting and Participants 
 
Subjects were recruited from two University-hospital based UK transplant centres 
(Queen Elizabeth Hospital Birmingham and University Hospital Coventry and 
Warwickshire). The inclusion and exclusion criteria are listed in Table 5-1 and adhere to 
the UK living kidney donor guidelines compiled by the Joint Working Party of The British 
Transplantation Society and The Renal Association (British Transplantation Society / the 
Renal Association, 2005). Where possible, control patients were recruited from the 
same living donor clinics at which donors were identified, by identifying individuals who 
after screening were found to be fit for donation but did not proceed to surgery (e.g. 
because of arterial anatomy, immunological mismatch or recipient-related health 
issues). If they also fulfilled donor criteria, donor-related family members were also 
invited to participate in the study as healthy controls. The remainder of healthy controls 
were recruited following advertisement made at blood donation and community care 
facilities using the identical inclusion and exclusion criteria for donors. In order to 
provide a closely matched control population with equivalent baseline health status to 
the donor cohort, both donor and control subjects underwent identical screening tests.
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Table 5-1. Study Inclusion and Exclusion Criteria. 
Inclusion criteria 
Age 18-80 yrs 
Acceptable GFR by donor age prior to donation* 
Exclusion criteria 
Hypertensive end-organ damage, uncontrolled hypertension or the requirement for more than 
2 anti-hypertensive medications 
Significant proteinuria† 
Left ventricular dysfunction 
Diabetes mellitus 
Atrial fibrillation 
Any history of cardiovascular or pulmonary disease that would preclude kidney donation 
Abbreviation: GFR, glomerular filtration rate 
*Based on the anticipation of having an eGFR of >50ml/min/1.73m2 aged 70 years. 
†Urinary albumin – creatinine ratio >30 mg/mmol, protein – creatinine ratio >50 mg/mmol or 
24-hour total protein >300 mg/day. 
 
 
5.2.3. Study Protocol 
 
A flow chart of the study protocol is presented in Figure 5-1. Investigations were 
performed in each participant at baseline (within 6 weeks prior to nephrectomy in 
donors), with subsequent follow-up studies performed at 6 and 12 months. Kidney 
donors underwent routine follow up by their local medical and surgical team with no 
alteration to normal care.  
 152 
 
 
Figure 5-1. Study Protocol 
Abbrevations: ACR, albumin – creatinine ratio; ABPM, ambulatory blood pressure monitor; AIx, 
augmentation index; BP, blood pressure; FGF-23, fibroblast growth factor-23; GFR, glomerular 
filtration rate; hsCRP, high sensitivity C-reactive protein; hsTnT, highly sensitive Troponin T; LV 
left ventricular; NT-proBNP, N-terminal pro B Natriuretic peptide; PTH; parathyroid hormone; 
PWV, aortic pulse wave velocity. 
 
 
5.2.4. Subject Withdrawal. 
 
Withdrawal criteria are listed in Table 5-2. In general, living kidney donors are a highly 
motivated population and it was therefore expected that the drop-out rate would be 
low.  
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Table 5-2. Study Withdrawal Criteria. 
Withdrawal criteria 
Pregnancy 
Occurrence of any serious adverse or cardiovascular event which in the opinion of the investigators, 
 warrants the subject’s permanent withdrawal from the study 
Repeated non-attendance to study visits 
Subject decision to withdraw 
Subject loss to follow up (loss of contact before final study visit) 
 
 
5.2.5. Outcomes 
 
The primary end point was change in LV mass at 12 months, as measured by cardiac 
MRI. Secondary end points were changes in (1) glomerular filtration rate by isotopic and 
creatinine based methods; (2) LV mass-volume ratio by cardiac MRI; (3) LV strain indices 
by MRI feature tracking; (4) brachial blood pressure, (5) central blood pressure, aortic 
PWV and AIx by SphygmoCor; (6) aortic distensibility by cardiac MRI; (7) T1 mapping 
derived ECV by cardiac MRI; (8) FMD of the brachial artery by MRI; (9) cIBS by 
transthoracic echocardiography; and (10) cardiac biomarkers including hsCRP, serum 
NT-proBNP, hs-cTnT and urinary ACR.  Potential mediators of increased LV mass were 
also measured including renin; aldosterone; uric acid; and PTH. The rationale for 
selecting the above end points is given in Chapters 1 and 2.  
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5.2.6. Investigations 
 
The techniques used to examine the above outcomes have already been described in 
detail in Chapter 2. 
 
5.2.7. Monitoring and Safety Assessments 
 
All adverse events, including SAEs, were recorded and followed up for the duration of 
the study or until resolution. Assessment of adverse events was performed by the study 
investigators. All SAEs were graded and reported to the sponsor. Any suspected 
unexpected serious adverse reactions were reported by the Chief Investigator within 15 
days of the event to the sponsor, and National Research Ethics Committee (NRES), using 
the NRES SAE form for a non-Clinical Trial of an IMP. 
 
5.2.8. Reproducibility 
 
Reproducibility was determined using the same technique described in Chapter 3. 
Briefly, to assess intra-observer report variability of LV mass measurement, ten baseline 
studies were re-analyzed by the same observer 4 weeks later, blinded to the original 
data (W.E.M). A random subset of participants (n = 10) also underwent repeat imaging 
within 7 days to determine inter-study reproducibility; both scans were analyzed by the 
same observer blinded to temporal sequence and patient identity (W.E.M). Reliability 
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was assessed using the intra-class correlation coefficient (ICC) with a model of absolute 
agreement. 
 
5.2.9. Sample Size Determination 
 
Sample size calculation was based on the primary outcome of change in LV mass. In a 
previous intervention study in CKD, the standard deviation of change in LV mass was 12 
g (Edwards et al., 2009). A sample size of 55 subjects per group provided 90% power to 
detect a change in LV mass of 7.5 g with an alpha value of 0.05. I therefore aimed to 
recruit 70 patients per group to allow for drop-outs. 
 
5.2.10. Statistical Analysis 
 
Statistical analysis was performed as described in Section 2.8. The primary analysis 
tested differences between groups over 12 months using repeated-measures ANOVA. A 
further quantitative analysis was performed using a last observation carried forward 
principle. Independent predictors of changes in LV mass and renal function were 
determined using multivariable logistic regression models. Generalised estimating 
equations were used to compare donors with controls for the likelihood of developing 
detectable serum and urinary biomarkers over 12 months. 
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5.3. Results 
 
5.3.1. Recruitment 
 
Recruitment for the study began in March 2011 and was completed in July 2013. During 
this period, a total of 216 subjects were screened (Figure 5-2). Of those, 40 were 
ineligible based on the inclusion and exclusion criteria, 32 declined, and 20 did not 
respond. In total, 124 subjects were recruited (68 donors, 54 controls). The decision to 
end recruitment before reaching our target number was based on cessation of research 
funding and the recruitment of adequate numbers to achieve the required power with 
respect to LV mass.  
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Figure 5-2. Study Timeline. 
Abbreviations: BP, blood pressure; LVH, left ventricular hypertrophy; GFR, glomerular filtration 
rate. 
 
5.3.2. Baseline Data 
 
Baseline characteristics of the two study groups are shown in Table 5-3. There were no 
significant differences between groups with respect to age, sex, ethnicity, 
cardiovascular risk factors, medication and renal function. Seven subjects (6%) were on 
anti-hypertensive therapy at baseline. For all participants, blood pressure was <140/90 
mmHg.  
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Table 5-3. Demographic and Clinical Characteristics at Baseline. 
Variable Donor (N = 68) Controls (N = 56) P Value  
Demographics    
  Age (yrs) 46.5 ± 12.1 44.1 ± 12.8 0.28 
  Male sex 23 (34) 27 (48) 0.14 
  Race or ethnic group    
    White 62 (90) 47 (86) 0.27 
    Asian 5 (7) 5 (9) 0.75 
    Black 2 (3) 3 (6) 0.66 
  Body mass index (kg/m2) 26.8 ± 4.1 26.0 ± 3.6 0.22 
Risk factors    
  Hypertension 3 (5) 4 (7) 0.70 
  Diabetes 0 (0) 0 (0) 1.00 
  Current smoker 8 (12) 3 (5) 0.34 
  Ex-smoker 21 (30) 13 (24) 0.42 
  Family history of cardiovascular disease† 19 (28) 11 (20) 0.30 
Medication    
  Statin 2 (3) 4 (7) 0.41 
  Antihypertensive agent 3 (5) 4 (7) 0.70 
  ACE inhibitor or Angiotensin-receptor blocker 1 (2) 3 (5) 0.33 
  Beta-blocker 1 (2) 1 (2) 1.00 
  Calcium channel blocker 1 (2) 1 (2) 1.00 
  Levothyroxine 3 (5) 2 (4) 1.00 
  Non-steroidal anti-inflammatory agent 1 (2) 1 (2) 1.00 
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Haematology and Biochemistry    
  Haemoglobin (g/dL) 13.7 ± 1.2 13.6 ± 1.2 0.66 
  Serum creatinine (μmol/L) 73 ± 14 72 ± 14 0.95 
  Estimated GFRCr (mL/min/1.73m
2) 88 ± 18 89 ± 19 0.72 
  Isotopic GFR (mL/min/1.73m2) 93 ± 12 91 ± 14 0.64 
  Cholesterol (mmol/L) 5.2 ± 1.1 5.0 ± 1.1  0.33 
  Fasting glucose (mmol/L) 4.7 ± 0.5 4.7 ± 0.4 0.56 
Data are presented as mean ± SD or number (%). 
†Defined as a first degree relative with a history of myocardial infarction or ischaemic stroke 
aged younger than 55 years in men and younger than 65 years in women. 
There were no significant differences between donor and control groups analyzed using 
independent samples Student’s t or Fisher’s exact tests. A two-tailed P value<0.05 was 
considered statistically significant. 
 
 
 
5.3.3. Follow up and Events 
 
Eleven donors did not complete follow up to 12 months (Figure 5-2); 2 declined 
continued participation because of the travelling involved and 8 could not be contacted. 
One subject was withdrawn after diagnosis of a malignancy, which was subsequently 
reported as a SAE. No subjects died or suffered a cardiovascular event during the study. 
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5.3.4. Change in Renal function and Biochemical Effects 
 
The changes in biochemical indices and cardiac biomarkers are presented in Table 5-4. 
There was a mean decrease in iGFR in donors of −30 ± 12 ml/min/1.73m2 with no 
change in controls (−1 ± 10 ml/min/1.73m2; P < 0.001). At 12 months, over a third of 
donors (35%) had an iGFR <60 ml/min/1.73m2 while more than half (53%) had an eGFR 
<60 ml/min/1.73m2. Compared with controls, donors had significant increases in uric 
acid (+56 ± 35 μmol/L vs. +2 ± 33 μmol/L; P < 0.001); iPTH (+1.1 ± 1.6 pg/ml vs. +0.4 ± 
1.3 pg/ml; P = 0.03) and hsCRP (+1.7 ± 5.3 mg/dl vs. −0.7 ± 5.2 mg/dl; P < 0.01). Donors 
also had significantly greater numbers with detectable hs-cTnT (odds ratio, 16.2 [95%CI, 
2.6 – 100.1]; P < 0.01) and microalbuminuria (odds ratio, 3.74 [95%CI, 1.09 – 12.75]; P = 
0.04). There were no significant changes in NT-proBNP or in circulating levels of renin 
and aldosterone. 
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Table 5-4. Haematological and Biochemical Effects of a Reduction in Renal Function. 
Biomarker Donor (N = 57) Control (N = 46) P Value 
 Month 0 Month 12 Month 0 Month 12  
Haemoglobin (g/L) 137 ± 12 134 ± 11 136 ± 12 137 ± 13 0.06 
Estimated GFRCr (mL/min/1.73m
2) 89 ± 19 59 ± 13 87 ± 17 86 ± 19 <0.001 
Isotopic GFR (mL/min/1.73m2) 92 ± 12 63 ± 9 90 ± 13 89 ± 12 <0.001 
Urinary ACR ≥ 3.0 mg/mmol† 0% 7% 0% 0% 0.04 
Serum hs-cTnT ≥ 5 ng/L† 0% 21% 9% 2% <0.01 
Serum NT-proBNP (pmol/L)‡ 0.3 (0.3 – 7.7) 0.3 (0.3 – 18.9) 0.3 (0.3 – 16.0) 0.3 (0.3 – 4.0) 0.23 
Serum hsCRP (mg/dL)‡ 1.20 (0.40 – 2.28) 1.90 (0.70 – 3.25) 0.85 (0.40 – 1.83 ) 1.0 (0.58 – 1.68) <0.01 
Serum calcium (mmol/L) 2.31 ± 0.11 2.33 ± 0.08 2.30 ± 0.09 2.33 ± 0.09 0.70 
Serum phosphate (mmol/L) 1.07 ± 0.18 1.05 ± 0.17 1.09 ± 0.17 1.13 ± 0.25 0.15 
Serum intact parathyroid hormone (pg/mL)  4.5 ± 1.5 5.6 ± 1.7 4.2 ± 1.3 4.6 ± 1.5 0.03 
25-hydroxyvitamin D (nmol/L) 50 ± 27 57 ± 32 52 ± 23 53 ± 21 0.20 
Serum uric acid (μmol/L) 276 ± 74 332 ± 72 289 ± 55 291 ± 54 <0.001 
Renin (ng/L) ‡ 9.4 (7.1 – 13.2) 7.9 (5.1 – 11.4) 9.2 (7.1 – 14.3) 10.1 (6.8 – 15.1) 0.24 
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Aldosterone (pmol/L) ‡ 129 (60 – 192) 120 (77 – 187) 111 (67 – 187) 189 (80 – 271) 0.22 
Total cholesterol (mmol/L) 5.3 ± 1.1 5.3 ± 1.0 4.9 ± 1.1 4.9 ± 1.1 0.74 
HDL cholesterol (mmol/L)‡ 1.6 (1.3 – 1.8) 1.5 (1.3 – 1.9) 1.5 (1.3 – 1.8) 1.5 (1.3 – 1.9) 0.26 
LDL cholesterol (mmol/L) 3.1 ± 1.0 3.2 ± 0.9 2.9 ± 0.9 2.8 ± 0.9 0.18 
Glucose (mmol/L) 4.7 ± 0.5 4.9 ± 1.0 4.7 ± 0.4 4.8 ± 0.6 0.50 
Data are presented as mean ± SD, or %. N is the number of subjects with available baseline and 12 month data. A repeated-measures ANOVA with 
time point (month 0 or 12) as the within-subjects factor and group (control or donor) as the between-subjects factor tested the difference in change 
over time between groups. 
† Generalised estimating equations were used to compare donors with controls for the likelihood of developing detectable serum and urinary 
biomarkers between month 0 and 12. 
‡ Data presented as median (interquartile range), log transformed prior to repeated-measures ANOVA analysis. 
A two-tailed P value <0.05 was considered statistically significant. 
Abbreviations: ACR, albumin – creatinine ratio; GFR, glomerular filtration rate; GFRCr, glomerular filtration rate according to the CKD-EPI equation; 
HDL, high-density lipoprotein; hsCRP; high sensitivity C-reactive protein; hs-cTnT, high sensitivity cardiac Troponin T; LDL, low-density lipoprotein; NT-
proBNP, N-terminal pro B Natriuretic peptide
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5.3.5. Effects on Ventricular Mass, Volumes and Function 
 
A summary of the data on the effects of nephrectomy on cardiac structure and 
function is presented in Table 5-5. In donors but not controls, LV mass increased 
significantly (+7 ± 10 g vs. −3 ± 8 g; P < 0.001; Figure 5-3 and Figure 5-4). In donors 
compared with controls, there were analogous increases in the LV mass index (+3.5 
± 5.0 g/m2 vs. -1.6 vs. 4.3 g/m2; P < 0.001) and LV mass – volume ratio (+0.06 ± 0. 12 
g/ml vs. −0.01 ± 0.09 g/ml; P < 0.01). Nephrectomy did not affect LV volumes or 
ejection fraction but was associated with a reduction in long axis function 
determined by septal AVPD compared to controls (−1 ± 2 mm vs. 0 ± 2 mm; P = 
0.03). There were no effects of kidney donation on right ventricular volumes or 
function.
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Table 5-5. Myocardial Effects of a Reduction in Renal Function by Cardiac MRI. 
 Donor (N = 50) Control (N =45)  
 Month 0 Month 12 Month 0 Month 12 P Value 
  LV mass (g) 114 ± 26 121 ± 29 117 ± 30 114 ± 29 <0.001 
  LV mass index by BSA (g/m2) 61 ± 9 65 ± 11 63 ± 13 61 ± 11 <0.001 
  LV mass-to-volume ratio (g/ml) 0.94 ± 0.16 1.00 ± 0.19 0.91 ± 0.16 0.90 ± 0.14 <0.01 
  LV ejection fraction (%) 70 ± 6 69 ± 5 67 ± 7 68 ± 6 0.48 
  LV end diastolic volume index (ml/m2) 66 ± 11 66 ± 12 70 ± 14 69 ± 14 0.43 
  LV end systolic volume index (ml/m2) 19 ± 6 20 ± 7 22 ± 8 22 ± 7 0.38 
  LV stroke volume (ml) 86 ± 16 85 ± 16 89 ± 20 88 ± 19 0.67 
  Aortic forward flow (ml)† 83 ± 21 81 ± 16 86 ± 19 89 ± 23 0.26 
  Septal AVPD (mm) 15 ± 2 14 ± 3 15 ± 2 15 ± 2 0.03 
  Lateral AVPD (mm) 15 ± 3 14 ± 3 15 ± 2 15 ± 2 0.12 
  LA volume (ml) 78 ± 22 81 ± 16 84 ± 20 80 ± 23 0.10 
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  LA volume index (ml/m2) 43 ± 9 44 ± 8 45 ± 10 44 ± 9 0.27 
  RV stroke volume (ml) 81 ± 14 80 ± 14 84 ± 17 82 ± 17 0.61 
  RV end diastolic volume index (ml/m2) 61 ± 11 63 ± 12 66 ± 13 65 ± 12 0.10 
  RV end systolic volume index (ml/m2) 17 ± 7 20 ± 7 21 ± 8 20 ± 6 0.22 
Data are presented as mean ± SD. N is the number of subjects with available baseline and 12 month data. Repeated-measures ANOVA with time 
point (month 0 or 12) as the within-subjects factor and group (control or donor) as the between-subjects factor tested the difference in change 
over time between groups. A two-tailed P value <0.05 was considered statistically significant.  †Left ventricular stroke volume as determined by 
aortic flow mapping; data available in 45 donors, 41 controls. Abbreviations: AVPD; atrioventricular plane displacement; BSA, body surface area; 
LA, left atrium; LV left ventricle; MRI, magnetic resonance imaging; RV right ventricle.
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Figure 5-3. 12-Month Change in Left Ventricular Mass in Donors versus Controls. 
Error bars (S.E.M.). Repeated-measures ANOVA with time point (month 0 or 12) as the 
within-subjects factor and group (control or donor) as the between-subjects factor tested 
the difference in change over time between groups. 
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Figure 5-4. Spread of 12-Month Change in Left Ventricular Mass in Donors and Controls. 
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Left ventricular systolic function as measured by global circumferential strain was 
reduced (Figure 5-5) with directionally similar but non-significant changes in global 
longitudinal strain (Table 5-6). There were no significant differences in left atrial 
volume or parameters of left atrial strain between donors and controls. 
 
 
Figure 5-5. 12-Month Change in Global Circumferential Strain in Donors versus Controls. 
Error bars (S.E.M.). Repeated-measures ANOVA with time point (month 0 or 12) as the 
within-subjects factor and group (control or donor) as the between-subjects factor tested 
the difference in change over time between groups. 
Abbreviation: GCS, peak systolic global circumferential strain. 
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Table 5-6. Effects of a Reduction in Renal Function on Myocardial Strain Parameters. 
 Donor (N = 50) Control (N = 45)  
 Month 0 Month 12 Month 0 Month 12 P 
Global short axis function (mid LV slice)      
  Peak systolic circumferential E, GCS (%) -27.14 ± 4.29 -26.07 ± 4.22 -25.35 ± 3.95 -25.71 ± 3.69 0.04 
  Peak systolic circumferential SR (s-1) -1.63 ± 0.32 -1.60 ± 0.34 -1.51 ± 0.33 -1.53 ± 0.32 0.39 
  Early diastolic circumferential SR (s-1) 1.44 ± 0.53 1.29 ± 0.57 1.30 ± 0.52 1.37 ± 0.34 0.07 
Global long axis function (HLA slice)      
  Peak systolic longitudinal E, GLS (%) -22.3 ± 5.3 -21.2 ±3.9 -20.4 ± 3.2 -21.1 ± 3.6 0.07 
  Peak systolic longitudinal SR (s-1) -1.30 ± 0.39 -1.28 ± 0.43 -1.16 ± 0.28 -1.17 ± 0.44 0.68 
  Early diastolic longitudinal SR (s-1) 1.29 ± 0.45 1.21 ± 0.40 1.16 ± 0.30 1.17 ± 0.33 0.30 
Left atrial long axis function      
  Global PLAS (%) 35.5 ± 9.1 32.9 ± 9.9  39.7 ± 12.6 33.8 ± 9.5 0.25 
  PreA-S (%) 14.4 ± 5.3  13.3 ± 5.4 15.1 ± 5.6 13.0 ± 4.3 0.52 
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Data are presented as mean ± SD. N is the number of subjects with available baseline and 12 month data. Repeated-measures ANOVA with time point 
(month 0 or 12) as the within-subjects factor and group (control or donor) as the between-subjects factor tested the difference in change over time 
between groups. A two-tailed P value <0.05 was considered statistically significant. Abbreviations: E, Lagrangian strain, HLA, horizontal long axis; GCS, 
global subendocardial circumferential strain; GLS, global subendocardial longitudinal strain; LV left ventricle; PLAS, peak longitudinal atrial strain; 
PreA-S, peak longitudinal strain before atrial contraction; SR, strain rate
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5.3.6. Effects on Blood Pressure 
 
There were no significant differences at 12 months between donors and controls in any 
parameter of blood pressure including brachial, central or ambulatory measures (Table 
5-7).
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Table 5-7. Effect of a Reduction in Renal Function on Blood Pressure. 
 Donor (N = 57) Control (N = 46)  
 Month 0 Month 12 Month 0 Month 12 P Value 
  Brachial systolic BP (mmHg) 124 ± 11 123 ± 10 124 ± 12 121 ± 11 0.38 
  Brachial diastolic BP (mmHg) 75 ± 8 78 ± 8 76 ± 9 76 ± 8 0.09 
  Central systolic BP (mmHg) 112 ± 10 112 ± 11 112 ± 13 111 ± 13 0.43 
  Central diastolic BP (mmHg) 76 ± 8 78 ± 9 77 ± 9 77 ± 9 0.25 
  Ambulatory brachial systolic BP (mmHg)† 121 ± 8 122 ± 12 122 ± 11  121 ± 10 0.55 
  Ambulatory brachial diastolic BP (mmHg)† 75 ± 6 76 ± 9 74 ± 8 76 ± 9 0.68 
Data are presented as mean ± SD. N is the number of subjects with available baseline and 12 month data. Repeated-measures ANOVA with time 
point (month 0 or 12) as the within-subjects factor and group (control or donor) as the between-subjects factor tested the difference in change 
over time between groups. A two-tailed P value <0.05 was considered statistically significant. †Data available in 46 donors, 36 controls; daytime 
brachial blood pressure measured between 08:00 and 22:00. Abbreviation: BP, blood pressure.
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5.3.7. Effects on Arterial Stiffness 
 
In donors, there was a graded increase in aortic PWV observed at 6 and 12 months post-
nephrectomy (Figure 5-6).  
 
Figure 5-6. 6- and 12-Month Changes in Aortic Pulse Wave Velocity in Donors versus Controls. 
Error bars (S.E.M.). Repeated-measures ANOVA with time point (month 0, 6 or 12) as the within-
subjects factor and group (control or donor) as the between-subjects factor tested the 
difference in change over time between groups. 
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An increase in arterial stiffness was observed in donors versus controls and was 
independent of blood pressure as confirmed by significant changes in PWVadj (+0.43 ± 
0.69 m/s vs. −0.02 ± 0.72 m/s; P < 0.01, Table 5–8). Directionally similar but non-
significant increases in AIx75 were demonstrated at 12 months (P = 0.07) (Table 5–8).
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Table 5-8. Effect of a Reduction in Renal Function on Arterial Stiffness. 
 Donor (N = 59) Control (N = 48)  
 Month 0 Month 12 Month 0 Month 12 P Value 
  PWV (m/s) 6.8 ± 1.1 7.3 ± 1.5 6.7 ± 1.1 6.7 ± 1.1  <0.001 
  PWVadj (m/s) 6.7 ± 0.9 7.1 ± 1.1 6.6 ± 1.1  6.6 ± 1.1 0.002 
  AIx (%) 22 ± 13 23 ± 13 19 ± 13 18 ± 11 0.20 
  AIx75 (%) 16 ± 13 18 ± 12 13 ± 14 13 ± 12 0.07 
Data are presented as mean ± SD. N is the number of subjects with available baseline and 12 month data. Repeated-measures ANOVA with 
time point (month 0 or 12) as the within-subjects factor and group (control or donor) as the between-subjects factor tested the difference in 
change over time between groups. A two-tailed P value <0.05 was considered statistically significant. Abbreviations: AIx, augmentation  index; 
AIx75, augmentation index adjusted for a heart rate of 75 beats per minute; PWV, aortic pulse wave velocity; PWVadj, aortic pulse wave velocity 
adjusted for mean arterial pressure.
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5.3.8. Effects on Aortic Distensibility 
 
Consistent with the observed changes in PWV, aortic distensibility at the level of the 
proximal ascending aorta was reduced following nephrectomy in donors compared to 
controls (−0.29 ± 1.38 × 10-3 mmHg-1 vs. +0.28 ± 0.79 × 10-3 mmHg-1; P = 0.03; Table 5-9). 
There were however, no differences in distensibility between donors and controls at the 
level of the proximal descending and distal descending aorta. 
 
5.3.9. Effects on Carotid Intima-Media Thickness 
 
At 12 months, there was no demonstrable change in carotid IMT in donors versus 
controls (+0.01 ± 0.03 mm vs. 0.00 ± 0.03 mm; P = 0.31; Table 5-9). 
 
5.3.10. Effects on the Left Ventricular Interstitium 
 
Compared with controls, there was a trend towards elevated ECV in donors post-
nephrectomy (mean effect size +2.1%) although this result was almost certainly 
underpowered (n = 13) and did not meet statistical significance (Table 5-9). There was 
no significant difference between donors and controls in the increases in ultrasonic 
reflectivity observed at 12 months (as determined by the change in cIBS). 
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Table 5-9. Effects of a Reduction in Renal Function on Large Artery Structure and Function and Myocardial Tissue Characteristics. 
 Donor (N = 45) Control (N = 43)  
 Month 0 Month 12 Month 0 Month 12 P Value 
Aortic distensibility      
  Proximal ascending aorta (× 10-3 mmHg-1) 3.75 ± 2.75 3.46 ± 2.32 3.62 ± 2.07 3.90 ± 2.13 0.03 
  Proximal descending aorta (× 10-3 mmHg-1) 4.33 ± 2.63 4.10 ± 1.56 3.79 ± 1.30 4.11 ± 1.55 0.18 
  Distal descending aorta (× 10-3 mmHg-1) 5.40 ± 2.28 5.64 ± 2.09 5.36 ± 2.31 5.66 ± 1.99 0.99 
Arterial structure      
  Carotid intima-media thickness (mm) 0.59 ± 0.10 0.60 ± 0.10 0.59 ± 0.11 0.59 ± 0.10 0.31 
Myocardial tissue characterization      
  Extracellular volume (%)† 25.9 ± 3.9 28.0 ± 3.1 27.8 ± 4.1 27.5 ± 3.0 0.27 
  Intracellular volume (%)† 74.1 ± 3.9 72.0 ± 3.1 72.2 ± 4.1 72.5 ± 3.0 0.26 
  Calibrated integrated backscatter (dB) -28.0 ± 3.0 -25.4 ± 3.7 -27.7 ± 2.0 -25.9 ± 4.4 0.57 
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Data are presented as mean ± SD. N is the number of subjects with available baseline and 12 month data. Repeated-measures ANOVA with time 
point (month 0 or 12) as the within-subjects factor and group (control or donor) as the between-subjects factor tested the difference in change 
over time between groups. †Data available in 13 subjects. A two-tailed P value <0.05 was considered statistically significant. 
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5.3.11. Effects on Endothelial Function 
 
There was a significant reduction in FMD in donors (the endothelial-dependent 
response to functional hyperaemia) compared with controls at 12 months (Table 5–
10). By contrast, there was no difference between donors and controls in the 
brachial response to GTN control (the endothelial-independent response). 
 
 
Table 5-10. Effect of a Reduction in Renal Function on Endothelial Function. 
 Donor (N = 30) Control (N = 32)  
 Month 0 Month 12 Month 0 Month 12 P Value 
Brachial reactivity*       
  FMD 7.02 ± 3.75 6.36 ± 3.32 6.62 ± 3.07 7.50 ± 4.13 0.03 
  GTN control 15.33 ± 5.63 14.93 ± 6.56 17.79 ± 5.30 17.61 ± 5.55 0.28 
*Percentage change in cross-sectional area from baseline. Data are presented as mean ± SD. N is the 
number of subjects with available baseline and 12 month data. Repeated-measures ANOVA with 
time point (month 0 or 12) as the within-subjects factor and group (control or donor) as the 
between-subjects factor tested the difference in change over time between groups. A two-tailed P 
value <0.05 was considered statistically significant. 
Abbreviations: FMD, flow-mediated-dilatation; GTN, glyceryl trinitrate. 
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5.3.12. Determinants of the Change in Left Ventricular Mass 
 
Univariate analysis showed an association between the increase in LV mass and the 
decrease in iGFR (β = −0.3, R2 = 0.19, P < 0.001; Table 5-11). This relationship 
remained significant after adjustment for sex and 12-month changes in aortic PWV 
and uric acid (β = −0.4, R2 = 0.17, P = 0.04). There was a less strong but still 
significant association between the reduction in eGFR and increase in LV mass 
(Figure 5-7). Consistent with the finding that blood pressure did not change in 
donors versus controls, there was no significant association between 12-month 
changes in mean arterial pressure and LV mass. 
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Table 5-11. Univariate and Multivariable Analyses with 12-Month Change in Left Ventricular 
Mass as the Outcome Variable. 
Variable Univariate Multivariable 
 R P value β 95% CI P value 
Age 0.03 0.76    
Sex -9.48 0.06 -0.04 -7.24 to 5.56 0.79 
Baseline LV mass (g) -0.12 0.25    
12 month change in iGFR 
(ml/min/1.73m2) 
-0.44 <0.001 -0.39 -0.51 to -0.01 0.04 
12 month change in eGFR 
(ml/min/1.73m2) 
-0.30 0.004    
12 month change in mean 
arterial blood pressure (mmHg) 
0.06 0.66    
12 month change in aortic PWV 
(m/s) 
0.26 0.02 0.05 -4.09 to 5.38 0.78 
12 month change in uric acid 
(μmol/l) 
0.26 0.02 -0.01 -0.09 to 0.08 0.94 
12 month change in intact PTH 
(pg/ml) 
-0.02 0.85    
Data analysed using Pearson correlation (univariate) and enter linear regression 
(multivariable). All variables that correlated with the change in left ventricular mass in 
univariate analysis were entered into the multivariate regression model. R2 for 
model = 0.17, P = 0.04. For gender; 0 = male, 1 = female. 
Abbreviations: β, standardised beta coefficient; eGFR, estimated glomerular filtration rate 
by the CKD-EPI equation; iGFR, isotopic glomerular filtration rate; LV, left ventricular; PTH, 
parathyroid hormone; PWV, pulse wave velocity; 95% CI, 95% confidence interval. 
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Figure 5-7. Univariate Associations Between Changes in Mean Arterial Blood Pressure and 
Estimated Glomerular Filtration Rate With Changes in Left Ventricular Mass. 
Abbreviations: eGFR, estimated glomerular filtration rate; LV, left ventricular; MAP mean 
arterial pressure. 
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5.3.13.  Reproducibility  
 
Reproducibility of cardiac MRI derived LV metrics are given in detail in Chapter 3. In 
brief, the intraobserver and interstudy variability for LV mass was low (ICC [95% CI]; 
0.99 [0.98-1.00] and 0.98 [0.91-1.00], respectively). 
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5.4. Discussion 
 
This study has demonstrated that a modest reduction in GFR caused by unilateral 
nephrectomy in healthy human subjects causes important structural and functional 
cardiovascular abnormalities within one year. Left ventricular mass was elevated 
with a graded independent association between the reduction in GFR and the 
increase in LV mass even after adjustment for demographic and haemodynamic 
factors.  In addition, there was an increase in LV mass – volume ratio, reduced LV 
myocardial deformation and increased aortic stiffness.  Although ED was observed, 
there was no effect on atherosclerosis progression as determined by carotid IMT 
measurement. The prevalence of microalbuminuria and detectable cardiac troponin 
was increased after donation along with a significant rise in serum hsCRP.  These 
findings provide powerful insights into the pathophysiological effects of CKD on the 
cardiovascular system suggesting that they are not primarily atherosclerotic but 
instead mediated via LV hypertrophy and fibrosis together with increased large 
artery stiffness.  
 
Despite robust epidemiological evidence of an association between reduced eGFR 
and increased cardiovasscular risk (Matsushita et al., 2010), clear proof of causation 
has been lacking. The debate has been heightened by an increasing body of opinion 
suggesting that early stage CKD is benign and that age-related nephron loss should 
not be “medicalised” (Moynihan et al., 2013). Distinguishing causality from 
association in CKD is made difficult by the numerous concomitant diseases that 
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invariably accompany reduced GFR including hypertension, diabetes mellitus, 
anaemia, dyslipidaemia and vasculitis. By studying kidney donors we were able to 
isolate the effect of a reduction in renal function on the cardiovascular system, free 
from such confounding disease processes. The results suggest that reduced GFR is 
an independent graded risk factor for adverse LV remodelling independent of blood 
pressure.  Because the prevalence of early stage CKD is high (up to 1 in 7 people in 
the US), it may be a major cause of increased LV mass in the community, a potent 
risk factor for cardiovascular death and adverse events (Zile et al., 2011). Further 
investigation is required to identify the mediators of “renal” cardiovascular disease. 
We have found no evidence to support effects mediated by blood pressure or 
activation of the renin angiotensin system. On the basis of the results presented in 
this Chapter, uric acid and PTH and FGF-23 are all worthy of further investigation as 
mediators of both increased ventricular mass and arterial stiffening (Velagaleti et 
al., 2008, Faul et al., 2011). 
 
5.4.1. Effects on Cardiovascular Structure and Function 
 
Our findings may have important clinical implications as many of the variables 
examined are of prognostic importance. Both LV mass and aortic PWV have been 
consistently associated with increased mortality in both the general population 
(Willum-Hansen et al., 2006, Cheng et al., 2009) and patients with CKD (Blacher et 
al., 1999, Foley et al., 1995). While no subject in the current study reached criteria 
for LV hypertrophy, both LV mass and mass-to-volume ratio have continuous rather 
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than dichotomous relationships with risk (Zile et al., 2011). Indeed, LV mass is 
second only to age in its ability to predict cardiovascular events, cardiovascular 
death, and total mortality (Levy et al., 1990). 
 
There was a marked reduction in global myocardial strain parameters in donors that 
was not seen in controls; such indices have become increasingly accepted as 
powerful predictors of cardiac events and may predate changes in gross measures 
of function such as LV ejection fraction (Cho et al., 2009). The observed increase in 
carotid-femoral PWV in donors was further supported by the significant reduction 
in proximal aortic distensibility demonstrated on MRI. Although there were no 
changes in distensibility at the level of the proximal descending and distal 
descending aorta, this pattern of disease appears to mimic age-related, regional 
increases in PWV which primarily affect the proximal aorta (Rogers et al., 2001).   
 
5.4.2. Effects on Cardiac Biomarkers 
 
Compared with controls, there was a 16-fold increase in the risk of developing 
detectable hsTnT in donors. Detectable troponin (rather than elevated above the 
99th centile) has been independently associated with structural heart disease and 
all-cause mortality in the general population and also predicts adverse 
cardiovascular outcomes in subjects with CKD stages 1 – 3, highlighting the 
importance of silent cardiac damage (Scheven et al., 2012, De Lemos et al., 2010, 
Defilippi et al., 2010). High-sensitivity troponin concentrations have been linked to 
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the magnitude of hypertrophic response in patients with aortic stenosis (Chin et al., 
2014). Consistent with this finding, the release of low quantities of hsTnT in donors 
may have resulted from concentric remodelling causing a supply–demand mismatch 
which precipitated a low grade hypoxia (Claeys, 2014, Mishra et al., 2013). 
 
There were also a significant proportion of donors who developed an ACR ≥ 
3.0mg/mmol. This finding of increased urinary protein excretion could reflect 
hyperfiltration in the remaining kidney but might also relate to the early onset of ED 
that was also evident among donors in the current study. Irrespective of the 
mechanism, even low levels of urinary albumin excretion have been shown to 
predict adverse cardiovascular outcomes independent of conventional cardiac risk 
factors (Klausen et al., 2004, Arnlov et al., 2005). Finally, there was a significant 
elevation in levels of hsCRP observed in donors and this biomarker has a strong 
independent association with mortality in healthy subjects as well as in the non-
dialysis CKD population (Boekholdt et al., 2006, Vickery et al., 2008). 
 
5.4.3. Implications for Kidney Donors 
 
The practice of living kidney donation is expanding rapidly; to date over 130,000 
such procedures have been performed in the US alone (OPTN, 2014).  While 
observational studies of kidney donors have been largely reassuring, (Fehrman-
Ekholm et al., 1997, Segev et al., 2010) there can be no complacency about the 
long-term safety of unilateral nephrectomy. Studies using carefully selected healthy 
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control groups suggest that there may be a small increase in the risk of 
cardiovascular events and in the risk of developing ESRD, particularly in non-white 
ethnic groups (Lentine et al., 2010, Muzaale et al., 2014, Mjoen et al., 2013). Our 
results provide an explanation of the mechanism by which adverse cardiovascular 
effects of kidney donation may be mediated. Further research is required to 
ascertain the natural history of the effects we have demonstrated. In the meantime, 
the transplant community should be open about the pathophysiological 
consequences of nephrectomy to subjects considering donation to ensure a process 
of fully informed consent is maintained. Further prospective clinical registry studies 
with appropriate control groups are essential to examine the effects of 
nephrectomy on long term cardiovascular mortality and morbidity (Thiel et al., 
2011).   
 
5.4.4. Other Studies 
 
Our results extend those which have been presented in the only other prospective, 
controlled study of kidney donors to date (Kasiske et al., 2013). Kasiske et al. also 
found no effect of kidney donation on peripheral blood pressure but similar 
biochemical effects including an increase in parathyroid hormone and uric acid. 
Both these factors have been associated with adverse cardiovascular outcomes and 
may themselves have direct adverse effects on LV geometry (Kao et al., 2011, 
Laflamme et al., 2014). 
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5.4.5. Limitations 
 
The detailed, prospective, pathophysiological design of this study is its major 
strength but there are some limitations. While over half of all subjects approached 
(53%) took part in this study we cannot completely exclude the potential for some 
selection bias. The number of donors undergoing T1 mapping to quantify ECV was 
small; while an increase in ECV was demonstrated in donors the result did not reach 
statistical significance and thus, these preliminary findings require confirmation 
with larger numbers. Even at 12 months post-nephrectomy, the effects of the 
operation itself on the cardiovascular system cannot be fully discounted. Finally, the 
study was not large enough, nor of sufficient duration to provide data on clinical 
end points in living kidney donors.  
 
5.4.6. Conclusion 
 
In conclusion, kidney donors exhibited adverse changes in LV mass and systolic 
function, increased aortic stiffness and a less favourable cardiovascular disease 
biomarker profile at 12 months after donation. The increase in LV mass was 
independently related to changes in renal function but independent of blood 
pressure. These findings suggest that reduced GFR should be regarded as an 
independent causative cardiovascular risk factor.   
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6. FUTURE STUDIES 
 
6.1. Summary of Main Findings 
 
Even early stage CKD is associated with increased cardiovascular morbidity and 
mortality, although until now it has been difficult to decipher how many of these 
excess events are caused by the reduction in GFR or the conventional risk factors that 
have a propensity to accompany CKD, such as hypertension and diabetes mellitus.  In 
this body of work, we have shown that the modest reduction in GFR caused by kidney 
donation (approximately 30 ml/min/1.73 m2) causes increased left ventricular mass 
and increased arterial stiffness with no effect on blood pressure at 12 months. 
Increases in LV mass had a graded independent association with the magnitude of the 
reduction in GFR, even after adjustment for demographic and haemodynamic factors.  
In addition, there was concentric remodelling, impaired short and long axis systolic 
function, and increased arterial stiffness. There was no effect on progression of 
atheromatous disease as measured by carotid IMT. The prevalence of 
microalbuminuria and detectable cardiac troponin was increased after donation along 
with a significant rise in serum hsCRP. In summary, these data provide powerful 
evidence that CKD is an independent causative cardiovascular risk factor exerting 
adverse effects on the myocardium and large arteries.  
 
I am confident in drawing the above conclusions because of the reliability of the data 
presented herein. I have presented a peer-reviewed validation of my CMR-FT analyses 
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against tagging which is the reference standard technique for quantifying myocardial 
strain. Moreover, there was excellent reproducibility in the blinded LV measurements 
performed using cardiac MRI.  
 
6.2. Implications of Findings  
 
These findings have major implications for both the general population, in whom early 
moderate CKD is highly prevalent, as well as for living kidney donors. After age, LV 
hypertrophy is the most potent risk factor for cardiovascular death and mortality in the 
community  (Levy et al., 1990). Our findings suggest that a reduction in GFR of 
approximately −30 ml/min/1.73m2 is sufficient to cause increases in LV mass leading to 
concentric LV remodelling. It is therefore highly plausible that early stage CKD is a 
major driver of LV hypertrophy in community dwelling subjects and thereby 
precipitates a substantial proportion of adverse cardiovascular events in the general 
population. The work presented in this thesis provides robust evidence that the 
relationship between CKD and cardiovascular disease is causative, which suggests up 
to a fifth of major vascular events among those aged over 70 years can be attributed to 
reduced renal function (Mafham et al., 2011). 
 
There is now a clear requirement for the prospective registration of all living kidney 
donors (Moody et al., 2012c). It is impossible to randomize an individual to become a 
living kidney donor (Reese et al., 2015) and for that reason we must continue to strive 
to generate new knowledge about long-term donor outcomes using an observational 
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approach with control groups that, while likely still imperfect, will represent 
improvements over existing work. In our own prospective study presented in this 
volume of work, we were able to ensure that the nondonor controls used for 
comparison with donors had equivalent baseline health status, by performing an 
identical screening protocol for both groups on study entry, as well as detailed 
cardiovascular and renal assessments. This is the major advantage of our detailed 
pathophysiological study over the existing data from epidemiological studies. A similar 
approach will need to be adopted by future prospective large-scale studies if we are to 
ever confirm or refute the possibility that kidney donation impacts adversely upon 
cardiovascular risk. 
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6.3. Future Directions 
 
We hypothesise that although the differences in LV mass and arterial stiffness between 
donors and controls were small at 12 months after nephrectomy, these may increase 
with time. Whether these adverse changes to the LV and aorta persist or increase can 
only be answered with extended follow up. Indeed, one of the major initial aims of this 
study was to establish a “donor cohort”. We plan to repeat ambulatory BP and arterial 
stiffness measures annually for 5 years whilst repeating cardiac MRI studies to 
determine LV mass along with functional measures at 3 and 5 years. Long-term 
longitudinal outcomes and mortality data will also be provided by the registration of 
participants with the NHS Medical Research Information System (MRIS) and accessing 
information from the UK National Transplant Register. 
 
6.3.1. Future Analyses 
 
To date, there are no longitudinal data on the effects of nephrectomy on FGF-23 and 
the results of these assays are eagerly awaited. One cross-sectional study has shown 
increased FGF-23 at a median time after donation of 5.3 years (Young et al., 2012a). 
Both serum FGF-23 levels and plasma iPTH levels were significantly higher in donors as 
compared with controls. If we observe an increase in levels of circulating FGF-23 in 
donors over 12 months, this would lend support to the theory that the FGF-23 
pathway is a key driver in adverse LV remodelling in CKD, and appears to exert its 
effects via a blood pressure-independent mechanism. This would provide further 
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impetus for the development of novel compounds to target the FGF-23 pathway with 
the aim of improving structural and functional cardiovascular parameters in early stage 
CKD. For example, the non-specific FGF-23 receptor antagonist PD173074, was 
recently shown to retard the development of LVH in animal models of CKD (Faul et al., 
2011).  
 
In the near future, the stored serum of donors and controls will undergo proteomic 
profiling (SomaLogic, Boulder, CO 80301 USA). There is already a validated panel of 
proteins available for patients with stable coronary artery disease which has been 
shown to very accurately stratify cardiovascular risk (SomaScan CVD Panel). Using the 
same technology, a recent US study examined the influence of circulating factors using 
heterochronic parabiosis, a surgical technique in which the joining of mice of different 
ages leads to a shared circulation (Loffredo et al., 2013). After 4 weeks of exposure to 
the circulation of young mice, LV hypertrophy in old mice significantly regressed. 
Modified aptamer-based proteomics identified growth differentiation factor 11 
(GDF11), a member of the TGF-β superfamily, as a blood-borne factor in young mice 
that declined with age. Supplementation of old mice with GDF11 restored youthful 
circulating levels which reversed age-related hypertrophy. Thus, it may prove 
illuminating to quantify changes in the proteome before and after kidney donation and 
assess for changes in GDF11 expression. This approach may help identify novel serum 
biomarkers responsible for the increased LV hypertrophy and excess cardiovascular 
risk associated with CKD. 
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A detailed CMR-FT assessment of LV systolic and diastolic function under resting 
conditions has already been presented in this body of work. In those subjects with 
appropriate image quality, transthoracic echocardiography was also performed during 
a progressive submaximal exercise test to derive stress-related changes in LV systolic 
and diastolic function using TDI and strain measures. Exercise uncovers abnormalities 
of both systolic and diastolic function in patients with heart failure with preserved 
ejection fraction (HFpEF), including torsional dyssynchrony which relates to LV 
hypertrophy as well as exercise capacity (Tan et al., 2013, Tan et al., 2009). In patients 
with advanced CKD, HFpEF is common and tends to overlap with uraemic 
cardiomyopathy (Wang et al., 2013). In the current study, subjects were installed on a 
dedicated semisupine cycling ergometer (Schiller ERG 911 BP/L, Baar, Switzerland). 
After a 15-minute rest period, each subject underwent an exercise test that included 3 
workload stages each of 4 minutes duration, at 20%, 30% and 40% of their maximal 
aerobic power estimated via the Wasserman equation: 
 
Semi-supine VO 2 max = 0.8*[(body mass (50.72 – 0.372 X age))–350]/10.3 
 
The maximal aerobic power was corrected for semisupine position by removing 20% 
from the normal values (Arena et al., 2009, Doucende et al., 2010). As for previous 
analyses, changes in TDI and strain measures in donors are to be compared with 
changes in controls over time. More specifically, left ventricular long-axis function is to 
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be examined during exercise because it offers important prognostic information (Wang 
et al., 2015). These data should provide valuable insight into the effects of reduced 
GFR on cardiac mechanics during stress. 
 
 
6.3.2. Other Studies in Progress 
 
The blood pressure and PWV data presented in this volume of work are also being 
entered into the EARNEST Study (Effects of A Reduction in glomerular filtration rate 
after NEphrectomy on Arterial STiffness). The rationale and methods for this study 
have been reported in detail (Moody et al., 2014b). EARNEST is a collaborative UK 
multicentre study with a prospective, longitudinal, parallel group design and is also 
being led by our group. The study plans to recruit 440 living kidney donors and 440 
healthy controls and is powered to detect an increase in peripheral and central blood 
pressure, and to detect very small increases in arterial stiffness in donors. In regard to 
the effects of kidney donation on peripheral blood pressure, the data remain 
inconclusive and the results of this study should therefore prove very informative. 
These data will also help to confirm or deny the results of the PWV measurements 
presented in the current work which have been performed by an unblinded observer 
(W.E.M.). 
 
After submitting an application to UK Transplant during the course of this work, I was 
granted access to data on over 10,000 UK living kidney donors operated on between 
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1990 and 2012. Using these data, I have already reported in abstract form that long-
term cardiovascular outcomes are superior in UK kidney donors compared with a 
contemporaneous control group, although this finding may have reflected residual 
confounding from selection and follow up biases (Moody, 2013). Acknowledging the 
difficulties in identifying an appropriately matched non-donor control group, the focus 
of this investigation has changed to examining changes in GFR exclusively in donors; 
there are marked differences in the extent of the recovery of renal function post-
transplant which offers a unique opportunity to examine the association between 
changes in eGFR and cardiovascular risk. Using linked datasets from the UK Transplant 
Registry and the NHS Hospital Episodes Statistics database, my aim is to examine the 
hypothesis that the size of the reduction in renal function associated with 
nephrectomy independently predicts long-term adverse cardiovascular events in UK 
living kidney donors. Findings from this study might support the need for intervention 
studies to help determine whether early cardiovascular risk reduction therapy should 
be instituted in the vast number of community dwelling subjects with only modestly 
impaired renal function, as well as in those that have undergone living kidney 
donation. Moreover, these data may provide yet further evidence that CKD should be 
regarded as a causative risk factor for cardiovascular disease.  
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